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ABSTRACT
My thesis develops and evaluates a novel, hybrid method for mass spectrometry based 
proteomics, with the goal of increasing the number of protein identifications, while also 
allowing quantitative analysis to be performed. The hybrid approach I developed uses 
classical SILAC labeling coupled to a “novel” scheme for enriching cysteic acid containing 
peptides which are generated by oxidizing the cysteine and cystine residues of proteins. 
The resultant acidic side chains are used for the selective enrichment of these peptides. 
As a result, I get the ease of labeling and enhanced quantitative performance of SILAC 
protocols with the added benefit of the reduction in sample complexity seen with ICAT 
protocols.
The hybrid method enabled me to study the proteomic profiles of H I229 cancer cells 
following sirtinol treatment. Sirtinol, which targets members of the sirtuin family, has been 
proposed as a treatment for neurodegeneration and cancer. In fact, sirtinol induces 
senescence in H1299 cells, and I was able to observe the long term therapeutic effects of 
sirtinol at the proteome level.
The optimized hybrid protocol yielded approximately 5 times the proteins identifications 
from H1299 cells, when compared to the standard protocol. Quantification of this data 
revealed that 140 proteins are downregulated and 88 proteins are upregulated following 
sirtinol treatment of H 1299 cells. Moreover, an additional benefit of the protocol was an 
increase in the total number of post translational modifications (PTMs) identified using 
the hybrid approach. This work will give a better understanding of the mode of action of 
these compounds, as well as revealing the biological mechanisms of their effects.
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In conclusion, the hybrid method is useful for increasing the number of protein 
identifications from complex samples. It is an accurate and straightforward method for 
comparative studies. This method is especially useful for drug analysis studies or other 
binary comparisons.
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I. IN TR O D U C TIO N
I . I . Overview
Proteomics is a powerful method for biological discovery, because it provides information 
directly about the proteins in a sample. Proteomics has gained significant importance for 
understanding disease mechanisms and for biomarker discovery. Together with genomic 
approaches, proteomic studies hold great promise in identifying the mechanisms of action 
of new drugs, especially for those drugs that have an indirect mode of action, such as 
transcriptional regulators. However, it needs to be recognized that proteomics is still an 
emerging technology that has its own drawbacks '.
Proteomics is a wide field of study that depends upon effective sample preparation 
techniques and sensitive instrumentation for the identification of proteins in complex 
biological samples. Unlike genomics studies, there are no proteomic methods that can 
identify and quantify the complete set of proteins from a complex biological sample. The 
general workflow includes several steps, including cell lysis, protein digestion and peptide 
purification. Given the complexity of the proteome 2, extensive sample manipulation is 
frequently required before the analytic technique can be applied. In this case the sample 
complexity is a mix of both the number of distinct components and the variability in their 
concentrations. There can easily be a million fold difference between the most abundant 
and least abundant constituents in a complex biological mixture, such as a cell lysate or 
serum sample.
Although, these issues may be daunting, the aim of proteomics has always been to analyze 
all the proteins from a sample and this aim continues to be the major force in the 
development of new instrumentation and techniques. Many different techniques are
16
available for proteomics studies, however they currently do not effectively meet the need. 
This creates the necessity for creating new, more effective techniques.
With this perspective, I aimed to develop a novel method for sample preparation that 
was designed to produce an increase in the number of protein identifications from a 
complex mixture. In addition, I sought to reduce the number of experimental steps, all 
while still permitting the quantification of the proteins in the sample.
Secondly, I used this method in comparative studies to investigate the global proteome 
response to, sirtinol, which targets sirtuins (suppressor of Sirtl). Sirtuins are involved in 
aging, senescence, neurodegeneration and cancer 3. Studying this compound is quite 
interesting, because sirtinol has been investigated as a potential treatment for cancer. 
Investigating such drugs is important for preclinical studies, because finding the protein 
targets of a compound is one if the keys to understanding its mode of action.
In this introductory chapter, the main goals and challenges of proteomics will be 
addressed. The classic proteomics workflows for identification of proteins with mass 
spectrometry will be explained. An overview of methods employed for comparative and 
quantitative proteomics analysis will be presented, highlighting the two well-known 
techniques that the idea of novel hybrid method is derived from. The main idea of hybrid 
method is presented next, but the detailed steps of optimization and development left for 
results section.
The second half of my thesis involves the application of the hybrid method for 
comparative studies to investigate the global proteome changes in biological systems. The 
effects of sirtinol treatment at the proteome level have been investigated in a cancer 
model; therefore I have also included an introduction to sirtinol, cancer, and senescence.
17
1.2. Proteomics
The genetic material of an organism contains the complete set of genes required to build 
RNAs and proteins. The goal of genomics is to determine and understand the structure 
and function of a complete. DNA sequence of an organism 4 and this information is often 
critical for understanding many biological problems, but genomic studies have their own 
limitations5. For example, genomics can only give an indirect measure of protein function, 
as the levels of gene transcription provides only a rough estimate of protein abundance 6. 
Furthermore, genomics does not take into account post-translational modifications that 
profoundly affect protein activities. Proteomic studies can overcome these limitations 
since they are focusing on the molecules which have the major functional role in living 
organisms, proteins4. However, the analysis of an organism at the protein level introduces 
a variety of analytical challenges, many of which still need to be overcome.
1.3. The Challenges o f Proteomics
The proteome is the complete set of proteins produced by the genome 7 which varies 
with time and depends on a variety of physiological or pathological conditions. A 
proteome contains a wide diversity of unique proteins. In this respect, a proteome is 
much more complex than genome or the transcriptome that gives rise to it, since proteins 
are quite dynamic in cell8. From the same genome, different proteins are expressed and 
each protein can be chemically modified in different ways after synthesis, such as( 
carbonylation, phosphorylation and acetylation etc 9 l0.
Unlike genomic studies, it is not possible to identify all the proteins in cell with simple 
methods. Unfortunately, there is no protein equivalent of PCR. Even when high resolution 
mass spectrometers are used, the sample complexity far exceeds the analytical capacity 
which results in undersampling of the data. Moreover, the nature of the protein can also
add difficulties to analysis. For example, some proteins, such as highly hydrophobic 
membrane proteins are more difficult to manipulate M. These characteristics of proteins 
create challenges in proteomics.
In order to deal with these problems, different sample preparation methods or data 
analysis methods need to be improved. Strategies aimed at reducing sample complexity 
at the mass spectrometer, or normalizing the dynamic range, are currently being explored 
to improve the effectiveness of MS based proteomics.
Although, much of the current development of proteomics has focused solely on protein 
identification, it is clear that quantitative proteomics is particularly important for 
understanding biological process, as very few biological processes are regulated in an all- 
or-none fashion. Quantitative proteomics has additional challenges and typically 
quantitative approaches result in fewer protein identifications then strategies which do 
not produce quantitative data.
1.4. The Goals of Proteomics
Since the proteins are the actual functional molecules in the cell, studying the proteome 
is quite important for understanding how a cell functions and how these functions are 
changing under different circumstances, and proteomics has provided key insights into 
various types of areas including aging, cancer, drug discovery and infectious disease 
mechanisms 4.
Proteomics includes the systematic study of the amounts, modifications, functions, 
localizations and interactions of all or a subset of the proteins found in particular cells, 
tissues or whole organisms. On a practical level, one of the major goals of proteomics is 
to provide useful information on mechanisms of human diseases (e.g., cancer) with a long
19
term aim of developing methods for diseases diagnosis and treatment. However, in a 
simpler explanation, the main goal of the proteomics is, identifying and characterizing all 
the proteins in cell and identifying the changes in the proteome in response to changes in 
cellular state.
Many different methods have been developed to expand the limits of proteomic 
approaches '. The methods of choice can be tailored for the specific goals of the study, 
such as whether quantification of the proteins is required. Although these methods should 
be straightforward and easy to perform, they typically require further optimization, and 
may require additional steps to adapt the protocol to particularly challenging samples and 
available analytical tools. For example, something as common as blood sera requires 
additional steps that typically are not required when analyzing whole cell lysates.
Although there are many different techniques, proteomics approaches can be broken 
down into several common steps such as sample preparation, separation of 
peptides/proteins, data collection and data analyses. In the next section, these steps and 
their importance will be explained in greater detail.
1.5. The Classic Proteomics W orkflow  for Protein Identification
The proteomics workflow involves the experimental techniques and instruments used for 
acquiring and analyzing the data of a particular proteomics analysis. There are different 
approaches in proteomic studies. Two main strategies have been used over the years: the 
‘top-down* and the ‘bottom-up*. The top-down strategy is based on the MS analysis of 
whole proteins l2. Top-down strategies are frequently targeted at a small number of 
proteins and are used for the thorough characterization of isoforms, PTMs, etc. of a 
handful of proteins at a time. On the other hand, the bottom up strategy, which is the 
strategy used in this thesis, is more frequently used, especially for the analysis of complex
20
samples. In this strategy the MS analysis is performed with peptides derived from the 
enzymatic digestion of proteins and protein identification is based on the mapping o f these 
peptide identifications back to  the ir source proteins. Typically bottom-up analysis is much 
more efficient than top-down approaches and results in many more protein 
identifications.
Many different workflows can be used fo r bottom-up proteomic analysis and they have 
different advantages and disadvantages (Table 1.1.). The majority o f these workflows 
involve, sample preparation, protein separation, data collection and data analysis w ith 
mass spectrometry fo r protein identification (Figure 1.1.). These steps will be covered 
in next sections highlighting the importance of sample preparation steps, since proteomics 
studies are highly depending on effective sample preparation and also fo r giving a better 
understanding to  the objectives o f the thesis.
dtejesrion
biological sample proteir peptides
4 ii V T \in in
opti onal 
fracti onati on
chromatograph y 
{EASY nLC 1000}
f
data analysis 
(MaxQuant/ And romed a/Pe rseus )
R A W  d a ta mass spectrometer 
(e.g. Q Exactive)
Figure 1.1. General workflow for proteomic analysis. The proteomics workflow entails the 
isolation of proteins from the biological source, processing the proteins into peptides, one or more 
separation steps and finally analysis by MS 253.
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PROS CONS
DIGESTION
TECHNIQUES
In-solution
Digestion
*Easy and fast procedure 
*Provides good coverage 
for peptides
*No sample 
simplification 
*Frequently needs to  be 
combined with sample 
cleaning techniques
In-gel
Digestion
^Simplifies complexity. 
*Orthogonal separation 
technique to all forms of 
chromatography. 
^Efficient contaminant 
removal
*More time consuming 
as there are many 
processing steps 
*Not all peptides can be 
recovered
QUANTIFICATION
TECHNIQUES
SILAC * Accurate quantification 
*Minimizes sample to 
sample variability 
*True in-vivo technique
increases sample 
complexity
ICAT *Decreases sample 
complexity 
increases protein 
identification
*Long sample 
preparation time 
*Sample to sample 
variability
Label-free
techniques
*Can be used for many 
types of samples 
* Reagents are not 
expensive
*Sampleto sample 
variability
Table 1.1. Pros and cons of some of the proteomic techniques.
1.5 .1. Sample Preparation
In proteomic studies, samples can be obtained from virtually any biological source, even 
from fossilized dinosaurs. Ideally, the sample preparation steps are designed to  change
22
the sample into a form that is suitable for analysis, as biological samples are typically not 
amenable to direct analysis by mass spectrometry or other analytical techniques.
Sample preparation is the most important step in order to obtain reliable and 
reproducible results. In general, these steps solubilize the proteins in a sample, while 
eliminating any interfering compounds such as salts, lipids, nucleic acids etc. There is no 
universal protocol for sample preparation. There are typically many methods that can be 
used, or adapted from a known method to fulfill the experimental aims and the methods 
can be varied depending on the biological sample and the objectives of the study ,3.
Sample preparation workflows mainly depend on the nature of the sample such as, type 
of sample, available amount, hydrophobicity, pH, and temperature stability l3. The other 
important factor is the biological question to be addressed. For example, analysis of 
membrane and/or soluble proteins, post-translational modifications and protein-protein 
interactions can be studied, but these studies require different sample preparation 
methods. Similarly, a difficult to extract sample, such as a fossil or the woody pulp of a 
tree, would require different steps from serum, plasma, or other samples rich in soluble 
proteins.
1.5 .1. 1. Sample Solubilisation
In order to analyze the proteome, as many proteins as possible should be extracted from 
the sample. Successful protein expression analyses via mass spectrometry relies on the 
solubilisation of proteins from complex mixtures. This can be done by several methods 
which use combinations of chemical and mechanical disruption strategies. Most common 
methods involve a chemical lysis using detergents or chaotropic agents coupled with 
mechanical forces typically generated by sonication or grinding that physically breaks the 
sample down l3.
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To maintain the solubility and stability of the protein samples, many different buffers, 
reductants, detergents and inhibitors are typically used in the early steps of sample 
preparation. The classic lysis buffer combination may include detergents like NP40 and 
Triton-XlOO or chaotropes such as urea. Lysis, extraction and denaturation of proteins 
can be obtained in same step with certain procedures such as boiling and agitating the 
sample with SDS. It is important to mention that, the choice of lysis buffer combination 
and mechanical disruption mainly depends on the target proteins and characteristics of 
the sample source. In addition, proteases might be activated during protein solubilisation. 
This can be avoided by adding protease inhibitors or by keeping all the solutions ice cold. 
There is no the absolute best way to lyse a sample but speed and cleanliness of 
preparation definitely affect protein identification.
1.5 .1.2. Removal of Contaminants
Once proteins are extracted from their source, many contaminants need to be removed 
because most of them are not compatible with the downstream steps, especially the LC- 
MS. For example, many extraction reagents, such as strong detergents will interfere with 
enzymatic digestion and most detergents interfere with reverse-phase separation and 
mass spectrometry l4. The removal of other contaminants such as, salts, nucleic acids, 
lipids, polysaccharides is also essential for MS analysis since these contaminants cause 
chromatographic interference and signal suppression.
Removal of contaminants such as DNA, lipids, detergents etc. are most often removed 
via dialysis, ultrafiltration, precipitation with TCA or organic solvents and solid-phase 
extraction techniques and have been incorporated into commercially available clean-up 
kits ,3.
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One common approach for contaminant removal is precipitation. There are various 
techniques for precipitation including using strong acids or organic solvents. Protein 
precipitation frequently causes selective sample losses, especially as solubilizing some 
proteins can be challenging. Similar selective sample losses are seen with other removal 
techniques, such as ultrafiltration. Therefore, different contaminant removal techniques 
are continually being introduced and are often tailored towards specific analytical 
challenges.
1.5 .1.3. Digestion Strategies
Protein digestion can be performed using in-gel, in-solution, in-filter approaches, etc. In­
solution and in-gel digestion are the two most widely used techniques to prepare bottom- 
up proteomic samples (Figure 1.2.).
In-solution digestion is a straightforward, yet extremely powerful technique that typically 
used in shotgun proteomics. It involves, denaturing, reducing, alkylating and digesting the 
proteins in liquid phase. Generally, in-solution digests are fractioned after digestion but 
fractionation can be also performed before digestion using different forms of 
chromatography (i.e., ion exchange, reverse-phase). Since the sample typically does not 
require a change from liquid phase, it is easier to minimize sample losses during the 
digestion phase.
SDS-PAGE is probably the most widely used technique today, since it has the ability to 
separate thousands of proteins in a single sample from a complex mixture ls. In-gel 
proteomics, involves separation of the proteins before digestion, using acrylamide gels 
and then processing the protein containing bands for analysis by mass spectrometry. In 
addition to fractionating the sample, SDS-PAGE is also incredibly useful for removing 
unwanted contaminants. It is also relatively simple procedure and the gel also acts as a
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good storage fo r proteins fo r future analysis l6. Gel based sample preparation is almost 
always used fo r bottom-up proteomics, because the full proteins are difficult to  elute from  
the gel, while the much smaller peptides produced by digestion are much easier to  
recover from the gel l7.
Many different endoproteases can be chosen fo r protein digestion but trypsin is widely 
used, because it generates peptides that are highly compatible w ith MS analysis. Trypsin 
cleaves C-terminal to  arginine and lysine l8. This typically generates peptides in the 800 
Da to  2000 Da range, which can be analyzed w ith high sensitivity via MS. Moreover, 
because of the basic nature of lysine and arginine, tryptic peptides are efficiently ionized 
during mass spectrometry, due to  the presence of a basic residue at both the N- and C- 
term ini of the tryptic peptides.
Lysate Preparation in-Solution Digestion Peptide Enrichment/Cleanup>
-Lysis
-Fractionation
-Depletion
•Enrichment
-Dialysis
-Reduction
-Alkylation
-Digestion
IDE Peptide
Extraction
M S Analysis
EE!
__ Gel Plug
In-Gel Digestion 
-Reducion  
-Alkylation 
-Digestion
Figure 1.2. A comparison of in-solution and in-gel digestion strategies in proteomics. Gel
electrophoresis is used to separate whole proteins. Bands containing proteins are excised from the whole 
gel and subjected to enzymatic digestion and peptide extraction. However, in the in-solution protocol, the 
proteins are digested directly from the solution containing them. In both cases, the resulting peptides are 
analyzed with mass spectrometry l9.
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1.5.2. Fractionation and Separation of Proteomic Mixtures
Fractionation and separation techniques for proteomic mixtures are used to separate the 
components of a mixture in order to make the identification of these components more 
efficient. As mass spectrometry is a time dependent analysis technique, these extra steps 
of separation are used to provide more time for the MS to analyze a single sample. In this 
regard, the separation is done in order to reduce the complexity of a sample entering the 
MS, so that any given time, the MS is not dealing with all the components at once.
Different characteristics of the components can be used for separation of mixtures such 
as polarity, electrical charge and molecular size. In mass spectrometry based proteomics, 
separation is usually performed with liquid-chromatography (LC). This on-line separation, 
helps reduce the complexity of a sample entering the MS, as the components of each 
“fraction” are dealt with independently from other resolved fractions. This separation is 
necessary, because even the digest of a single protein is too complex to allow the MS to 
analyze all the resulting peptides. Therefore, sample separation is one of the crucial steps 
for MS-based proteomics l3.
Complete separation of highly complex mixtures is technically impossible, as there will 
be some overlap of components with similar characteristics. The main goal is to provide 
enough separation to allow the MS ample time to analyze the co-eluting components. A 
single chromatographic step is typically not sufficient for separating digests from more 
than a handful of proteins at a time. This is especially true, when some components, PTMs 
for example, are present at a much lower stoichiometry. Multidimensional 
chromatography techniques can be used for these situations. In this case, the peptides are 
fractionated by two or more steps of chromatography that are designed to have the least 
amount of co-eluting components as possible. Ion exchange chromatography is often
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coupled to reverse phase chromatography as these typically have completely different 
chromatographic profiles. In fact, most gel based workflows can be considered multi­
dimensional. The need for fractionation and separation is a result of the complexity of the 
samples.
1.5.2.1. Sample Complexity
Sample complexity refers to two main characteristics: the diversity of proteins in the 
sample and the range of concentration of these proteins. A typical proteome can contain 
thousands of unique proteins. Coded from 20.000-25000 genes 20, it is estimated that 
human body can contain over a million unique protein products 21 that result from 
alternative splicing, proteolytic processing, etc. This number goes even higher if the 
various types of PTMs are considered. For example, human plasma has been estimated to 
have more than 10.000 core proteins 22 and only small fraction of it can be efficiently 
characterized with current technologies. This is not just an effect of the complexity in 
number of proteins but is also impacted by the large disparity in their concentrations.
Proteins from biological samples typically display a large dynamic range between low and 
high abundance (Figure 1.3.). The range of abundances of these proteins can be quite 
high 2. Plasma proteins can have 10l2-fold concentration range, from millimolar (for 
albumin) to attomolar or lower for certain cytokines 23. This large dynamic range swamps 
the linear range of current proteomics methods, which is typically between 3 and 4 orders 
of magnitude 24. Selective enrichment or depletion of components has been used to help 
alleviate the problem of the naturally occurring dynamic range, but even a 99.9% depletion 
of albumin, results in albumin still being one of the most abundant components of plasma.
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W hen it comes to  mass spectrometry, the sensitivity fo r detection and identification of 
peptides is strongly affected by sample complexity. For instance, the highly abundant 
peptides will be identified much more easily and they will shadow the less abundant ones. 
This is largely due to  the fact that in most MS systems, there is a competition fo r ionization 
and highly abundant peptides suppress the signal from less abundant ones. This is a general 
issue with all sorts o f proteomic methods and increased separation combats this problem 
by decreasing the overlap of between high abundant components and other components 
in the sample.
Figure 1.3. Proteins in serum have a large dynamic range. The concentration of various serum 
components has been estimated using mass spectrometry, Multiple Reaction Monitoring (MRM), and other 
analytical methods. Adapted from “Proteomic retrenches” by P. Mitchell, 2010 Nature Biotechnology 28, 
665-670 2.
1.5.2.2. On-line Separation of Proteomic Mixtures
Many different mass spectrometry and pre-fractionation combinations have been 
developed to  improve the analysis o f complex proteomic samples. High-performance 
liquid chromatography (HPLC) is a classic separation technique which provides a wide
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variety of separation modes. This has been improved with ultra-performance liquid 
chromatography (UPLC), which provides an increased resolving power and speed of 
separation 2S. HPLC and UPLC use the same functional principles for separation, with 
UPLC having highly optimized columns and flow paths. The optimization is almost solely 
aimed at reducing column particle sizes and reducing the extra column dead volumes, 
which result in “ultra-high” pressure systems.
In bottom-up proteomic analyses, the most used HPLC/UPLC stationary phase is the 
reverse-phase column 26. It is usually used as the last separation step before MS because 
the chromatographic buffers are highly volatile and are ideally suited for interfacing with 
a MS instrument. RP-HPLC separates peptides according to their partition coefficient 
between a polar mobile phase and a hydrophobic stationary phase. In this type of 
separation, proteins and peptides are bound to the stationary phase and the separation 
carried out by application of gradually increasing concentrations of an MS compatible 
organic solvent. In addition to using MS compatible solvents, RP-HPLC is one of the 
highest capacity and resolution chromatography modes for peptide separation.
While reverse-phase columns are widely-used, many other stationary phases can be used
for proteomic analysis in one and two-dimensional separations. A separation technique,
known as electrostatic repulsion and hydrophilic interaction chromatography 27 (ERLIC)
is a recent development, and has been used specifically for phosphoproteomic studies.
ERLIC uses two characteristics for separation: hydrophilicity and charge state. ERLIC
usually uses low-organic and high-pH gradient as the initial mobile phase and moves to
high organic and low-pH mobile phase to separate the bound peptides. Hence, ERLIC
elutes peptides in order of increasing hydrophobicity and acidity. Other separation modes
include, ion-exchange chromatography, exclusion chromatography 28. The separation can
be performed with column effluent flowing directly into the instrument (online
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separation) or fractions can be collected prior to analysis on the instrument (offline 
separation). Online separations tend to be faster and have less sample loss, while offline 
separation allows for modes that are not directly compatible with MS to be incorporated 
into MS based workflows and many multiple dimension LC-MS/MS protocols are based 
on performing the first separation offline and the second separation online.
Multiple dimension separations greatly reduce the sample complexity entering the MS, 
especially when the two dimension are orthogonal. The number of peptide and protein 
identification is greatly increased when two or more chromatographic systems based on 
different selectivity are used together before MS analysis (2D-LC) 29. Strong Cation 
Exchange (SCX) chromatography coupled to Reverse Phase Chromatography (RPC) is 
one of the most popular pairings 30. In this system, the peptides are first separated based 
solely on their charge state in the first dimension and then these fractions are separated 
based on their hydrophobicity by RP-HPLC. Since the charge state and the overall 
hydrophobicity are independent, only a small subset of the peptides co-elute on both 
columns 30. This type of chromatographic system allows for a high number of 
identifications since the resolution (the power of separation) increases because of two 
dimensions of separation. However, this is also coupled to an increase in the time it takes 
to run a single biological sample, and this increased time is also critical to allow the MS 
increased time to analyze each component.
1.5.2.3. Reducing Sample Com plexity by Off-line-Fractionation of Proteins
Reducing sample complexity can be accomplished as part of the sample preparation steps 
using, immunoprecipication, immunodepletion and fractionation of proteins with SDS- 
PAGE. Some of these methods, such as immunoprecipitation, are targeted reductions 31 
that enrich a target protein and its interactors at the expense of proteins that do not
interact with the affinity matrix. Similarly, removal of the most abundant proteins can be 
performed to reduce protein concentration variability. For example, albumin can be 
removed from samples by immunodepletion 32. This allows proteomics analysis to begin 
to probe proteins that are initially present at much lower concentrations. However, 
potentially significant proteins can be lost from the final sample due to non-specific binding 
or other factors33. Non-targeted approaches include methods where the “whole” sample 
ends up on the MS. For example, if an entire lane from a gel is analyzed, chromatographic 
prefractionation where every fraction is analyzed 34, and affinity approaches such as 
Isotope Coded Affinity Tag (ICAT)35 where specific peptides are enriched without regard 
to their protein of origin.
An often overlooked form of untargeted protein separation is gel electrophoresis (e.g., 
SDS-PAGE) before MS analysis36. SDS-PAGE is still the highest resolution technique for 
proteins 37. Since this separation is based on whole protein size, it is orthogonal to any 
peptide based separation performed on the digested gel pieces. After separation with on­
line or off-line techniques data is acquired by a mass spectrometer.
1.5.3. Data Acquisition in Mass Spectrom etry Based Proteomics
Data acquisition is the third step in proteomics workflows. It includes the ionization of 
the samples and these ions are then analyzed by the mass spectrometer. Importantly, 
mass spectrometers can only analyze charged species.
Mass spectrometry is a technique in which molecules are ionized and their mass-to-charge 
ratio (m/z) is measured 38. The m/z ratio is calculated by simply dividing the mass of an 
ion by the net number of charges it carries. A single protein or peptide may possess a 
variety of m/z ratios, depending the distribution of charge states. It is not uncommon for 
even short peptides to produce + 1, +2, +3, forms.
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Identification of peptides and proteins in a mass spectrometer depends on the ability to  
control the behavior o f these molecules. For example, in a typical instrument, 
electrospray is used to  produce the ions, which are accelerated into the mass 
spectrometer via high voltage. Ions with a specific m/z can be selected by deflecting them 
with a magnetic field. Each m/z will be deflected differently resulting in a separation of 
the ions. The selected ions are directed at a detector resulting in the formation o f a peak 
fo r the selected m/z ratio. These procedures are done in the mass spectrometer’s 
components which are the ion source, the mass analyzer and the detector (Figure 1.4.).
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Figure 1.4. The components of a mass spectrometer. A schematic of a typical mass spectrometer, 
showing the flow of ions from the ion source, through the mass analyzer and finally to the detector.
The ion source is an ionization chamber where the stream of ions is generated. There 
are different ionization methods, including, electron impact ionization (El), chemical 
ionization (Cl), matrix-assisted laser desorption ionization (MALDI) and electrospray 
ionization (ESI), etc. MALDI and ESI are the predominant modes fo r biological mass 
spectrometry since they are considered ‘soft’ ionization methods that do not destroy 
fragile biological samples. Since my w ork  solely relied on ESI as an ionization source, the 
emphasis of the discussion will be on this method.
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ESI is an evaporation based ionization mode. It includes the generation o f charged liquid 
droplets as a fine spray. It is a form  of atmospheric pressure ionization (API) since the 
ionization does not take place under vacuum. In this mode, the sample is in a liquid matrix, 
which is ideally a m ixture o f aqueous and organic solvents. Typically the sample is sprayed 
from  a very fine needle, which maintained at high voltage (1-5 kV) to  generate charged 
liquid droplets. The high voltage concentrates the charge in the flowstream at the tip of 
the needle. Electrostatic repulsion at the tip of the needle causes the flowstream to  
“ explode”  into fine droplets (Figure 1.5.). A heated gas (e.g., nitrogen at 70 °C) is used 
to  accelerate the evaporation o f the solvent, resulting in the transformation of the analyte 
from  liquid phase to  gas phase. The residual charge in the droplet is transferred to  the 
analyte and the ions are directed to  the mass analyzer by the high voltage.
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Figure 1.5. Schematic of an electrospray ionization source. A fine spray is formed at the tip of the
needle and the plume of ions is drawn into the mass spectrometer by the high voltage field l9.
The analyzer is where the m/z ratio of the analyte is measured. D ifferent types of mass 
spectrometers do this differently and they all use different properties o f an ion in an 
electric field fo r this measurement. In addition, the analyzer also directs the ions to  the 
detector. Many types o f mass analyzers have been used fo r proteomics including:
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Quadrupoles (Q), time of flight analyzers (TOF), ion-traps (IT), and Fourier transform 
based instruments, such as the Orbitrap™. Each mass analyzer has its own unique set of 
advantages and drawbacks 39. For example, ion trap analyzers consist o f three electrodes: 
tw o  end cap electrodes and one ring electrode (Figure 1.6.). An oscillating voltage is 
applied between the ring electrodes and as ions pass into this analyzer, they are trapped 
by the electrostatic field created by these electrodes. When the amplitude of the field 
within the device is changed, certain trapped ions begin to  resonate within the trap, 
ultimately resulting in them leaving the trap where they can be detected. Each m/z has 
its own characteristic resonance amplitude, so it possible to  selectively remove o r retain 
ions from  the trap based on the ir m/z. This behavior allows fo r the production of a mass 
spectrum, as well as allowing fo r the isolation of a particular analyte (m/z ratio) fo r further 
study inside the ion trap.
End-Cap
Ionization Ui
Collision Induced Dissociation Gas 
(often helium, nitrogen or argon)
Figure 1.6. General scheme of ion trap analyzers. Ion trap analyzers consist of three electrodes: 
two end cap electrodes and one ring electrode and ions produced at the ion source are retained in the 
trap where they can then be manipulated.
For example, the analyte can be fragmented within the mass analyzer and then the 
fragment masses can be determined. This is typically referred to  as MS/MS mode. MS/MS 
is the favored mode of analysis fo r the identification of peptides as the fragments have a 
higher information content then is contained in the m/z ratio o f the originating, o r
Ring Electrode
Ion Detector
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precursor ion, and there are a variety of methods to determine the sequence of a peptide 
from the fragment ions it produces in a mass analyzer.
It is often assumed that in order to identify each peptide, the sequence of the peptide 
needs to be obtained. To be able to do this, mass spectrometers typically make two 
separate mass measures. The first to determine the components currently eluting from 
the column, and the second mass measure to determine the fragmentation pattern of one 
of the components. In the second run, the peptide ions are typically resonated or 
otherwise collide with molecules of an inert gas, in a process called Collision Induced 
Dissociation (CID).
How peptides break into pieces, their dissociation pathways, mainly depends on the actual 
peptide sequence. However, depending on the fragmentation method used, different 
fragment ion types can be produced. When peptides break apart during CID, the charged 
ions are retained on one or more of the fragments. These charged fragment ions are 
measured by the mass analyzer, and this forms the fragment mass spectrum. In an ion trap 
mass analyzer, peptides tend to fragment along the peptide backbone, which produces a 
series of ladder ions that reveal the peptide’s amino-acid sequence. When the N-terminal 
fragment retains a proton, the fragment ions are typically named ‘a’ or ‘b’ ions. The other 
predominantly formed fragment ion, the y ion, forms when the C-terminal fragments 
retains a proton. CID mostly form a-, b- and y-ions (Figure 1.7.), while other modes of 
fragmentation produce other classes of ions, for example chemically induced 
fragmentation by Electron Transfer Dissociation (ETD) produces mostly c and z-ions. 
Fragments with a, b, or c in the name denote ions with a proton on the N-Terminus while 
those with x, y, or z are the corresponding ions with the proton at the C-Terminus.
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Figure 1.7. Theoretical backbone fragmentations for Glu-Fib. b and y ion series is shown using 
the nomenclature of Roepstorff2S4.
The detector is the third component of a mass spectrometer. On ejection from the ion 
trap, ions are directed to the detector. The ions strike the detector which amplifies this 
signal. The strength of that signal is directly related to the number of ions that strike the 
detector. In the case of an ion trap mass spectrometer, this results in an ion count for 
each displaced m /z.
A mass spectrum is a histogram of these detector based ion-counts where the Y-axis 
represents the number of ions impacting the detector and the z axis is the m /z  ratio 
(Figure 1.8.). In other words, it is a record of mass-to-charge ratios (m /z  values) and 
intensities of all the ions which were trapped or generated in the ion trap 40. In a specific 
proteomic experiment, this mass spectrum represents the ions that were trapped at the 
time they were scanned out to the detector.
After the acquisition, the spectra are analyzed with ‘peak detection algorithms’, to simplify 
the spectra by removing noise, removing multiple charge states for the same compound 
and deisotoping finds the mass of the peptide that does not contain heavy isotopes of 
carbon, nitrogen, oxygen etc. Eventually a peak lists is created for further analysis. In these 
lists, each peak is typically denoted by its m/z, charge state, and intensity. These peak lists 
are then used to identify the peptides found in the sample.
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Figure 1.8. A  representative mass spectrum. MS/MS spectrum of Glu-Fibrinopeptide 
(EGVNDNEEGFFSAR).
1.5.4. Data Analysis in Mass Spectrom etry Based Proteomics
In a typical proteomic experiment, the mass spectrometer can generate thousands of 
MS/MS spectra per hour and manual interpretation is not a practical option 4I. Several 
computational approaches and software tools have been developed fo r automated 
assignment o f peptide sequences to  MS/MS spectra. There are roughly three different 
methods to  make this match. In the first method, peptide sequences are directly extracted 
from spectra, w ithout referring to  a sequence database fo r help 42. This is called as, ‘de 
novo’ sequencing. This method allows identification o f peptides whose exact sequence is 
not in the database, but it is computationally intensive. As CID produces a series o f ladder 
fragments, the sequence can be determined by matching the differences between peaks 
to  the masses of the amino acids. This is much more complicated than it sounds, as there 
can be hundreds of ions in a spectrum compounded by 20 amino acids, compounded by 
3 common types of ions that can form, compounded by spurious peaks, etc. However, if 
a fairly complete sequence database is available fo r the source organism, then other more 
efficient methods can be used. For example, peptide identification can be obtained by
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correlating experimental MS/MS spectra with a sequence database. In this case, the 
spectra are turned into a series of short amino acid sequences, and then compared to a 
sequence database. This approach allows for a less sophisticated de novo interpretation 
of the spectra to be performed as you are relying on the sequence database to find the 
best interpretation43. The most efficient and popular search engines are based on spectral 
matching, where the sequence database is converted into theoretical spectra, which are 
then compared to the experimentally derived spectra 44. The main differences between 
search engines is how they score the matching and how they separate statistically 
significant matches from random matches.
1.5 .4 .1. Peptide Identification by MS/MS Database Searching
There are a growing number of MS/MS database search tools that are available for use, 
such as SEQUEST 43, MASCOT 4S, XITandem 46, OMSSA 47. These tools operate in a 
similar manner. They take an experimental spectrum and compare it against the 
theoretical fragmentation patterns established for peptides derived from the searched 
database. A single experimental spectrum may be compared to thousands of theoretical 
spectra as typically all theoretical spectra with a mass similar to the precursor mass are 
compared. Therefore, the search does not involve all the database but a subset of it, based 
on user specified criteria, such as mass tolerance, proteolytic enzyme constraints and 
types of posttranslational modifications allowed, etc.
Theoretical fragmentation patterns are calculated for each of the candidate peptide using 
common peptide fragmentation rules. List of matches (peptide sequences) are the output 
of the database search tools, which are ranked according to the scoring scheme used by 
each particular tool. The best scoring peptide match is assumed to have the highest 
possibility if being correct.
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Several parameters are commonly used with MS/MS database searches. These would 
include; types of fragment ions to include (such as c, b, y, z-ions), peptide ion charge state, 
parent ion mass tolerance (depends on the mass spectrometer used), enzymatic digestion 
constrains (i.e., trypsin cleaves after K and R), and chemical or posttranslational 
modifications. Appropriate choices in search parameters is quite important, since it can 
affect the quality of the output and also the time required for the database search 38.
1.5 .4 .1. 1. Databases
Many sequence databases are available. They vary in completeness, redundancy and quality 
of sequence annotation. The choice of which database to use mainly depends on the goals 
of an experiment. For example, if the identifications of polymorphisms are important, the 
search should be done against a very complete, highly redundant database. However, 
overall protein identification may be more efficient using a database with less redundancy, 
as the extra copies of sequence are difficult for the statistical algorithms to interpret. 
Therefore, large, redundant databases introduce more false identifications. In fact, if the 
identification of sequence variants is not crucial, it is better to use a well-curated and 
well-an notated databases such as UniProt or RefSeq. Often times a well-curated, 
redundant database, such as the IPI databases offer a good balance between completeness 
and redundancy.
1.5.4.2. Scoring Schemes and Evaluation of Results
When MS/MS spectra are searched against a sequence database, the best scoring peptide 
assignment is returned from the database search tool with no guarantee of its 
correctness. For more accurate analysis, search results typically undergo a statistical 
analysis that is used to remove false identifications 41.
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The raw database search score is a score that indicates the degree of similarity between 
the experimental spectrum and the theoretical spectrum. However, it is important that 
these raw scores be given a statistical framework to aid in filtering out false identifications. 
Since Mascot and XiTandem is used in this thesis, the emphasis will be on this two search 
tools.
Mascot45 computes a probability-based score called an ion score. The Mascot scoring 
scheme is proprietary, but it has been described in general terms. Instead of reporting 
the number of matched peaks, Mascot estimates the probability of that number of 
matches occurring by chance given the number of peaks in the searched spectrum and 
the cumulative distribution of m lz  values of predicted ions for all candidate peptides in 
the database. For example, a matched ion that is found in many theoretical spectra, for 
example the fragment ion for lysine, does not add as much statistical weight to the score 
as a match to a much less common ion. Mascot then performs this comparison iteratively 
with more and more experimental ions, in an attempt to maximize the ion score.
On the other hand, XiTandem 46, calculates each peptide assignments by a statistical 
confidence measure called the expectation value. The scoring functions in XiTandem is 
based on the shared peak count approach, where only peaks shared between the 
experimental and theoretical spectra are counted. The process of validating peptide 
assignments to spectra is assisted by the conversion of the search scores into expectation 
values 48. A smaller expectation value means that the match is less to have occurred by 
random chance. XiTandem assumes that the highest scoring match is correct and then 
uses all the other “wrong” matches to calculate the expectation value. In practice an 
expectation value is similar to the more commonly used p value, but the expectation value 
also takes into account the number of trials. However, even with statistical based scoring, 
the best match obtained from database search tool is not necessarily correct and there
are many reasons why database tools can fail to assign correct peptide sequences to 
MS/MS spectra.
Even when the correct peptide sequence is in the database, another peptide can score 
higher than the correct one owing to deficiencies of the scoring scheme used. Scoring 
schemes implemented in the database search tools involve a simplified representation of 
the peptide ion fragmentation process. Since it is currently impossible to correctly predict 
the intensity of each fragment ion, the theoretical fragmentation spectrum sets all the 
fragment ion intensities to be the same. Furthermore in experimental spectra, the 
intensity of a fragment ion depends on the amino acids located on the sides of the 
corresponding peptide bond and fragmentation frequently fails to form between some 
bonds, resulting in drop outs from the experimental spectra and results in incorrect 
peptide matches 38.
Correct interpretation of MS/MS spectra is also dependent on spectrum quality. When a 
spectrum contains very few high intensity peaks or has missing fragment ions peaks, owing 
to poor fragmentation of the peptide, the spectra is considered low quality. Peaks from 
low quality spectra contain less information about the sequence of the peptide, they are 
more likely to result in incorrect sequence assignments. Importantly, sample preparation 
can play a key role in maximizing the number of high quality spectra4I. Another significant 
source of errors can occur when assigned peptide sequences are mapped back onto their 
proteins of origin.
1.5.4.3. Protein Inference
Identifying proteins, can be managed by grouping the peptides according to their 
corresponding proteins. There are several difficulties in assembling peptides into protein,
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principally due to distinct proteins often producing peptides that are also produced by 
other proteins.
Peptides that are correctly identified tend to group to a smaller number of proteins, as 
the digestion of most proteins produces many peptides. Furthermore, the number of 
peptides identified in a protein is correlated to its abundance in the sample and the size 
of the protein. However, the peptides that are incorrectly assigned typically do not cluster 
within a small subset of proteins and are distributed more of less randomly across the 
database49. As a result, incorrectly matched peptides cause a high error rate at the protein 
level 49 and this problem is often referred to as the protein inference problem, as the 
presence of a protein is “inferred” from the identified peptide sequences. The 
nonrandom grouping of correctly matched peptides has been used to help solve the 
protein inference problem 50.
Identification of a shared peptide, whose sequence is present in more than one entry in 
the protein sequence database, makes it difficult to infer which of these candidate proteins 
was actually present in the sample. These redundant peptide sequences are mostly due 
to the presence of homologous proteins, splicing variants, and poor annotation of the 
database 49,SI. This issue is especially important for organisms where alternative splicing 
generates many related protein sequences.
The difficulties mentioned above are addressed in the computational tool
Protein Prophet49. This program uses the nonrandom grouping of correctly assigned
peptides to help solve the protein inference problem. Peptides corresponding to single
hit proteins are penalized while peptides corresponding to multihit proteins are
rewarded. Therefore a protein identified by single peptide will only be included if the
spectral match is very high, while a protein with multiple peptide matches will include
spectral matches of much lower quality. In addition, the shared peptides are apportioned
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among all corresponding proteins, and a minimal protein list of proteins is produced that 
is sufficient to account for all observed peptides. For example, if there are 10 peptides 
that map to 2 variants of actin, and a-actin accounts for 9 of these peptides and p-actin 
includes all 10 peptides, then only p-actin will be included in the final list. The output file 
includes a list of proteins, their computed probabilities, the matching peptides, and any 
annotations coming from the searched protein sequence database. ProteinProphet is a 
powerful way to remove incorrect peptide and protein assignments and has been 
integrated into a number of other tools, including those used for quantitative analysis such 
as XPRESS 52 and ProteolQ S3. With these programs, relative protein abundance ratios 
can be obtained in case of quantitative proteomics experiments are performed with ICAT, 
SI LAC or similar techniques. Importantly the quantitative data can also be used to help 
solve the protein inference problem, as the relative abundance of a peptide can be used 
to map it back to the correct protein, because all the peptides from that protein should 
have a similar quantitative value.
Quantification of the proteins in a sample is important, because most biological process 
are not regulated by the presence or absence of a protein, but based on its specific activity 
or concentration in the sample.
1.6. Quantification of Proteins
One of the goals of proteomics is the identification of proteins in given sample. While 
proteomics is often used in these qualitative studies, there is also a growing need to be 
able to quantitate the protein levels. Quantitative proteomics is often considered more 
complex than the qualitative identification of proteins, but quantitation is required in 
order to understand the kinetics and biological mechanisms of most normal and 
pathological processes.
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There are many approaches for protein quantification. For example, ELISAs and 
radioisotopes, and even western blotting have been used for quantification. Despite the 
high sensitivity of these approaches, they cannot be used for high throughput studies.
However, MS has become the default method when the quantification of many proteins 
is required. Importantly, MS can be coupled to many types of quantification schemes. For 
example, MS can be used to identify proteins, while the quantification can be performed 
in-gel by measuring the color intensity after fixation of dyes to the protein. In much the 
same way that radioactive isotopes have traditionally been used for quantitation, mass 
spectrometry allows for quantitation to be performed by labeling with stable, non­
radioactive isotopes 54. In addition to these labeling approaches, it is also possible to 
perform MS based quantitation in a label free manner (Figure 1.9.). Each approach has 
some advantages and disadvantages and these will be discussed in the next sections.
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Figure 1.9. Diagram of different quantitative workflows in proteomics 2SS. MS can be used to  
quantitate proteins using label free approaches, such as peak counting, or labeled approaches, such as 
SILAC, where stable isotopes are used to track how much of each peptide comes from each sample. In 
addition, targeted approaches such as MRM are used when the proteins to be quantitated are already 
known. This is typically used in biomarker workflows or when absolute quantification is required. Almost 
all these techniques use Data Dependent Acquisition (D D A ) where the precursor scans are used to  
determine further analysis.
1.6 .1. Gel-based Quantification of Proteins
Gel-based quantification involves electrophoresis 5S. Gel electrophoresis fo r proteomics 
involves a porous polyacrylamide medium where proteins migrate according to  the ir 
physicochemical properties under the influence of electric fields 5S. The proteins can be 
separated via different properties, fo r example separation based on size is the most 
commonly used technique.
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Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is the most 
used. The tris-glycine discontinuous buffer system, originally perfected by Laemmli, is still 
in widespread use S6. In this technique, SDS binds non-covalently to the proteins and 
simultaneously denatures them and normalizes their charge state S7. Therefore, the 
proteins act like they have identical charge and shape, and their electrophoretic mobility 
principally depends on their molecular mass.
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) separates proteins by 
two successive rounds of electrophoresis: the first round separates the proteins based 
on their isoelectric points, as they stop moving in the gel when they obtain a net neutral 
charge and the second round uses SDS-PAGE to separate the proteins by their molecular 
mass. Since 2D separation has a better resolving power than ID, it has been classically 
used for the quantification and identification of proteins from complex samples 58.
1.6 .1. 1. Staining of Proteins for Gel-Based Quantification
The protein spots or bands can be detected after electrophoresis by direct in-gel staining 
59. Commassie brilliant blue and silver nitrate, are two of the most commonly used protein 
stains, but fluorescence based dyes are also available. Importantly, the fluorescent based 
dyes can be customized in unique ways, such as for the detection of glycosylation or 
phosphorylation.
Proteins can also be stained prior to electrophoresis. This system is used in the 
‘Difference gel electrophoresis’ (DIGE) method that needs only one gel to detect and 
quantitate three samples labeled with three different fluorescent dyes 60. However, not 
all fluorescent dyes can be used in this approach, as the dyes can change the mobility of 
the proteins on the gel. Typically fluorescent stained proteins are detected with digital 
imaging and then quantitated using specific software tools.
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1.6.1.2. Advantages and Limits of In-gel Quantification
Gel based methods typically produce a stable image of the protein pattern, which should 
be reproducible. Importantly, the proteins are stabilized by being encapsulated in the gel 
matrix, allowing for both protein diversity and PTMs to be preserved so they are available 
for further studies, such as MS. One of the principle problems with gel-based approaches 
is that they typically require many repeats due to the variability between gels. This is also 
compounded by other problems, such as protein overlap, and the need to process many 
spots or bands for mass spectrometry, as there is little value in seeing a change in 
abundance on a gel without a corresponding protein identification. Even when a large 
number of spots are identified, the total number of proteins identified is much lower than 
expected, because proteins typically run as multiple spots in 2D gel systems.
1.6.2. Gel-free Quantification of Proteins (Peptide-based Quantification)
Peptide-based quantifications by MS are widely used in proteomics. In this approach, 
proteins in a sample are digested enzymatically and the resulting mixture of peptides are 
separated and subsequently analyzed by MS. This approach actually increases the sample 
complexity, because single proteins are converted into many peptides via enzymatic 
digestion. To deal with this problem, fractionation of the proteins or peptides is 
performed. The complexity can also be reduced by subcellular fractionation 37.
Once the sample has been appropriately prepared, peptide-based quantification of 
proteins can be carried out by MS. Two approaches are generally used: label-free 
quantification or labeled quantification. A variety of quantitative information can be used 
for label-free quantification. For example, the relative abundance of a peptide can be 
determined by comparing the peak area during LC-MS. For example, the SILAC data
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shown in Figure 1.9 is used for relative quantification. The peak areas for the heavy (shown 
in red) and light (shown in blue) isotopes are compared.
In labeled quantification, stable isotopes are used to mark which sample a peptide came 
from. In this case, the peptides are chemically identical, but the mass shifts caused by the 
isotopes allows them to be discriminated in a MS. Several different stable isotope labeling 
techniques have been developed such as: lsO incorporation, Stable Isotope Labeling with 
Amino acids in Cell culture (SILAC), Isotope-Coded Affinity Tags (ICAT), Isobaric Tags 
for Relative and Absolute Quantification (iTRAQ) etc. These techniques have different 
advantages and disadvantages and they can be used for different types of experiments. 
Stable isotopes labeling can be used for both relative and absolute quantification methods 
in proteomic studies. I will mostly focus on relative quantification methods since they are 
related to my work.
1.6 .2 .1. Label-Free Quantification
Label-free quantification is used to determine the relative amount of proteins in two or 
more samples. Label-free quantification methods can be mainly divided into two 
categories; spectral counting and signal intensity measurements.
1.6 .2 .1.1. Relative Q uantitation by Peak Intensity (MS-signal Intensity)
Peak intensity is based on the integrated measurement of chromatographic peak areas for 
any given peptide in an LC-MS runs. Importantly, the measured peak intensity is 
proportional to the concentration of the measured peptide 6I. After the sample has been 
analyzed and peptides identified, the ion chromatograms for every identified peptide are 
extracted from the LC-MS/MS run and their peak areas are integrated over the 
chromatographic time scale 62. These extracted ion chromatograms (XIC) are used to
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determine the relative abundance of each peptide. The measurement is basically done by 
comparing peak areas for the same peptide in different samples. However, peak areas are 
compared only if they fall within the same m/z and retention time windows. Quantification 
is based on the MS-response of the precursor ion. Therefore it is important that the same 
peptide is identified in every run, otherwise the quantification becomes inaccurate.
The main problem of this approach is the experimental variations between samples. Since 
each sample and replicate is processed and run independently, even small technical errors 
can affect the resulting MS-signal intensities of peptides. Normalization with internal 
standards and/or normalization coefficients are typically used to correct for these errors 
and provide accurate quantification.
1.6 .2 .1.2. Relative Quantitation by Spectral Counting
Spectral counting is based on the idea that the number of peptides sequenced for a given 
protein is correlated to its quantity. Accordingly, quantification involves comparing the 
number of identified spectra of the same protein in different samples 63. This method 
requires proteins to be identified by a sufficient number of spectra to be accurately 
quantitated. In this approach, the more abundant proteins produce more MS/MS data than 
the less abundant ones, so more abundant proteins are sample more frequently by the 
MS than low abundance peptides. Therefore, this method favors the quantification of the 
higher abundance proteins, while the quantification of low abundance proteins can be 
problematic, especially if the identification is based on only one or two spectra.
In contrast to peak intensity methods, which requires specialized algorithms to align and 
compare LC-MS peaks, no specific tools or algorithms are needed for spectral counting 
due to its easy implementation. The data is typically normalized to the number of peptides 
a protein produces 64. Since large proteins tend to contribute more spectra (since they
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have more peptides) than small proteins, a normalized spectral abundance factor (NSAF) 
is used to account for the effect of large proteins on spectral count. Furthermore, an 
additional step of normalization to the total number of spectra identified in sample is also 
frequently used to normalize for technical errors that effect the overall quality of the 
whole data set64.
The disadvantages are very similar to label free quantitation based on ion intensity 
measurements. Since each sample is run separately, sample to sample variability needs to 
be addressed, and similarly to the ion intensity based studies, internal standards play an 
important role.
In general, label-free techniques work really well on samples that are mostly the same, 
because large variations in the expression of many proteins, will affect the quantification 
of co-eluting peptides. This is principally due to the fact that all the peptides that enter 
the mass spectrometer at the same time are competing to be ionized and for mass 
spectrometer acquisition time. For example, the loss of a highly abundant peptide will 
result in new peptides being selected for MS/MS. Over the course of a run this is usually 
not an issue so long the samples being compared are similar. Label-free techniques are 
frequently used because they do not required expensive reagents or specialized tools.
1.6.2.2. Labeled Quantification
Labeled quantification involves the incorporation of stable isotopes into the sample. The 
isotope labeling takes advantage of the fact that the same peptide, which has incorporated 
different isotopes will be chemically identical, but will have different masses due to the 
presence of heavy isotopes in one of the peptides. This allows samples labeled with 
different stable isotopes to be mixed together and analyzed in the same LC-MS/MS run. 
The two samples will undergo the exact same separation, the exact same competition for
ionization, have the exact same chance to be acquired for MS/MS etc. The relative amount 
of each peptide in each sample is detected in the spectra because there will be a 
characteristic mass shift depending on the isotopes used.
Labeling techniques can be divided into three groups; metabolic, chemical or enzymatic. 
Metabolic labeling involves labeling in vivo during growth by adding isotope labeled amino 
acids in cell culture medium or in food. On the other hand, the chemical approach usually 
involves covalently labeling the proteins after they are extracted from the cells. Finally, 
the enzymatic labeling is performed during enzymatic digestion. Any stable isotope (heavy) 
can be used as tags, such as carbon-13 (l3C), oxygen-18 (l8-0 ), nitrogen-15 ( ISN) or 
deuterium (2H). The naturally occurring light isotopes for these elements are: l2C, 'H, 
l4N, l60  6S. However, the elements that are not commonly found in proteins typically are 
not used for metabolic labeling.
1.6.2.2.1. Chemical Labeling
In the chemical labeling approach, the sample is not limited to living systems, and it is 
applicable to all types of biological samples. Chemical or enzymatic labeling can be 
performed using a variety of isotopically labeled chemicals which are covalently attached 
to the proteins or peptides. Typically the amino, carboxyl, or sulfhydryl groups in proteins 
are targeted for labeling.
Labeling of the amino groups is based on the idea that, proteins can be covalently labeled 
on the amines found at the N-terminus of peptides and on the side chains of lysine and 
arginine. These amines are typically targeted because the chemistry involved is typically 
robust and specific. The isotope<oded protein label (ICPL) and the iTRAQ labeling approach 
both involve the labeling of amino groups and both can be used for multiplex (comparing 
4 to 8 samples at a time) analysis by varying the number of stable isotopes in the chemical
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label66. iTRAQ labeling has the added advantage of being isobaric. In this case the overall 
mass of the label is the same for all isotope forms, as it contains an isotope labeled group 
and a balancer group. The isotopically labeled group is only detected when it is split off 
from the balancer during MS/MS acquisition and this allows for multiplexing without 
increasing the complexity of the sample 67.
Besides labeling amino groups, labeling of the thiol groups in cysteines is also commonly 
used, and can also be used to reduce sample complexity. Since it is related to my work, I 
will describe a specific method where thiol groups are tagged, ICAT.
1.6.2.2.1. 1. Isotope Coded Affinity Tags (IC A T )
ICAT is a relative quantitation method that was introduced by Aebersold and co-workers 
in 1999 68. In this technique, the thiol groups of cysteine are labeled with either light or a 
heavy tags using a custom designed alkylating reagent.
ICAT reagents consist of three general elements: (I) a reactive group capable of labeling 
sulfhydryl groups (e.g., iodoacetamide to modify cysteine residues), (II) an isotopically 
coded linker, which can contain multiple, l2C, 'H, l3C, or 2H atoms to give an 8 Da mass 
difference, (III) and a biotin tag, which is used for the affinity isolation of labeled proteins. 
Labeling can be performed on proteins or peptides. The mass shift observed in the mass 
spectra depends on the linker. A linker with 8 hydrogen/deuterium would give a ~8 Da 
mass difference.
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For the quantitative comparison, one sample is labeled w ith an isotopically light probe 
and the other w ith an isotopically heavy probe. A fte r labeling, the samples are combined, 
digested with a protease and subjected to  avidin affinity chromatography to  enrich fo r the 
labeled cysteine containing peptides (Figure 1.10). These peptides are then analyzed by 
LC-MS/MS 69. In the same mass spectra, the peptide pairs are seen as doublets and the ir 
relative intensity reflects the relative abundance of the corresponding protein in both 
samples.
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Figure 1.10. W orkflow for IC A T  experiments 2S6. ICAT involves the chemical labeling of cysteine 
residues with an isotopically coded affinity tag. The cysteine containing peptides are purified using the tag 
and then analyzed by MS. The peak intensities of the isotope pairs (48) are used for relative quantification.
The principle advantage of ICAT is that, it only labels a subset o f peptides, in this case 
peptides w ith cysteine residues, which results in reduced sample complexity and 
potentially more protein identifications. However, these advantages are offset by a 
number of disadvantages. First of all, cysteine is a relatively rare amino acid. Since most
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proteins have only I or 2 cysteines, quantitative data becomes weak due to lower 
sequence coverage. Moreover, there are many intervening steps between cell lysis and 
sample mixing and these steps invariably result in systematic errors being introduced 
between the samples.
One of the experimental steps involves the use of Biotin: Avidin affinity chromatography. 
Although this step is performed after sample mixing, it creates a variety of problems. The 
strength of this interaction results in significant sample losses, which greatly affects 
sensitivity and naturally occurring biotinylated peptides also interfere with analysis. 
Several techniques have been improved for removal of biotin tags such as using acid- 
cleavable and photocleavable biotin tags 70,71. However, ICAT has been supplanted by 
other methods, primarily because, even with these improvements, the workflow is too 
labor intensive.
1.6.2.2.2. Enzymatic Labeling
lsO-labeling, which is also known as Enzyme Mediated Oxygen Substitution (EMOS), is 
the principle form of enzymatic labeling. This labeling is performed during enzymatic 
digestion by performing the digestion in lsO  labeled water. Digestion with trypsin results 
in the incorporation of one or two lsO at the C-terminus of the peptide. The presence 
of one or two labels at the end complicates the analysis and even with two labels of lsO, 
many mass spectrometers do not have the resolution to completely separate the isotopic 
peaks from multiply charged peptides 72.
1.6.2.2.3. Metabolic Labeling
Metabolic labeling of peptides has a long history. Although, the incorporation rate of 
radioactive isotopes is typically rather low, the incorporated radioactivity can be detected
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with great sensitivity, especially when the sample is separated by ID  or 2D gel 
electrophoresis 73. However, coupling isotope labeling to MS detection and quantification, 
the rate of isotope incorporation becomes a critically important factor.
There have been a limited set of studies where the precursor for metabolic labeling is not 
an amino acid. For example, using metabolites such as ( l3C)-glucose or ( l5N)H4CI as the 
carbon and nitrogen sources. This type of labeling will incorporate a variable number of 
atoms depending on the length of the peptide and the number of specific atoms that each 
peptide. As a result, due to the lack of uniformity, data analysis is quite complex. However, 
using isotopically labeled amino acids as a metabolic precursor is much more 
straightforward and reproducible.
As stable isotope labeling techniques developed, new names have been used such as, 
stable isotope labeling with amino acids (SILAA) and stable isotope labeling with amino 
acids in cell culture (SILAC) 74. These labeling techniques use the metabolic activity of 
living cells to incorporate stable isotopes and can be applied to tissue culture cells or even 
living plants and animals. However, metabolic labeling of tissue culture cells is typically 
used for quantitative proteomics as labeling whole organisms is typically too expensive. 
The mass shifts produced by the labeled amino acids can be carefully selected and it is 
even possible to multiplex as amino acids with differing numbers of isotopes can be 
selected. In addition to quantification of protein levels, SILAC has been adapted for other 
purposes, including monitoring post translational modification, such as acetylation.
1.6.2.2.3.1. Stable Isotope Labeling with Am ino Acids in Cell C ulture (S ILA C )
SILAC is a widely used quantitation technique for mass spectrometry studies because it 
is a relatively simple and straight forward approach for MS based quantitative proteomics
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7S. SILAC utilizes the metabolic incorporation of a ‘heavy’ or a ‘light’ version of specific 
amino acids into proteins.
In the SILAC method, the metabolic labeling is performed during protein synthesis in living 
cells, and growth medium is prepared where natural (‘light’) amino acids are replaced by 
‘heavy’ SILAC amino acids (Figure 1. 11.). After a number of cell divisions, the label 
becomes incorporated to a very high extent, as cell division and protein turnover depletes 
the non-isotopically labeled precursors from the sample. Like other stable isotope labeling 
techniques, SILAC results in the production of two chemically identical groups, which can 
be separated by the presence of either heavy or light isotopes. The cells grown in the 
two different media are combined and further treated as a single sample. Since one sample 
contains light isotopes and the other contains heavy isotopes, the relative amount of 
proteins is determined by the ratio of the signal intensities of peptide pairs (light and 
heavy).
Once the metabolic incorporation is complete, either the heavy or light enriched group 
can be perturbed and allowed to recover and then the two groups are combined prior 
to cell lysis. The early mixing of the two samples minimizes the systematic errors that 
often creep into quantitative experiments. The mixed sample is digested with a protease 
and then analyzed by mass spectrometry. Mass difference from the stable isotope labeling 
amino acids are measured. Typically peak areas from the precursor mass of heavy and 
light peptide are used to perform the quantification 76. Changes in protein level between 
the two groups are indicative of the cellular response to the perturbation.
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In principle, any amino acid can be used fo r metabolic labeling. However, all the amino 
acids should be abundant in the medium to  avoid de novo amino acid synthesis in cells, 
which can scramble the isotope labeling 11. Leucine, lysine, tyrosine and arginine are the 
most used amino acids fo r SILAC 11. A  double labeling, using Arg/Lys ( l2C6/ l3C6- 
arginine/l2C6/ l3C6-lysine) is frequently used, because all of the peptides in a sample can be 
labeled if trypsin is used fo r the digestion.
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Figure 1.11. W orkflow  for SILAC experiments 78. Cultures are grown in the presence or absence 
of isotopically labeled amino acids and then combined. Following sample preparation and analysis by mass 
spectrometry, the peak intensities for the isotope pairs are used for relative quantification.
1.6.2.2.3.1. 1. Adaptations of SILAC
Comparative proteomics is the most common application of stable isotope metabolic 
labelling. However SILAC can be used fo r different studies such as, quantification o f PTMs 
and measurement o f protein turnover rates.
The study and quantification o f PTMs can be performed w ith isotope labeling using tw o  
different strategies: by labeling the peptide o r by labeling the PTM. The firs t approach 
involves stable isotope labeling all of the peptides and purification of the peptides carrying
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PTM of interest. The PTM itself is not labeled in this category. The second approach 
involves direct targeting of PTM and their replacement by reporter group 79. However, 
direct labeling of PTM is distinct from strategies for labeling proteins or peptides.
The use of SILAC for quantification of several protein modifications was demonstrated in 
several studies. One of them is heavy methyl SILAC. This method allows identification 
and simultaneous quantification of protein methylation sites, by labeling the peptide. In 
this method, since quantification in SILAC is based on individual peptides, site-specific 
quantification of protein methylation is achieved by determining the intensity ratios of 
methylated peptide pairs. These ratios can be normalized against the protein ratio 
obtained from unmethylated SILAC-labeled peptides 80.
The SILAC approach also used for more comprehensive analysis of several protein 
modifications. One group studied the dynamics of histone modifications such as, 
acetylation, methylation and phosphorylation, throughout the cell cycle81. Another group 
used SILAC coupled to a histone peptide pull-down approach to screen specific 
interactors of histone H3 trimethylated on Lys-4 (H3K4me3). Same group used triple 
SILAC pull-down assays to further analyze these interactions 82.
The SILAC approach was also used for Sirt3-regulated acetylome analysis 83. Acetylated 
peptides were enriched from the sample by pull-down assays and SILAC ratios were 
determined. The SILAC technique was also used in several other studies for mapping the 
acetylation sites 84,8S.
Ubiquitination studies are another area where SILAC approaches have been used. Large 
scale quantification of ubiquitination sites using SILAC has the advantage of simultaneously 
identifying and quantifying site specific ubiquitination 86. Quantitative analysis of
59
ubiquitination has also been studied in HeLa cells by using tandem affinity purification of 
ubiquitinated proteins from cell lysates 87.
Another PTM study that can be done with SILAC approach is the analysis of 
phosphorylation. Phosphopeptides are enriched using immobilized metals or metal oxides 
(IMAC, MAOC) or using antibodies and the sites of phosphorylation were quantified by 
amino acid labeling using SILAC 88. In this case, there is only one stable isotope for 
phosphorous, so it is impossible to directly target the PTM.
SILAC can also be used for in vivo animal experiments 89,90 and it is known as stable isotope 
labeling of mammals (SILAM). This is performed with a diet that is composed of stable 
isotope-enriched proteins. Although, this ensures that all the cells from these animals will 
contain labeled proteins, the procedure is lengthy, since it requires at least two 
generations of labeling, and is quite expensive. The TTMSILAC technique was introduced 
to help overcome the expense of SILAM 9I. This method involves adding a mixture of 
lysates from several different SILAC labeled cell lines as an internal standard to the 
samples to be quantitated. It has mostly been used for comparison of cell lines to patient 
tumor samples.
In the "culture-derived isotope tags’ technique which derived from SILAC 92, a labeled 
internal standard is used for quantifying the proteome of a given tissue. This enables using 
SILAC to quantify changes in samples that are too difficult to label, such as in human tissue 
samples.
These studies show that metabolic labeling approaches, especially those based on SILAC 
are a powerful tools to qualitatively and quantitatively study complex proteomes.
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1.6.2.2.3.1.2. Advantages and Limits of SILAC
SILAC has several important advantages. SILAC labeling is very efficient and the 
downstream sample processing and mass spectrometry protocols are virtually identical 
to standard, non-quantitative workflows. Up to five different cellular states can be 
compared using a multiplex SILAC-based strategy 93. However, due to the nature of the 
isotope labeling, SILAC greatly increases the complexity of the sample entering the MS. 
The increased sample complexity may result in fewer overall protein identifications, 
especially when multiplexed.
Although, SILAC increases the sample complexity relative to label-free methods, the 
quantification is particularly accurate. This is largely due to the early mixing of the samples 
and the relatively straightforward sample processing steps.
1.7. The Novel Hybrid Method
In this thesis, I aimed to develop and evaluate a method for mass spectrometry based 
proteomics. The main goals were to improve the rate of protein identification and 
quantification.
The first step in my project was to develop a hybrid quantification protocol that has the 
advantages of both SILAC and ICAT. The hybrid approach I developed uses classical 
SILAC labeling coupled to a “novel” scheme for enriching cysteine containing peptides. 
This enrichment step resembles ICAT since cysteine and cystines are targeted for 
modification and enrichment. In the hybrid protocol I developed (Figure 1.12.), this 
modification involves oxidizing the cysteine/cystine residues to cysteic acid and selective 
enrichment of these peptides based on the properties of cysteic acid. In brief, I aimed to
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integrate the advantages of these tw o  techniques into one simple, straightforward 
technique.
Cells
1 SILAC
Labelling and Mixing
Enrichment of cysteic acid peptides
Mixed M ode Exchange Column
Cysteic Acid Oxidation O H
Cysteine -----> Cysteic Acid
/
Mass Spectrometry Analysis
1
A -L -M -C -C -E -T -Q -N -K -C  
S uper negative p art
Data Analysis
Figure 1.12. W orkflow  of Hybrid Method. The various steps of the hybrid workflow are shown.
For cysteic acid enrichment, I adapted a chromatographic technique called, ‘Electrostatic 
Repulsion and hydrophilic Interaction Chromatography’ (ERLIC). ERLIC affords 
convenient separations of highly charged peptides that cannot readily be resolved by o ther 
means. There are tw o  different modes fo r performing ERLIC. It can be used w ith cation 
exchange columns (PolySULFOETHYL A  o r PolyCAT A) fo r positively charged analytes 
o r it can be used with anion exchange columns (PolyW AX LP) fo r negatively charged 
analytes, such as cysteic acid containing peptides. ERLIC chromatography is based on 
superimposing electrostatic effects on hydrophilic interactions and this selects o r de­
selects fo r specific functional groups. Therefore, the influence of ionic groups can either 
be minimized o r maximized, thereby altering the degree of retention. Ideally, in the hybrid 
method only peptides with cysteic acid will strongly interact w ith the positive surface of 
the resin, resulting in a quick and efficient enrichment of cysteic acid containing peptides 
(Figure 1.13.).
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Figure 1.13. The selection of cysteine containing peptides with PolyW A X LP column by 
ERLIC chromatography. ERLIC chromatography can be used to select for certain peptides, and in 
this case positive charges are being repelled.
1.7.1. Advantages and Limits of Hybrid Method
The Hybrid technique uses the classical SILAC technique, coupled to  a novel scheme fo r 
enriching cysteine containing peptides. Hence, the hybrid technique possesses all the 
advantages of the SILAC technique itself.
On the other hand, since ICAT only labels approximately 2-5% of the peptides, it is 
reducing the sample complexity. However, instead of the complex chemistry o f the ICAT 
reagents, I am using a much more streamlined chemistry, where perform ic acid is used to  
convert cysteine and cystine into cysteic acid. This results in the creation o f a “ super 
negative”  side chain that can be used fo r selective enrichment o f these peptides (Figure 
1.12.). As a result, I get the ease of labeling and enhanced quantitative performance of 
SILAC protocols with that added benefit of the reduction in sample complexity by 
cysteine enrichment as seen w ith ICAT protocols. Moreover, while ICAT uses only 
cysteine-containing peptides fo r quantification, the unbound peptides from  the ERLIC 
chromatography can be collected, analyzed and quantitated. Since, the hybrid method
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uses all the fractions (cysteine-containing peptides, and the others), it quantitates a much 
larger set of peptides and proteins.
The initial optimization and eventually was performed using BSA. BSA contains 35 cysteine 
residues out of some 580 total residues, or roughly means nearly 6% of BSA is cysteine 
residues, which makes it ideal protein for these optimizations. After the development of 
method is finish, I moved the second part of the thesis.
In the second part of my study, I used the hybrid protocol I developed, to study a 
biological system. I decided to use my protocol to study the effects of a cancer therapeutic 
compound, sirtinol, on a tumor cell line. Chemically induced models are easy to 
reproduce and reproducibility is an important factor for proteomic studies, especially 
when evaluating new protocols. Importantly, sirtinol is able to induce senescence in many 
tumor cell lines, and this system should also provide insights into cellular senescence and 
therapeutic compounds that activate this response.
1.8. Pharmacological Induction of Senescence as a Cancer Therapy
Cancer is one of the most important causes of death around the world. A number of 
human malignancies can be cured with current therapies and prolonged survival can be 
obtained. However, there are many situations where current therapeutic approaches are 
not sufficient, thus there is still a great need for preclinical studies and further drug 
development.
A promising approach for cancer treatment is permanently disabling the proliferative 
capacity of cancer cells without inducing the cell death. This can be achieved by therapy- 
induced senescence. It has been more than a decade since it was initially suggested that 
cellular senescence may be one of the mechanisms by which cancer chemotherapy drugs
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work in vivo 98. Many chemotherapeutic agents cause DNA damage and induce 
senescence in normal cells. Interestingly, it has been shown that they can also induce 
senescence in tumor cells. Anticancer chemotherapeutic agents and ionizing radiation 
have also been shown to induce senescence-like growth arrest in human cancer cell in 
vitro and in vivo 94_97. The induction of senescence was verified by the induction of SA-0- 
gal staining in vivo in rodents 95,98,99. Moreover, it has been observed in patients with breast 
cancer96.
Genetic abnormalities are one of the major hallmarks of cancer. However, studies over 
the past decades indicate that epigenetic regulation is also involved in the development of 
cancer. DNA methylation and histone modifications are the major epigenetic factors that 
are frequently altered in tumor cells. Acetylation of histones is controlled by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are a group of 
enzymes that catalyze the removal of acetyl groups from both histone and non-histone 
proteins. They are involved in modulating many key cellular processes such as 
transcriptional regulation, DNA damage repair, apoptosis, cell cycle progression, 
metabolism and senescence.
The functional activity of the HDACs varies depending on their structure and intercellular 
localizations. There are four classes of HDAC. Class III HDACs are more generally called 
sirtuins, which were named after the yeast gene ‘silent mating-type information regulation 
2 \  In mammalian systems, sirtuins are divided into five subclasses which have different 
enzymatic activities. Sirtuins have been shown to be the master regulators of cellular 
senescence100.
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Currently, histone deacetylase (HDAC) inhibitors are under intensive investigation as 
cancer therapeutics, since they have shown promising effects for various cancers. A major 
barrier for HDAC inhibitors is that they have cytotoxic effects on normal host cells 101.
In this thesis, I used a SIRTI-specific HDAC inhibitor, sirtinol, to treat H1299 cancer cells. 
Importantly, sirtinol induces a senescent-like growth arrest in these cells. Since 
senescence is a potential tumor suppressor mechanism, sirtinol is a promising drug 
candidate. However, the aim of this study was mostly elucidating the proteome changes 
in response to sirtinol, rather than characterizing its efficacy as a cancer therapeutic drug. 
My work will give a better understanding of the mode of action of sirtinol, as well as 
revealing the long-term biological responses to sirtinol treatment.
The causes of senescence and its relationship with cancer will be explained broadly in the 
next sections.
1.8 .1. W h a t is Cellular Senescence?
Cellular senescence was originally defined as ‘irreversible cell cycle arrest’ caused by 
‘replicative exhaustion’ in human diploid fibroblasts (HDFs) l02. Experiments showed that 
fibroblast in culture divide robustly when first placed in culture. However, after many cell 
doublings, their proliferation rate declined l02. This suggested that all cells in culture lose 
the ability to divide, even when provided with enough space and nutrients. This led to 
two important hypothesis about senescence. The first hypothesis was that senescence 
could be an anti-cancer or a tumor-suppressive mechanism, since many cancer cells 
proliferate indefinitely in cell culture l03. In this respect, senescence is considered 
beneficial for an organism, since it puts an end to proliferation of cancer cells. The second 
hypothesis, on the other hand, considered senescence a deleterious response, based on 
the fact that tissue regeneration and repair deteriorates with age and is correlated with
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an increase in senescence. However, it is clear that many types of stimuli can induce 
senescence such as, DNA damage, oncogene activation, and physiological stress.
1.8.2. Characteristics of Senescent Cells
In multicellular organisms, such as mammals, there is typically a mix of both mitotic and 
post-mitotic cells. There are some characteristics of senescent cells that can be used to 
discriminate them from normal post-mitotic cells. Irreversible growth arrest, resistance 
to apoptosis and altered gene expression are the major hallmarks of the cellular 
senescence.
Growth arrest is the main hallmark of the cellular senescence. Although mitotic cells can 
proliferate, they can also be in a state which called ‘quiescence,’ or GO, where they 
reversibly stop dividing. Quiescent cells can start dividing in response to appropriate 
signals. On the other hand, post-mitotic cells (i.e. neurons, myoblast and osteocytes) and 
senescent cells permanently stop dividing. Senescent cells usually have a DNA content 
that is typical of GI phase, but they remain metabolically active. Once a mitotic cell enters 
senescent growth arrest, it cannot start DNA replication, even in adequate growth 
conditions. This replication failure is primarily caused by the expression of cell-cycle 
inhibitors.
Together with growth arrest, senescent cells undergo a morphological change and are 
generally enlarged, often doubled in volume and they adopt a flattened morphology. 
Histochemical staining for senescence-associated Beta-galactosidase (SA-pgal) is a 
commonly used marker for senescent cells l04. The SA- |3gal activity is produced by the 
lysosomal {3-galactosidase, which reflects the elevated lysosomal biogenesis that 
frequently occurs in senescent cells l0S.
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Another characteristic of senescent cells is the resistance to apoptosis. Apoptosis is a 
process of programmed cell death, which occurs in many organisms. Like senescence, 
apoptosis is an extreme response to cellular stress and it is considered one of the most 
important tumor-suppressive mechanisms. However, while senescence prevents the 
growth of stressed or damaged cells, the cells remain metabolically active, while apoptosis 
completely eliminates the cells l06. Interestingly many senescent cells are resistant to 
apoptotic signals. For example, senescent human fibroblast resist apoptosis caused by 
oxidative stress and growth factor deprivation l07, however they do not resist apoptosis 
caused by the Fas death receptor l08. This resistance to cell death of helps explain why 
the number of senescent cells increases with age and why they are so stable in culture.
Another feature of senescent cells is altered gene expression, including the genes for cell- 
cyde inhibitors or activators l09. In senescence cells, the levels of cell cycle inhibitors 
increases and the genes promoting cell cycle progression decrease. For example, the 
expression of the tumor suppressor protein pi 6 is low in most normal cells, it is readily 
detectable in senescent cells M0. Moreover, it is interesting that many gene expression 
changes do not seem related to growth arrest but they are mostly related to changes in 
the micro-environmental state of the tissue m. For example, senescent fibroblast 
overexpress proteins that remodel the extracellular matrix. Given the fact senescent cells 
increase with age, it is possible that they might be responsible for the age dependent 
alterations in tissue structure and function.
Some senescent cells can also be identified by the presence of senescence-associated 
DNA-damage foci (SDFs) ll2_l14. SDFs are present in senescent cells (both human and 
mouse cells) and contain proteins that are associated with DNA damage, such as 
phosphorylated histone H2AX and p53-binding protein-1.
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Senescence-associated heterochromatin foci (SAHFs) are also considered to be a 
cytological marker for senescence. SAHFs preferentially bind to DNA dyes such as DAPI. 
However, since pericentromeric foci in mouse cells are much more prominent than in 
human cells, they can be mistaken for SAHFs.
1.8.3. Senescence-Associated Secretory Phenotype (SASP)
SASP is the final feature of senescent cells. This feature is considered important since it 
explains the role of cellular senescence in organismal aging lll,Ms. SASP components 
include growth factors, proteases, cytokines and chemokines IIUI6. There are a myriad of 
biological activities associated with this phenotype. Some SASP factors are known to be 
beneficial for senescent cells, while others have deleterious effects.
SASP, together with its biological activities, can be considered a very complex system. In 
some situations, depending on the physiological context, SASP can stimulate or inhibit 
W N T  signaling and cell proliferation. Chronic W N T  signaling can cause senescence in 
both differentiated cells and in stem cells ,l7.
Related to senescence and age-associated diseases, SASP factors such as IL-6, IL-7, MCPs 
(monocyte chemoattractant proteins), and MIPs (macrophage inflammatory proteins) 
directly and indirectly promote inflammation. Secretion of these proteins is assumed to 
cause chronic inflammation locally and perhaps systematically "6. It’s known that chronic 
inflammation is involved in many age-related, degenerative and hyperplastic diseases ll8.
1.8 .3 .1. W h a t Causes SASP
Normal cells that senesce due to overexpression of p21 or p 16INK4A do not express SASP, 
but they go under growth arrest and show other characteristics of senescent cells. 
However, if the cells senesce due to DNA damage, dysfunctional telomeres, epigenetic
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disruption, oxidative stress, mitogenic signals and other senescence inducers, they 
develop SASP of varying types ,l9. The function of SASP may be for communication with 
neighboring cells to prepare the tissue for repair or to aid in the clearance of damaged 
cells by the immune system.
Many of the SASP components are positively regulated by DDR proteins such as ATM 
and CHK2 (checkpoint kinase 2) l20121. These proteins activate p53, which normally acts 
to restrain the SASP. It should be noted that DDR induces SASP, only when it is 
persistent. How DDR signaling promotes the expression of SASP components is not very 
well known.
1.8.4. Causes o f Cellular Senescence
There can be many triggers for senescence such as dysfunctional telomeres, DNA- 
damage, chromatin perturbation and stress. Regardless of the type of trigger, the 
establishment of the senescent phenotype requires different effectors, but once 
established the phenotype is remarkably similar. For example, replicative senescence 
corresponds to a response to modest but long-term exposure of cells to the stress that 
occurs from many rounds of proliferation, while oncogene-induced senescence is a more 
acute and dynamic process. How these different conditions trigger similar pathways 
involved in senescence is a matter of great interest (Figure 1. 14.).
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Figure 1.14. Different factors that can trigger senescence.
1.8.4.1. Telom ere-dependent Senescence
Telomeres have a major role in cellular senescence and the shortening of telomere puts 
a lim it to  cellular replicative capacity. Telomere shortening was one of the firs t causes fo r 
the cessation of cell proliferation l22,123. Normal cells typically lack the enzyme, telomerase, 
which functions to  lengthen the telomere after each round of cell division. In the absence 
of telomerase, the telomere get successively shorter. W hen telomeres become 
sufficiently short, cells enter in a growth arrest called senescence. However this situation 
only applies normal cells. Telomerase is often found in cells w ith a larger replicative 
potential, such as stem cells, reproductive cells, and cancer cells l24. This places a lim itation 
on the cellular renewal of most tissues and telomere shortening is believed to  a major 
contribu tor to  the aging phenotype.
Telomeres consist o f repetitive nucleotide sequences (5’TTAG GG -3’ in vertebrates) and 
these repeats are associated with proteins that form  a chromatid cap that stabilize the 
end of the chromosomes. The chromatid cap protect chromosomes from  degradation
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and fusion with neighboring chromosomes 12s. In each round of cell division, the linear 
DNA becomes shorter than its template, since DNA polymerases cannot replicate DNA  
ends completely. This phenomenon, ‘the end-replication problem’, causes 50-200 base 
pairs of telomeric DNA loss per round of replication. Since telomeres range from 10-15 
kb in humans, only a certain number of cell divisions are possible before the telomeres 
become critically short and dysfunctional.
Dysfunctional telomeres trigger a classic DNA-damage response (DDR) which enables 
cells to sense the damaged DNA, specifically as double-strand breaks (DSBs) ll2,113. 
Response to DSBs can be either to repair the damage, apoptosis or entry into cell-cycle 
arrest. Importantly, senescent cells respond to telomere shortening with a prolonged 
DDR activation. Although the severity of the damage is an important factor, how cells 
choose between transient DDR activation and the persistent DDR signaling seen in 
senescent cells is not quite clear. Moreover, it has been shown that even a few short 
telomeres are enough to trigger senescence l26,127.
Several proteins are involved in DDR, such as, protein kinases (i.e., ATM, DNA-PKcs), 
adaptor proteins, and chromatin modifiers such as histone acetylases, deacetylases, 
histone methylases and demethylases. The protein kinases, ATM and ATR are the central 
components of the checkpoint mechanisms that signal the presence of damaged DNA or 
collapsed replication forks. While the ATM/ATR system is the main double strand break 
signaling pathway, another kinase DNA-dependent protein kinase (DNA-PKcs) also 
participates DSB signaling. These kinases work together with their regulatory subunits, 
DNA repair proteins and adaptor proteins to sense the abnormal DNA structures and 
implement the appropriate DNA damage response. Most of these proteins can also be 
found in the DNA-damage foci seen in senescent cells. Moreover, chromatin modifiers
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are involved in DDR. Specific histone modifications accumulate at the sites of damaged 
DNA and facilitate the recruitment of a subset of damage response proteins. For example, 
phosphorylation of the histone variant H2A contributes the repair by recruiting the sister 
chromatid cohesion factor cohesin, which is important for efficient DSB repair l28. DNA  
damage foci also contain a subset of telomeres in dysfunctional-telomere-induced 
senescent cells, suggesting that dysfunctional telomeres resemble DSBs.
The length of telomeres can vary in different species. For instance, laboratory mice have 
very long telomeres (40-60 kb) comparing to human cells (5-15 kb) and moreover they 
express telomerase, therefore they are more resistant to senesce induced by telomere 
shortening. Human fibroblasts typically senesce due to rapidly shortening telomeres, while 
mouse fibroblast in culture typically senesce due to environmental factors. This is often 
referred as oxidative stress induced senescence.
Telomere shortening does not occur in cells that express telomerase l29. The numbers 
and types of telomerase-expressing cells vary widely between species l3°. For example, in 
mice many cells in the adult animals express telomerase, while in humans, such cells are 
rare. They are mainly, cancer cells, stem cells and some somatic cells ,3I>132.
The end replication problem can be prevented by telomerase. This enzyme adds 
telomeric DNA repeats directly to chromosome ends by using its catalytic component, 
telomerase reverse transcriptase (TERT) and a template RNA component. Cells normally 
do not express TERT or they express it at very low levels just to prevent telomere 
shortening l33. On the other hand, germ line cells and many cancer cells express TERT. It 
has been shown that ectopic TERT expression in normal human cells can prevent 
telomere shortening and the senescence caused by it. However, telomerase cannot 
prevent senescence that is triggered by other inducers l34.
1.8.4.2. DNA-dam age-initiated Senescence
Severe DNA-damage, especially damage that creates DSBs, causes many cell types to 
undergo senescence l3S I36. Both DNA-damage and telomere initiated senescence depend 
on p53 and usually involves p2l expression ll3,114. However, in many cells, p 16 can also 
induce cell cycle arrest caused by DNA damage or telomere dysfunction l37>138.
DSBs are very strong inducers of senescence. It has been shown that even a single 
unresolved DSB can induce senescence 136. The effective induction of senescence requires 
persistent DDR signaling after genomic damage. This response is different than a DNA  
damage response that causes transient growth arrest. Persistent DDR signaling can be 
identified by the long-term presence of nuclear DNA damage foci.
DNA-damage induced senescence can be seen as a general trigger of the senescence 
response, especially considering dysfunctional telomeres trigger a DDR. However, since 
the first trigger is the dysfunctional telomeres, it is considered as a different pathway. 
Interestingly, dysfunctional telomeres, can be considered among the senescent inducers, 
which create a DDR without physical damage to the DNA. Chromatin perturbations can 
also induce a DDR when there is no physical DNA damage. Moreover, by inducing 
proteins involved in DDR signaling, such as ATR, senescence can be initiated without 
DNA damage 139.
Many chemotherapeutic agents function by physically damaging the DNA. These drugs 
can also induce senescence in normal cells. Sometimes this type of senescence is referred 
to as therapy-induced senescence l40.
Oxidative stress causes DNA damage and single-strand breaks. These lesions need to be 
repaired or they can be converted into DSBs during DNA replication. Moreover,
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oxidative stress can accelerate telomere shortening, presumably because the G-rich 
telomeric DNA is specifically vulnerable to oxidative damage l41. When oxidative stress 
is the initial trigger, this type of senescence is also referred as oxidative-induced 
senescence.
1.8.4.3. Chrom atin Perturbation-Induced Senescence
Chromatin affects the global control of transcription by helping to determine which genes 
are active (euchromatin) or silent (heterochromatin). This control depends on histone 
modifications, for example, methylation, and acetylation. It has been shown that, global 
chromatin relaxation with broad-acting histone deacetylase inhibitors (HDAi) induces 
senescence by derepressing the p 16INK4a gene, which causes the formation of senescence 
associated heterochromatin ,42. Notably, the pl6,NK4a tumor suppressor is expressed by 
many senescent cells and is considered a biomarker for aging l43. The exact mechanism of 
chromatin perturbation-induced senescence is poorly understood but it is assumed that 
it depends on the cell type. For example, in human fibroblasts, HDAi sequentially induces 
p21 and p 16 expression, and the senescent growth arrest depends on the presence of 
pRb. On the other hand, in mouse fibroblasts, the p53 pathway is more important for the 
senescent response to HDAi l44. It is possible that HDAi may cause senescence by 
initiating a p53-dependent DDR, since it is known to induce ATM kinase activity l39.
It is interesting that HDAi, which can cause reversible disruption of heterochromatin and 
centromere function145 also cause senescence. Especially given the role of 
heterochromatin and senescence-associated heterochromatin foci (SAHF) in establishing 
and maintaining the senescence growth arrest l42. Moreover, the down regulation of 
histone acetyl transferases which promotes heterochromatin formations also induces 
senescence l46. It is not known how senescence can be induced by both heterochromatin
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formation and heterochromatin disruption. Each manipulation may change the expression 
of different genes and the response may be cell type specific. Understanding this conflict 
is important since HDAi are good candidates for certain cancer treatments l47.
1.8.4.5. Stress and O th er Inducers of Senescence
Stress-induced senescence or premature senescence (SIPS) is a very broad concept, which 
includes a variety of stresses and sources of cellular damage. During SIPS the cell is held 
in growth arrest by combination of gene expression changes, heterochromatin formation 
and the activation of CDK inhibitors. Although the mediators are different, common 
pathways are involved in the mechanism of this type of stress.
Importantly, even in a culture of fibroblasts, a single stimuli can induce senescence through 
different pathways. Some cells in a culture may senesce because of the expression of p 16, 
while others senesce due to p53-dependent DDR ll4148. The induction of senescence by 
the p 16 pathway is one of the least understood l49. It has been shown that expression of 
p16 increases with age in mouse tissues 150 and stem cells in vivo ISI. Expression of p i6 is 
controlled by many different factors including HDACs and chromatin formation ,44152. 
Moreover, it has been shown that oxidative stress also induces expression of p 16 in MEFs
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Persistent DDR signaling initiates senescence growth arrest. This signaling is also 
accompanied by the activation of other signaling pathways including, p38MAPK and the 
protein kinase C pathways l53. Although it is not known how these pathways are initiated, 
these additional pathways also stimulate the expression of p i6, which acts through pRb 
and ensures the irreversible growth arrest l54.
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Oncogene Induced Senescence (OIS) is another major type of senescence that is induced 
by oncogenes and other drivers of cell proliferation. Senescence studies with tissue 
culture models of OIS have proven very useful for characterizing senescence effector 
mechanisms, and provide a framework for understanding the cancer-senescence 
connection l55>156.
1.8.5. Cancer-Senescence Connection
Starting from telomere dysfunction, DNA damage, and chromatin disruption, senescence 
can be triggered by many stimuli. All these stimuli have one thing in common. All of them 
have the potential to promote cancer. As stated earlier, normal human and mouse cells 
can senesce in response to intense mitogenic signals. Thus it follows that senescence can 
be a mechanism for tumor suppression by irreversibly arresting the growth of cells which 
are at risk for turning into tumors.
Cancer cells have deficits in the regulatory circuits that govern normal cell proliferation 
and homeostasis. Most cancer cells have six essential alterations in cell physiology that 
collectively lead to malignant growth. First of all, cancer cells must obtain self-sufficiency 
in growth signals. Similarly, they must become insensitive to growth-inhibitory signals and 
obtain limitless replicative potential. Cancer cells also have to evade apoptosis, and be 
able to sustain angiogenesis. Each of these physiological changes is necessary for tumor 
development. And each step also represents an anti-cancer mechanism that must be 
overcome by the mutation of key regulatory proteins.
Acquisition of the six main capabilities during the course of tumorigenesis is linked directly
to changes in the genomes of cancer cells. However, there are a number of efficient
systems to reduce the mutation rate and maintaining genomic stability. These systems
work to ensure the DNA sequence remains intact. These systems ensure that mutations
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are rare and that multiple mutations in key genes are highly unlikely to occur at the same 
time. Still, cancer cells acquired increased susceptibility to mutations 157 that leads to the 
tumorigenic phenotype. This paradox is explained by malfunctions in the systems that are 
responsible for genomic stability. The most prominent member of these systems is the 
p53 tumor suppressor protein, which induces a cell cycle arrest to allow for DNA repair 
to take place and can induce apoptosis if the damage is irreparable. It is now known that 
the functioning of p53 DNA damage signaling pathway is lost in most of the human cancers 
l58. Moreover, an increasing number of other genes which are involved in sensing and 
repairing DNA damage or providing correct chromosomal segregation during mitosis 
have been found to be lost in different cancers. This is one reason why they are referred 
to as tumor suppressors ,S9. Their loss of function is thought to produce genomic 
instability and eventually the generation of mutant cells with acquired advantages.
Most normal cells needs growth factors to pass from quiescence to active proliferation. 
Tumors arise from the abnormal proliferation of a subset of cells which do not respond 
to normal signals that limit cell division. Hence, cells have clever defense mechanisms to 
tumors, primarily based on blocking the expansion of these abnormal cells. Two major 
mechanisms are involved in this defense; apoptosis and senescence. However, apoptosis 
may fail if the complete elimination of tumor cells is not achieved. On the other hand, 
cells can follow a different defense mechanism; senescence.
It has been found that certain oncogenes, genes that have the potential to cause cancer, 
or the loss of anti-mitogenic tumor-suppressor genes can also induce senescence in 
normal cells l6°. This type of senescence is known as oncogene induced senescence (OIS). 
This mechanism was first discovered when an oncogenic form of RAS was expressed in 
normal human fibroblasts l61. RAS chronically stimulates the Mitogen-Activated Protein
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Kinase (MAPK) signaling pathway and induces senescence in normal cells l61. Although the 
initial response to RAS is abnormal proliferation, the cells sense this abnormality and 
undergo senescence as a delayed response to counter these oncogenic signals l62. Later 
on, other members of the RAS signaling pathway including RAF, MEK, MOS and BRAF as 
well as, pro-proliferative nuclear proteins such as E2FI were shown to induce senescence 
when overexpressed l63_l6S. The senescence of cultured human fibroblasts can be avoided 
by disabling their pRb and p53 tumor suppressor proteins, enabling these cells to continue 
multiplying for additional generations until they enter into a second state termed crisis. 
This crisis state is characterized by massive cell death, karyotypic disarray associated with 
end-to-end fusion of chromosomes, and occasional emergence of a variant (I in 107) cells 
that has acquired the ability to multiply without a limit, this trait is referred to as 
immortalization ,66.
Most tumor cells that propagated in culture are immortalized, suggesting that the limitless 
potential of proliferation is a phenotype that tumor cells must acquire. Normal cells have 
a telomere shortening problem, while cancer cells are able to maintain their telomeres. 
Most cancer cells do this by upregulating the expression of the telomerase enzyme, which 
adds hexanucleotide repeats onto the end of telomeric DNA ,67. Even in the absence of 
telomerase, some cancer cells have evolved another mechanism called ALT, which 
maintain telomeres through a recombination-based interchromosomal exchanges of 
sequence information l68.
Since oncogenes induce senescence by stimulating cell growth, excessive mitogenic 
stimulation can push cells into oncogenic transformation. In fact, it has been shown that 
when mouse cells are cultured in serum-free medium (normal medium carries high 
mitogenic pressure), they resist RAS-induced senescence l69.
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1.8 .5 .1. Tum or Suppressors Control Cellular Senescence
In parallel with its role in suppressing cancer, cellular senescence is controlled by several 
tumor suppressor genes l70. The most important of these encode the p53 and pRb 
proteins. Potential cancer cells must lose p53 and/or pRb in order to overcome the 
proliferative barrier imposed by cellular senescence. This can occur by mutation or 
epigenetic silencing of one or more important components of the pathways. The pathways 
controlled by p53 and pRb are crucial for cells to establish and maintain the senescence 
growth arrest in response to different triggers.
p53 is a transcriptional activator and repressor which controls the expression of genes 
that cause cell cycle arrest or apoptosis in response to genomic damage. p53 mutations 
are found in approximately half of human cancers. Not surprisingly, its activity and protein 
levels increase when cells become senescent m. The activation of p53 involves complex 
set of PTMs such as phosphorylation and acetylation. Since p53 is an important factor in 
senescence, significant emphasis has been placed on p53 targets, specifically p21, which is 
elevated in senescent cells and mediates cell-cycle arrestl72.
pRb regulates transcription indirectly by interacting with transcription factors and 
recruiting chromatin remodeling proteins to genes that control cell cycle progression and 
differentiation. At the molecular level, if not all many antiproliferative signals are funneled 
through the pRb and its relatives p i30 and p i07. When pRb is hypo-phosphorylated, it 
blocks proliferation by sequestering and altering the function of E2F transcription factors 
that control the transcription of many genes essential for progression through the cell 
cycle l73. Disruption of pRb liberates E2Fs and allows cell proliferation to proceed.
In addition, loss of pRb makes cells insensitive to antigrowth factors that normally operate 
along this pathway to block the advance through the GI phase of the cell cycle. For
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example, TGF beta, prevents phosphorylation of pRb, which inactivates pRb. In some cell 
types, TGF beta suppresses the expression of the c-myc gene, which is required for 
progression through Gl l74. However, TGF beta can also cause expression of the 
p 15INK4B and p21 proteins, which block the cyclin: CDK complexes responsible for pRb 
phosphorylation l7S.
pRb is largely hypo-phosphorylated in senescent cells. pRb is hypo-phosphorylated, 
because senescent cells express high levels of p2l and p 16 l70. These proteins inhibit the 
cyclin-dependent protein kinases, which phosphorylate and inactivate pRb during cell- 
cycle progression. Elevation of p2l levels is partly because the gene is a direct target of 
p53 transactivation. While p16 levels increases in senescent cells partly because Etsl, a 
transcriptional factor that stimulates p 16 expression, accumulates in senescent cells. 
Whereas Id I levels, which negatively regulates Ets activity, declines l70.
It is clear that cellular senescence entails the activation of several tumor suppressor 
pathways and inactivation of several oncoproteins that engage both the p53 and pRb 
pathway. Moreover, ectopic overexpression of p21, p 16 also cause growth arrest with a 
senescent-like phenotype ,70.
There are several differences in establishing senescence in human and mouse systems. In 
mouse cells, inactivation of Rb or p53 is enough to bypass oncogene-induced senescence, 
while in human cells both pathways need to be inactivated to inhibit OIS l6‘. This could 
be due the longer telomeres found in mice or to the shorter life span of mice than humans, 
which requires a less robust senescence response to avoid tumors.
Although oncogene-induced senescence does not involve telomere dysfunction, it induces 
pl6 and SAHFs formation like in telomere-induced senescence and many oncogenes 
induce a robust DDR owing to promiscuous DNA replication. This DDR response is
thought to be the main reason for the initiation and maintenance of the oncogene-induced
160,176senescence
Senescent cells repress the genes that encode the proteins that stimulate cell-cycle 
progression, such as, c-FOS, cyclin A, cyclin B and PCNA. Some of these genes are 
repressed because E2F (transcription factor) induces them, and E2F is inactivated by pRb
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In mice, strong oncogenic signals, or the loss of the tumor suppressor protein PTEN, 
results in the formation of benign lesions which include senescent cells in addition to 
normal cells l77. Moreover, benign lesions in human skin which contain cells that express 
oncogenic BRAF are also senescent l78. These findings suggest that oncogene-induced
• • • 179 IfiOsenescence can suppress tumorigenesis in vivo
Loss of these tumor suppressors is essential for oncogenic transformation of human cells 
in vitro l8\  and these pathways are frequently disrupted in human cancer cells l43. It has 
even been hypothesized that of aging is a byproduct of the crucial role that senescence 
plays in blocking cancer.
1.8.6. Potential Benefits of Cellular Senescence
One of the main benefits of cellular senescence is that it suppresses tumorigenesis in vivo. 
A recurring question in cellular senescence is why cells that are susceptible to cancer do 
not simply choose apoptosis, which does not involve complex responses such as SASP. 
The answer may lie in the very complexity of the senescent response, including SASP, and 
these additional responses an also offer beneficial effects such as increased immune 
clearance and tissue repair.
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Although much of the evidence that links cellular senescence and tumor suppressor 
pathways comes from cell culture system, there is also a great deal of supporting evidence 
from intact organisms. Inactivation of the genes encoding p53 or INK4a results in cells 
that fail to senesce in response to several stimuli and in all the cases, these animals 
developed tumors at an early age l82. Similarly, genetic manipulations in mouse models 
which cause premature senescence in mammary epithelial cells suppressed the 
development of breast cancer even after exposure to the mouse mammary tumor virus
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A number of studies showed that cellular senescence is induced in “premalignant” tumors, 
but that it is rarely induced in more advanced malignant tumors ,64-179-184. These data 
strongly suggest that cellular senescence is an important in vivo tumor response to 
prevent tumor development. Importantly, some SASP factors have been shown to induce 
senescence in neighboring cells. For example, the SASP component, GROa, promotes 
senescence in human ovarian fibroblasts l8s, and PAI-I (plasminogen activator inhibitor I) 
promotes replicative senescence 186 in mouse cells. Therefore, the induction of 
senescence in a single cell can spread to neighboring cells which is a potent mechanism 
to stop cancer progression.
Besides suppressing tumorigenesis by growth arrest, senescent cells can also suppress 
cancer by stimulating the immune system. Senescent cells are attacked by immune cells 
including leukocytes, macrophages, natural killer cells and T cells of the immune system. 
This reaction, seems to result in the clearance of senescent cells and could also function 
by stimulating the local immune system to eliminate nearby oncogene-expressing cells ll9. 
The cytokines released in SASP that are responsible for these immune responses are not 
completely understood. Another function of senescence response and SASP is to
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promote optimal healing of the wound after tissue injury. It has been shown that in case 
of acute liver injury 187 and cutaneous wounds 188 senescent cells limit the development of 
fibrosis.
Besides these benefits, senescent cells also contribute to age-related pathology. In many 
cases, senescent cells have been shown to cause degenerative changes mostly through 
secreted proteins found in SASP ll5. Besides causing degenerative pathology, senescent 
cells can also drive hyperplastic pathology. It has been thought that senescent cells 
accumulate with age and create a micro-environment that makes cells vulnerable to 
cancer development or cancer progression. This seems to be counter-intuitive as 
senescence prevents the proliferation of damaged cells, and they are the major risk factor 
for cancer development. However, senescence in response to radio- or chemo­
therapeutic agents, results in the secretion of factors which have been shown to protect 
neighboring tumor cells from being killed by those same therapeutic agents ,89 ,9°. There 
is an obvious irony in these studies of cellular senescence, but they demonstrate that the 
effects of senescent cells in the tumor microenvironment are quite complex and highly 
dependent on the physiological context.
Although senescence is not completely understood, it is clear that senescence plays a 
major role in tumor suppression. Importantly, many chemotherapeutic drugs have been 
found to induce senescence in cancer cells. A new class of chemotherapeutic agents, the 
histone deacetylase inhibitors, are being developed and these agents are strong inducers 
of senescence.
84
1.8.7. Using Sirtinol, a Sirtuin Inhibitor, for Inducing Senescence in Cancer 
Cells
In budding yeast, the SIR genes (silent information regulator); SIR I, SIR2, SIR3 and SIR4 
were first identified as necessary components for the transcriptional repression of the 
mating type loci (H M L and H M R ) l91. Sir2 was one of the first of these genes to be 
characterized and it was shown to be a NAD dependent deacetylase that removes acetyl 
groups from another protein. It was reported in 1999, Sir2, could also increase the life 
span in S. cerevisae l92. In this study, sir2, sir3 and sir4 were disrupted in several strains. 
While disruption in sir3 and sir4 caused a modest 20% decrease in life span, the sir2 
mutant strains showed a 50% reduction in life span. Later studies demonstrated similar 
effects of Sir2 on the lifespan of worms and flies l93.
Mammals have seven sirtuins (SIRT 1-7), which have a highly conserved NAD+-binding 
domain and a catalytic domain. They are categorized as class III histone deacetylases 
(HDACs). HDACs are a group of enzymes that catalyze the removal of acetyl groups. 
However, not all of them have deacetylase activity or use histones as substrates and many 
non-histone substrates have been characterized ,94. Sirtuins have been shown to protect 
against aging diseases by altering a variety of cellular mechanisms such as the stress 
response, DNA repair and apoptosis I95J96. They are involved in modulating most key 
cellular processes such as transcriptional regulation, DNA damage repair, apoptosis, cell 
cycle control, metabolism and senescence l97.
The finding that sirtuins play a beneficial role in increasing life span has increased the 
interest in determining the effect of sirtuins in mammalian cells. Specifically Sirtl has been 
extensively characterized for its role in aging 198 and age-related diseases. In fact, caloric
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restriction, which has a great effect on life span 199,200 is also partly linked to sirtuin levels 
in several model organisms l96.
In addition, Sirt I has an important role in the regulation of cell fate and stress responses 
in mammalian cells. It promotes cell survival by inhibiting apoptosis and DNA-damage 
induced senescence. Several proteins have been identified as Sirt I substrates including: 
p53 201, peroxisome proliferator-activated receptor-gamma 202, FOXO transcription 
factors 203 and Ku 70 204.
It is important to mention that Sirt I has a role in cancer20S. It has been shown that SIRT I 
expression is elevated in many types of cancers. Overexpression of SIRT I has been shown 
in human tumor tissues and also during experimental carcinogenesis 206>207. This elevation 
indicates that SIRT I may be a tumor promoter. SIRT I has been suggested to have an 
important role in DNA damage repair, genomic integrity and inhibition of tumorigenesis 
208. SIRT I levels are also modulated by oncogenes and tumor suppressor genes such as 
HICI and DBCI 209,210. Moreover, SIRT I deacetylates non-histone proteins in cancer cells. 
Therefore, inhibition of SIRT I was suggested as a potential cancer therapy and this idea 
is supported by studies reporting that reduced SIRT I activity results in cancer cell death 
211>212. Similarly, the SIRT I activator, SRTI720, has been shown to cause metastasis in a 
mouse model of breast cancer213. However, it has been shown that, increased expression 
of SIRT I reduces colon cancer formation in mouse models 2I4. Therefore, it is not 
completely clear how modulating SIRT I results in both tumor suppression and 
promotion.
A number of SIRT inhibitors have been discovered and tested as anticancer agents 
including, nicotinamide, sirtinol, cambinol etc 2IS. It has been shown that Sirt I inhibition 
by sirtinol or by genetic means, results in the induction of SA-(3-gal staining and the
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induction of a flat and large cell morphology in cancer cells 2I2. Similar results have also 
been seen in human diploid fibroblasts 2I6.
Since senescence is a potential tumor suppressor mechanism, sirtinol and other 
senescence inducing drugs may be useful as cancer therapeutics. In order to explore the 
effects of sirtinol, I used the drug to treat H 1299 cancer cell line and I used a novel hybrid 
sample preparation method that I developed to explore changes in the proteome in 
response to sirtinol. This work will help to understand the long term response of cancer 
cells to sirtinol treatment.
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2. AIMS OF THE PROJECT
For my research project, I had three major aims;
1. Developing a hybrid technique for quantitative mass spectrometry;
Obtaining and studying proteome data can be challenging in many ways. One of the biggest 
challenges arises from sample preparation steps. These steps can be modified according 
to the final goals of the study. One of the issues with mass spectrometry analysis is 
maximizing the number of protein identifications from the analysis. Samples where the 
complexity and dynamic range of the proteome is high makes these studies even more 
challenging. In this part of my project, I developed a sample preparation methods to 
increase the number of protein identifications during MS analysis.
2. Verification of the hybrid method by obtaining proteome profiles of H1299 cells after 
sirtinol treatments;
I developed the hybrid method using Bovine Serum Albumin (BSA) as a test protein, as it 
is easy to obtain and contains many cysteine residues. I also used the hybrid method to 
perform a proteomic analysis of H1299 cells treated with the sirtinol, an anti-cancer agent. 
I found that sirtinol causes a robust phenotype in H 1299 cells, so it would make an ideal 
test compound to extend the hybrid technique to real world samples. Furthermore, by 
performing a pairwise comparison, I was able to demonstrate the adaptability of the 
hybrid method to quantitative analysis. Furthermore, working with a potentially 
therapeutic agent may give insights into the mode of actions of this compound.
3. Validating the proteomic analysis and comparing results with senescent mouse 
embryonic fibroblasts (MEFs) to obtain biologic relevance;
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The final aim of my work was to verify the proteomic changes revealed by the hybrid 
technique using standard cell biological and biochemical means. I chose several proteins 
and verified the proteomic changes by western blot analysis. I included both up and down 
regulated proteins and I also analyzed the levels of pRb, and important mediator of 
senescence, whose levels appeared unchanged in the proteomic analysis. Finally, I also 
determined if the levels of these proteins were altered in the classical mouse embryonic 
fibroblast model of senescence.
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3. MATERIALS AND METHODS
3.1. Reagents and Antibodies
Chemical Reagents - All chemical reagents were purchased from Sigma-Aldrich unless 
otherwise noted.
Standard Solutions - All solutions used in this stud/ are described in the text with the 
exception of the following:
PBS buffer: 137 mM NaCI, 2.7 mM KCI, lOmM NaH2P04, 2mM K2HP04, 2mM K2HP04, 
pH 7.4
Antibodies - The antibodies used in this work are listed in Table 3.1.
A N T IB O D Y  NA M E C O M P A N Y , C A T A L O G  #
AHNAK (E-5) Antibody Santa Cruz, sc-390743
Anti-rabbit IgG, HRP-linked Antibody Cell Signaling, 7076
Anti-mouse IgG, HRP-linked Antibody Cell Signaling, 7074
EIF2a Antibody Cell Signaling, 9722
Fatty Acid Synthase (C20G5) Rabbit mAb Cell Signaling, 3180
Pan-Actin Antibody Cell Signaling, 4968
Phospho-Sirt 1 (Ser-47) Antibody Cell Signaling, 2314
PPP2R3A Antibody Abeam, 126195
p-Rb (Ser795) Antibody Cell Signaling, 9301
p-Rb (Ser795) Antibody Cell Signaling, 9301
p-Rb (Ser807/811) Antibody Cell Signaling, 8516
Rb (IF8) Antibody Cell Signaling, 9309
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Sirt I (D ID 7) Antibody Cell Signaling, 9475
Sirt 2 (D4050) Antibody Cell Signaling, 12650
Sirt 3 (D22A3) Antibody Cell Signaling, 5490
Sirt 5 (D8DI2) Antibody Cell Signaling, 8782
Sirt 6 (D8DI2) Antibody Cell Signaling, 12486
Sirt 7 (D3K5A) Antibody Cell Signaling, 5360
Table. 3.1. List of antibodies. For each antibody, names and product numbers are reported.
3.2. General Biochemical Techniques 
Protein Concentration Assay
Protein concentration was measured with Bradford Reagent (Bio-Rad Protein Assay) in 
this study 2I7. The measurements were carried out according to the manufactures 
instructions.
SDS-PAGE Gel Electrophoresis and W estern  Blot
Lysates were supplemented with 6X Laemmli sample buffer (Sigma Aldrich) and boiled 
for 10 minutes. The sample was separated by 12% SDS-PAGE218 and then electroblotted 
onto PVDF membranes (Millipore). The membranes were blocked at room temperature 
for 2 hours in PBS buffer supplemented with 0.1% Tween-20 and 5% milk. The blocked 
membranes were then incubated with the appropriate primary antibodies, diluted in the 
blocking buffer and incubated with the membranes overnight at 4°C. The membranes 
were washed extensively with PBS supplemented with 0.1% Tween-20, and then 
incubated for I hour with a horseradish peroxidase (HRP)-conjugated secondary 
antibody. After extensive washing, the blots were developed with enhanced
chemiluminescence reagents (ECL) (GE Healthcare) following the manufacturer’s 
instructions.
Colloidal Blue Coomassie G-250 Staining
To visualize proteins after SDS-PAGE, the gels were washed once with distilled water and 
incubated for one hour at room temperature with colloidal blue G-250 coomassie 
solution (10% (w/v) (NH4)2S04, 20% Ethanol, 0.4% (w/v) Coomassie Brilliant Blue G250 
and 3% phosphoric acid.) Then gels were washed with distilled water in order to remove 
the background staining and to enhance the visualization of protein bands.
3.3. Cell Handling Procedures
Non-small Lung Cancer H I 299 Cell Culture
H I299 cells were grown in DMEM media (Sigma Aldrich) supplemented with 10% fetal 
bovine serum (Hyclone), 2 mM L-glutamine, 50 U/ml penicillin, 100 ng/ml streptomycin B, 
and 25 ng/ml amphotericin B.
Stable Isotope Labelling o f H I 299 Cells
Isotopic Labeling of H I299 cells was performed with the SILAC technique 75. SILAC 
medium was purchased commercially (Silantes, #  282946423) and supplemented with 10% 
dialyzed FBS (Silantes, #281000900) and 2mM L-glutamine. The media was also 
supplemented with unlabeled or labeled lysine and arginine (Lys-,2C6 and Arg-l2C6 or Lys- 
l3C6 and Arg-l3C6) (Silantes, #282926433). Cells were grown in SILAC medium for 
minimum 5 passages and mass spectrometry was used to ensure that the incorporation 
of heavy isotopes was complete.
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Sirtinol T rea tm en t of H 1299 Cells
H I299 cells were plated at a density of 10,000-15,000 cells per cm2 and allowed to 
recover overnight and were treated with the indicated concentrations of sirtinol 
(Adipogen, Lot No. A00055) for the indicated period. Control cells were treated with 
and equivalent dose of DMSO, as this served as the carrier solvent for sirtinol. After 
exposure to Sirtinol, the cells were washed three times with sirtinol-free medium and 
cultured for the indicated times in complete media without sirtinol. Cell viability was 
determined by the Alamar blue assay and Trypan blue exclusion test and viable cells were 
counted.
A lam ar Blue Assay
At the appropriate time points, growth media was replaced with 500 ul of fresh media 
supplemented with Alamar Blue reagent (Sigma) at the final concentration of 100 ug/ml. 
Cells were incubated with Alamar Blue for 2 hours, then 100 ul of the media was 
collected, transferred to a black 96 multiwell ViewPlate™ (Perkin Elmer) and the 
fluorescence was measured with excitation/emission wavelengths set to 560/590 nm 
respectively using an EnVisionR Multilabel Plate Reader (Perkin Elmer). Values were 
normalized to the fluorescence obtained from adding Alamar Blue to growth media and 
cultured in the absence of any cells.
Mouse Prim ary Fibroblast Cultures
Mouse Embryonic Fibroblast (MEFs) were isolated from PTEN LOXLOX mice. Pregnant 
females at 13-14 days of gestation were euthanized and the embryos were isolated from 
the uterus and washed with sterile PBS three times. Heads and livers were removed and 
each embryo was minced on a plate with a scalpel. Each diced embryo was transferred to
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its own tube and 500 ul of pre-warmed trypsin-EDTA solution (Sigma-Aldrich) was added 
to the tubes and incubated at 37°C for 10 minutes. The tissue was then homogenized by 
trituration through pipette tips. The content of each tube was transferred to one 25 cm2 
flasks with 5 ml of complete media (DMEM media (Sigma Aldrich) supplemented with 10% 
fetal bovine serum (Hyclone), 2 mM L-glutamine, 50 U/ml penicillin, 100 ng/ml 
streptomycin B, and 25 ng/ml amphotericin B) and the MEFs were left in culture with 
periodic media changes until they reached full confluence. The MEFs were then maintained 
on the 3T3 protocol l66.
SA-pgal Staining
Cultured H I299 cells were washed with PBS and fixed with 3.7 % formaldehyde for 5 
minutes and incubated overnight at 37 °C in freshly prepared X-gal staining buffer (Img 
mL'1 X-gal (5-bromo-4chloro-3-indolyl p-D-galactosidase), 5 mM K3Fe[CN]6, 5 mM 
K4Fe[CN]6 and 2 mM MgCI2 in PBS, pH 6.0. At the end of the incubation period, the cells 
were washed with H20  and examined at x20 magnification.
Cell Lysis
Cells were washed twice with PBS and then lysed in ice-cold NP40 buffer (50 mM Tris- 
HCI pH 7.5, 150 mM NaCI, 0.5% NP40), and the lysate sonicated in 0.5 second bursts at 
50% power for I minute using a vial tweeter (Hielscher Ultrasound Technology), and 
spun at 13,000 rpm for 10 minutes to remove cell debris.
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3.4. General Proteomics Sample Preparation Methods 
In-solution Digestion
Dithiothreitol (DTT) was added to a final concentration of 5 mM and the sample was 
heated to 55°C for 10 minutes, lodoacetamide or Chloroacetamide was added to 15 mM 
and the reaction was allowed to proceed for I hour at room temperature. Trypsin was 
then added at a ratio of ~ 1:20 (Trypsin: substrate) followed by digestion for overnight at 
37°C or I h at 57°C. The digested sample is desalted and concentrated using filter tips 2I9.
In-gel Digestion
Samples separated by SDS-PAGE were stained with Commassie blue as previously 
described. Visualized bands, or discrete areas of the gel, were excised using a scalpel and 
chopped into ~ I mm3 pieces. Reduction and alkylation steps are performed similarly to 
the in solution digest protocol and then subjected to extensive washing with 20 mM 
Triethyl Ammonium Bicarbonate, pH 8.5 in 50% Acetonitrile. The gel pieces were 
dehydrated with 100% Acetonitrile and then 20 ng/ul trypsin (Promega) was added to 
completely cover the gel pieces and the digestion was allowed to proceed overnight at 
37°C. The supernatant was harvested and any remaining peptides were extracted from 
the gel by sonicating for 20 minutes with I % Formic acid (FA). Recovered tryptic peptides 
are then purified using filter tips as described.
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3.5. Hybrid Method 
Performic Acid T reatm ent
Performic acid was produced by mixing equal concentrations of formic acid and hydrogen 
peroxide. The mixture was left to react at room temperature for I h before use. Performic 
acid was added to a final percentage of 3% in the sample to be oxidized.
Preparing P o lyW A X  in-Tip Column
PolyWAX resin (PolyLC) was washed with 30 bed volumes of Acetonitrile (Fluka) and 
then with 30 bed volumes of HPLC-grade Water (Fluka). The resin was then incubated 
with a concentrated salt solution for at least 12 hours. Prior to its initial use, the resin is 
washed with 30 bed volumes of HPLC-grade water to remove the salts and finally 
equilibrated with 30 bed volumes of binding buffer (e.g., 70% ACN, 10 mM Ammonium 
Bicarbonate, pH 7).
Preparing Stage Tips
Stage tips were prepared with reverse phase filters (Empore, SDB-XC, 710265). The 
volume of the filter disk and the tips are determined based on the amount of sample used. 
Reverse phase filters are used both for sample desalting and as a frit in cysteic acid 
enrichments steps. A small core of the reverse phase filter is punched out of the filter 
using a 2.5 ml combi-tip (Eppendorf) and then lodged near the end of a 20 or 200 ul 
pipette tip (Eppendorf).
For enrichment of cysteic acid containing peptides, PolyWAX resin (Poly LC, 10-139-2) 
is used. The indicated amount of conditioned PolyWAX resin was layered on top of the
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reverse phase filters. Loading, washing and elution steps are performed by pushing the 
appropriate solvent over the tip.
The Hybrid method is used both with in-solution and in-gel solution approaches.
Hybrid Method w ith in-Solution Digestion
For BSA samples, various amounts of BSA samples were digested with sequencing grade- 
modified trypsin (Promega) overnight at 37°C or I h at 57°C. Samples were oxidized with 
performic acid (3%) for Ih at room temperature and desalted with 0.1% FA using filter 
tips (Empore SDB-XC). The tryptic peptides are then fractioned off-line with ERLIC 
chromatography using weak anion exchange resin (Poly LC, PolyWAX LP™) in a filter tip. 
The volume of the resin was adjusted according to the amount of sample. Mobile phase 
was 70% ACN and 20 mM Ammonium Bicarbonate at pH 7 and cysteic acid containing 
peptides were eluted with the indicated buffer. All fractions of in-tip chromatography 
were analyzed by LC-MS/MS.
Hybrid Method w ith in-Gel Digestion
For complex samples from tissue culture cells, 25 ug protein was separated by SDS-PAGE 
and the gels were stained with Commassie blue as described. Instead of reduction and 
alkylation steps, cysteine residues were oxidized by addition of performic acid (3%) to the 
excised gel pieces for I h at room temperature. The gel pieces were washed extensively 
and digested with sequencing grade-modified trypsin (Promega) for overnight at 37°C, as 
previously described. Peptides were subsequently extracted from the gel with 5 % FA. 
Recovered tryptic peptides were then fractionated off-line with ERLIC chromatography 
using PolyWAX resin, as previously described. Finally, the peptides were analyzed with 
LC-MS/MS.
Making Methyl Esters
Methanolic HCL reagent was made by adding 800 ul acetyl chloride slowly to 5 mL of dry 
methanol while stirring. 50 ul methanolic HLC was added to desalted and lyophilized 
tryptic peptides. The mixture is let stand for 2 hours at room temperature.
3.6. LC/MS-MS Analysis
Chromatographic separation was accomplished using 3 um C I2  resin (Phenomenex) 
packed into a 75 um x 15 cm fused silica capillaries (Polymicro) using an EASY-nLC II 
system (Bruker) at a flow rate of 500nl/ml. 90 minute gradients from buffer A (99.9% 
water with 0,1% FA) to buffer B (100% methanol) were used develop the column. The 
column effluent was sprayed directly into an Amazon ETD mass spectrometer (Bruker 
Daltonics) using a homemade electrospray interface.
Data collection was controlled by the HyStar program (Bruker) using a data-dependent 
acquisition mode. MS spectra were acquired in the range of m /z  380-1600 followed by 
maximum of five MS/MS analyses. The typical duty cycle was approximately 2 seconds. 
The precursor selection was based on peak intensity and all charge states were selected 
except for I +, which was excluded. Dynamic exclusion was set to allow each peak to be 
analyzed 3 times in a I minute window.
3.7. Data Analysis 
XITandem
Data analysis was performed on 3 independent replicates for each experimental 
condition. Data from each experiment was merged and the searches were performed on 
both merged data and on individual experimental runs using XITandem. Data was
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searched against the UniProt human database (forward and decoy). Trypsin was selected 
as protease with maximum one missed cleavage allowed. Carbomidomethyl or full 
oxidation of cysteine (47.97-C) were set as complete modifications and partial oxidation 
of methionine and partial deamidation of glutamine and asparagines were also allowed in 
the search parameter. For SILAC labeled samples, l3C6 arginine & l3C6 lysine are chosen 
as partial modifications. MS tolerance was set to 500 ppm while MS/MS tolerance was set 
to 0.4 Da.
Mascot
Data analysis was performed on 3 independent sample replicates for each experimental 
condition. Data from each experiment were searched individually on Mascot. Data was 
searched against the UniProt human database (forward and decoy). Trypsin was selected 
as protease with maximum one missed cleavage allowed. Full oxidation of cysteine (47.97- 
C) is chosen for complete modifications. Deamidation (NQ), oxidation (M), are chosen 
as partial modifications. Peptide tolerance was set to 0.5 Da. MS/MS tolerance is set to 
0.5 Da. SILAC support is built into MASCOT and SILAC was chosen as quantification 
method when needed.
3.8. Peptide/Protein Verifications and Quantifications
ProteolQ software was used for verifying peptide identifications and also for SILAC based 
quantifications. Peptide probability and peptide false discovery rate were used for 
establishing a threshold of confidence for peptide identifications generated from the 
database search tools. Peptide probability is set to 0.2 (80% likelihood) and the protein 
probability is set to 0.5 (50% likelihood). False discovery rate (FDR) was estimated based 
on decoy database searches in ProteolQ software. FDR cut-off was set to 5%.
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The quantification based on SILAC is performed with ProteolQ Software. For every 
peptide, the precursor ions are detected based upon the SILAC parameters specified. 
Precursor ion intensities are then saved for each peptide throughout the scan. Ratios are 
calculated by dividing each precursor ion intensity by the intensity of the reference group 
precursor ion.
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4. RESULTS
In mass spectrometry based proteomics, sample preparation is critically important 
because it has an impact on the quality of the data produced and in the overall number of 
protein identifications. There are many methods in proteomics that have been developed 
for different purposes.
I developed a sample preparation technique, which selectively enriches the oxidized 
cysteines and cystines in proteomic mixtures. BSA was used as a target protein for the 
development and optimization of the technique. However, more complex samples such 
as cell lysates were also used for further improvement of technique. Several factors 
including the appropriate reagents, the pH and the column capacity were found important 
in the efficiency of the hybrid technique. Results show that the hybrid method greatly 
increases the number of peptide and protein identifications when compared to classical 
methods, Besides providing increased numbers of identifications, the hybrid technique 
was also efficient in increasing the identification of several different PTMs such as 
phosphorylation, acetylation etc. The ease of implementation and the reproducibility 
were also found to be advantages of the technique.
In the second part of the project, I chemically induced cancer cells to enter senescence
with sirtinol, a Sirtl inhibitor. I used the hybrid technique that I developed to investigate
the effect of sirtinol on the proteome of the treated cells. I used a variety of approaches
to verify the changes in the proteome identified using my technique. Mass spectrometry
analysis revealed that 220 proteins were differentially expressed, which indicates the
utility of the hybrid technique in binary comparisons. Some of these proteins have already
been investigated for their role in senescence and cancer, while the role of other
candidate proteins in senescence is currently unclear. Moreover, bioinformatic software
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revealed that the acetylation pathway was strongly affected after sirtinol treatment which 
is consistent with the nature of the drug.
4.1. Developm ent of the Hybrid Technique
I developed a protocol taking advantage of the conversion of cysteine to cysteic acid by 
peroxide treatment. The method can be coupled to SILAC for accurate quantification of 
proteins. As a result, my method has the ease of labeling and enhanced quantitative 
performance of SILAC protocols with that added benefit of the reduction in sample 
complexity seen with ICAT protocols and my method can be thought of as a hybrid 
between these two techniques.
I chose to perform the initial optimizations using BSA as a target protein. BSA is cheap, 
abundant and contains many cysteine and cystine residues, which makes it particularly 
useful for optimizing the steps involving the enrichment of cysteic acid containing peptides. 
Although, the idea of the hybrid technique is conceptually simple, there were many steps 
that required optimization.
The method has mainly two steps; creating cysteic acid residues by oxidation of the 
cysteine residues in peptides and enrichment of these peptides with an optimized form of 
chromatography.
4 .1. 1. Creating Cysteic Acid Residues
The cysteine thiol groups in peptides are nucleophilic and can be easily oxidized. However 
the level of oxidation can vary depending on the oxidants. The most common reaction of 
this groups is a reversible oxidation, which forms a disulfide bond between two molecules 
of cysteine to cystine.
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Complete oxidation of cysteine occurs in three steps. In the first oxidation step, the 
hydrogen on the sulfur atom is replaced with a single hydroxyl group (OH) to  create 
cysteine sulfenic acid. A  second oxidation steps adds an oxygen atom to  create cysteine 
sulfinic acid. The th ird  and final oxidation step adds another oxygen atom to  create 
cysteine sulfonic acid, which is also called cysteic acid (Figure 4.1) no. For the analysis o f 
oxidized cysteine residues by mass spectrometry, it is important that the cysteines be 
fully oxidized, as incomplete oxidation w ill make quantification difficult and unnecessarily 
increase the sample complexity.
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Figure 4.1. Conversion of cysteine to cysteic acid by oxidation 22°. Oxidation of cysteines 
schematized in three steps. In the first oxidation step, the hydrogen on the sulfur atom is replaced with a 
hydroxyl group (O H ), creating sulfenic acid (cysteine sulfenic acid). The second oxidation adds another 
oxygen atom to produce a sulfinic acid (cysteine sulfinic acid). A third oxidation step adds another oxygen 
atom to produce a sulfonic acid (cysteic acid). Cystine is the amino acid formed by the oxidation of tw o  
cysteine molecules to form a covalent link via a disulfide bond.
In my initial experiments, I tried several different oxidants fo r oxidizing the cysteines and
cystines. These studies involved the oxidation o f BSA and also complex samples such as
H I299 cell lysates with different oxidizing agents and the use of different agents to  halt
the oxidation. For example, using hydrogen peroxide (even at high concentrations) was
not enough to  completely oxidize cysteines and cystines and other very strong oxidizing
agents, such as perchlorate, also resulted in the destruction of the sample. I have found
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that perform ic acid (a m ixture of form ic acid and hydrogen peroxide) is a quick and 
efficient reagent fo r oxidizing cysteines and cystines w ithout damaging non-sulfur 
containing amino acids. W hile hydrogen peroxide was able to  oxidize approximately 35 
%  o f the cysteine containing peptides, performic acid was able to  oxidize all the cysteine 
containing peptides in the sample (Figure 4.2).
Treatment time and concentration of performic acid were also optimized using several 
different combinations and a I hour treatment w ith a final concentration of 3% perform ic 
acid was found be optimal.
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Figure 4.2. Comparison of hydrogen peroxide and performic acid in cysteine oxidation. Total 
cell lysates were separated by SDS-PAGE gel and gel pieces were treated either with hydrogen peroxide 
(200 uM, 2 h, room temperature) or performic acid (3%, 2h, room temperature). A fter peptides were  
digested and extracted from gel pieces, LC-MS/MS experiments were performed. The percentage of 
oxidized cysteines were calculated for each sample. The total number of cysteine containing peptides and 
the total number of cysteic acid containing peptides is shown. Assays were performed in triplicate and the 
graph displays the mean + /- s.d.
In addition, I examined where during the protocol it is best to  perform the perform ic acid 
treatment. The treatment step can be quite critical as any extra steps required to  prepare 
the sample fo r treatment, o r to  remove the peroxides can greatly impact on the overall 
efficiency of the method. I found that performic acid treatment can be used directly in
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place of the classically used reduction and alkylation steps and therefore no additional 
steps were needed. Whereas, treating the samples with performic acid prior to gel 
electrophoresis requires extra steps. After the cysteines and cystines are oxidized to 
cysteic acid, I began searching for a technique to specifically enrich these peptides.
4.1.2. Specific in-Tip Chromatography Technique for Cysteine Enrichment
The use of several different chromatographic techniques were explored that in principle 
can be used for the selective enrichment of cysteic acid containing peptides such as strong 
cation exchange chromatography (SCX), strong anion exchange chromatography (SAX) 
and electrostatic repulsion and hydrophilic interaction chromatography (ERLIC). These 
chromatography techniques are different variants of ion exchange chromatography.
These chromatography techniques are usually performed with dedicated chromatography 
equipment and the columns are developed with gradients of different buffers. However 
in this study I took advantage of using these systems off-line, in-tip. This in-tip technique 
has been previously described as Stop and Go Extraction Tips (Stage-Tips) where small 
disks of reverse phase beads embedded in a Teflon meshwork is placed into pipet tip as 
a microcolumn. However the embedded beads can also be used as a porous fr it221. This 
technique has been altered to be used in enrichment of cysteic acid peptides. In this case, 
C|8 disks are used as a frit and different types of resins (SCX, SAX or ERLIC) are packed 
on top of Cis disks. Loading, washing and enrichment steps are done off-line with these 
tips (Figure 4.3.). All of the fractions are then analyzed with mass spectrometer.
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Figure 4.3. General workflow for cysteic acid enrichment experiments. The enrichment process 
was performed with the help of pipet tips. Depending on the experiment, SCX, SAX or ERLIC resins were  
used. Cis disks, which is a reverse phase resin embedded into a filter, were used to form a frit. Oxidized 
peptide mixtures were passed through pipet tip and collected (flow through). The mixture was then washed 
with binding buffer to remove unspecific bindings (wash) and finally all the peptides left in the column were 
removed with elution buffer (elution) and all fractions were analyzed by mass spectrometry.
4.1.2.1. SC X for Enrichment of Cysteic Acid Containing Peptides
I initially attempted to  use Strong Cation Exchange (SCX) chromatography fo r cysteic 
acid enrichment. In the case of SCX, the cysteic acid containing peptides were expected 
to  elute very early from the column as, SCX binds to  positively charged peptides. The 
early elution of negatively charged residues has been used extensively in phospho- 
proteomics. However, the cysteic acid containing peptides eluted from  the column in 
each step and were not enriched in the flow  through. The difference in behavior between 
phospho-peptides and cysteic acid containing peptides, is most likely caused by the
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extremely low pKa of the phosphoryl group. I have tried different binding and washing 
conditions, especially in the range where cysteic acid will be ionized, the results indicated 
that SCX was failing to  enrich fo r cysteic acid. Some of the best results were found at pH 
7 and these are shown in Figure 4.4.
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Figure 4.4. Enrichment of cysteic acid peptides with SCX. BSA was oxidized and digested and the 
resulting peptides were loaded onto SCX columns and washed with 10% A C N , 10 mM ammonium 
bicarbonate at pH 7. Peptides were eluted from the column with 70 % A C N  and 0.1 % TFA. After 
enrichment, peptides from all fractions were analyzed with LC-MS/MS. The graph shows the number of 
peptides (total number of peptides, number of peptides with single cysteic acid, number of peptides with 
more than one cysteic acid and the total number of cysteic acid containing peptides) that were identified 
in each experimental step (flow through, washes and elution). (+ /- s.d.)
4.1.2.2. SA X  for Enrichment of Cysteic Acid Containing Peptides
A fte r the failure of SCX, I decided to  use SAX columns fo r cysteic acid enrichment. SAX 
works oppositely to  SCX, and in SAX chromatography the negatively charged peptides 
bind strongly to  the column, while the positively charged peptides are eluted from  the 
column in earlier steps. In a manner similar to  SCX, there was no significant enrichment 
o f cysteic acid containing peptides (Figure 4.5.).
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Figure 4.5. Enrichment of cysteic acid peptides with SAX. BSA was oxidized and digested and 
the resulting peptides were loaded onto SAX columns and washed with 10% A C N , 10 mM ammonium 
bicarbonate at pH 2.2. Peptides were eluted from the column with 70 % A C N  and 0.1 % TFA. After 
enrichment, peptides from all fractions were analyzed with LC-MS/MS. The graph shows the number of 
peptides (total number of peptides, number of peptides with single cysteic acid, number of peptides with 
more than one cysteic acid and the total number of cysteic acid containing peptides) that were identified 
in each experimental step (flow through, washes and elution). (+ /- s.d.)
A fte r I analyzed the list o f the peptides eluted from each step, I realized that background 
from peptides with Aspartic acid (D) o r Glutamic acid (E) were quite high and the failure 
to  enrich fo r cysteic acid may be due to  these residues competing fo r binding on the 
column. In order address this, I decided to  neutralize these residues by the form ation o f 
O-methyl esters. Methyl esterification was performed after cysteine oxidation. Although 
it helped reducing the binding of Aspartate and Glutamate to  the SAX resin (Figure 4.6), 
the overall coverage of cysteic acid containing peptides did not change. The failure o f both 
SAX and SCX suggests that additional characteristics o f the peptides are strongly 
influencing their behavior on classical ion exchange resins.
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Figure 4.6. The effect of methyl esterification for the enrichment of acidic residues 
(Asparagine (D ) and Glutamine (E)) in samples. BSA was oxidized and digested and split into equal 
pools. One pool was methyl esterified to neutralize the acidic amino acids and the other pool was treated 
similarly except that no Acetyl chloride was used to induce esterification. Pools were loaded onto 
conditioned SAX columns and washed with 10% A C N , 10 mM ammonium bicarbonate at pH 2.2. Peptides 
were eluted from the column with 70 % A C N  and 0 .1 % TFA. After enrichment, peptides from all fractions 
were analyzed with LC-MS/MS. The graph shows the number of enriched acidic residues in each fraction 
(flow through, wash and elution) for each treatment. Assays were performed in triplicate and the graph 
displays the mean + /- s.d.
4.1.2.3. ERLIC for Enrichment of Cysteic Acid Containing Peptides
A fter these experiments, I decided to  use a mixed mode chromatography technique, 
electrostatic repulsion and hydrophilic interaction chromatography (ERLIC) 30. ERLIC 
uses a combination of the hydrophilicity and charge of the peptides fo r separation. It is a 
specific mode of chromatography that allows many separations to  be done isocratically 
that normally require a gradient. In ERLIC, the mobile phase contains enough organic 
solvent so that hydrophilic interaction keeps the solutes on the column despite 
electrostatic repulsion. It has been used specifically fo r phospho-proteomic studies. Since 
phosphates add negative charges to  the column, I hoped that ERLIC may also w o rk  fo r 
enrichment of cysteic acid containing peptides.
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Like in the other tested chromatography methods, ERLIC was used off-line, in-tip, for 
cysteic acid enrichment2I5. C|8 disks are used to form a frit and PolyWAX resin is packed 
on the top of C|8 disks. Loading, washing and enrichment steps are done off-line with 
these tips.
Parameters for ERLIC chromatography are different than ion-exchange chromatography. 
Normally ERLIC uses high percentage of organic phase and low pH and an appropriate 
buffer for example, 65% ACN 20mM NH4-formate, pH 2.2. In this mode, I aimed to keep 
the cysteic-acid containing peptides on the column and elute them at last with no gradient 
used for the mobile phase.
Starting with a high concentration of organic solvent (70% ACN) at pH 2.2., the 
enrichment of cysteic-acid-containing peptides was already improved relative to SCX and 
SAX (Figure 4.7). Although the enrichment in the eluate was clearly visible some cysteic- 
acid containing peptides were lost in the binding and washing steps. I therefore began to 
explore ways to further optimize the binding of cysteic acid peptides to the PolyWAX 
resin.
I believed that there may be some residual salt contamination that would prevent some 
cysteic acid containing peptides from binding to the PolyWAX resin. Therefore, I added 
more washes to the in-gel digestion protocol and I switched to a buffer that was more 
volatile than Ammonium Bicarbonate. In this case, Triethyl Ammonium Bicarbonate was 
chosen as it is highly volatile and is at the correct pH. The effect of this change was 
unconvincing and I decided to optimize the pH of the binding step. Importantly, the ERLIC 
separation is highly dependent on the charge state of the peptides with both attractive 
and repulsive forces playing a role in selectivity.
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Figure 4.7. Enrichment of cysteic acid peptides with ERLIC. BSA samples were oxidized and 
digested. Sample mixtures were loaded to conditioned ERLIC column and washed with 70% A C N , 10 mM 
ammonium bicarbonate at pH 2.2. Peptides were eluted from the column with 70 % A C N  and 0.5 % FA. 
After enrichment, peptides from all fractions were analyzed with LC-MS/MS. The graph shows the number 
of peptides (total number of peptides, number of peptides with single cysteic acid, number of peptides with 
more than one cysteic acid and total number of cysteic acid) that are identified in each experimental step 
(flow through, washes and elution). (+ /- s.d.)
4.1.2.4. Effect of pH on Cysteine Enrichment
pH is one of the most important factor that affects retention on ion exchange resins, as 
the pH can change the net charge state o f the peptides. For example, SCX is normally 
done at low pH to  minimize the repulsion due to  negatively charged residues, such as 
Aspartate. Normally in ERLIC, the pH of the mobile phase is selected to  make sure that 
the solutes have the same charge as the column. For example, when phosphopeptides are 
separated with ERLIC, the chromatography is normally performed at a pH of 2. This is 
low enough to  neutralize the carboxyl groups in peptides. However, the phosphate 
groups retain the ir negative charge and are attracted to  the column electrostatically.
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The selectivity and the capacity of a weak ion exchanger is different at different pH values. 
In order to  see the effect o f pH on enrichment, I repeated the experiments w ith a range 
o f pH (from 2.2 to  8.5) to  find the pH that gives the best separation of cysteic acid. 
Importantly, pH 7 produced the highest enrichment o f cysteic acid containing peptides 
(Figure 4.8.). Significantly, even at the optimal pH, the selectivity can be lost when the 
columns are overloaded.
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Figure 4.8. The effect of pH on the enrichment of cysteic acid peptides. BSA was oxidized and 
digested and loaded onto ERLIC columns and washed with 70% A C N , 10 mM ammonium bicarbonate at 
several different pH values (only pH 2.2 and pH 7 are shown). Peptides were eluted from the column with 
70 % A C N  and 0.5 % FA. After enrichment, peptides from all fractions were analyzed with LC-MS/MS. The  
graph shows the number of peptides (total number of peptides and total number of cysteic acid containing 
peptides) that were identified in each experimental step (flow through, wash and elution). Assays w ere  
performed in triplicate and the graphs display the mean + /- and s.d.
4.1.2.5. Column Volum e and Loading Am ount Effects
Column size often effects its performance, and this is especially true when the volume of 
resin has been reduced to  enhance the overall sensitivity o f the method. However, when 
the column begins to  reach its capacity, it also begins losing its ability to  separate all the
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components, because strongly binding components displace weaker binding components. 
Therefore, I determined the maximum amount of sample that can be loaded on a certain 
amount of resin w ithout losing the ability to  retain cysteic acid containing peptides. I 
initially tested this by evaluating the performance of identical ERLIC columns to  enrich 
different amounts of BSA and doubling the amount of BSA loaded onto the column, 
resulted in a breakdown in separation performance (Figure 4.9.).
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Figure 4.9. The effect of column volume on the enrichment of the cysteic acid peptides.
Different amounts of BSA ( IX  BSA and 2X  BSA) were oxidized and digested. Sample mixtures were  
loaded onto identical ERLIC columns and washed with 70% A C N , 10 mM ammonium bicarbonate at pH 
7. Peptides were eluted from the column with 70 % A C N  and 0.5 % FA. After enrichment, peptides from  
all fractions were analyzed with LC-MS/MS. The graph shows the number of peptides (total number of 
peptides and total number of cysteic acid containing peptides) that were identified in each experimental 
step (flow through, wash, and elution). Assays were performed in triplicate and the graphs display the 
mean + /- s.d.
However, in practice it is probably easier to  scale up the column size, rather than adjusting 
the amount being loaded onto the column. The effect of doubling the amount o f ERLIC 
resin in the column is shown (Figure 4.10), which demonstrates that the column size 
can be effectively adjusted to  handle more sample.
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Figure 4.10. The effect of loading amount on the enrichment of the cysteic acid peptides.
Different amount of BSA samples ( IX  BSA and 2X  BSA) were oxidized and digested. Sample mixtures were 
loaded to ERLIC column and washed with 70% A C N , 10 mM ammonium bicarbonate at pH 7. Peptides 
were eluted from the column with 70 % A C N  and 0.5 % FA. After enrichment, peptides from all fractions 
were analyzed with LC-MS/MS. The graphic shows the number of peptides (total number of peptides and 
total number of cysteic acid containing peptides) that are identified in each experimental step (flow through, 
washes, and elution). Assays were performed in triplicate and the graphs display the mean + /- s.d.
4.1.2.3. Reducing Unnecessary Steps
In the initial optimization of the ERLIC chromatography at least 3 wash steps were 
employed w ith the idea that these wash steps would improve the enrichment o f cysteic 
acid containing peptides and to  remove non-specific binding. The wash buffer was same 
as loading buffer (70% ACN, 10 mM AB, pH 7). However, since every fraction (loading, 
washes and elution) is analyzed in hybrid method, including all three of the wash steps, 
these extra steps increase the total time amount of analysis time. This effect is even bigger 
when working with samples that require multiple repeats. More importantly, I realized 
that the extensive washing starts removing cysteic acid containing peptides, because the 
large volume of wash buffer begins to  develop the column in isocratic gradient mode. In 
order to  overcome these tw o problems, I tested the effect of reducing the wash steps to
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one. The separation efficiency o f this shortened protocol can be easily seen in Figures 4.9 
and 4.10. Eliminating the wash steps decreased the overall steps of the method and 
reduced the total analysis time (Figure 4.1 I).
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Figure 4.11. W orkflow of cysteic acid peptide enrichment with ERLIC chromatography.
Enrichment of cyteic acid peptides is performed in five steps. I .  Sample is oxidized. 2. Oxidized sample is 
loaded to conditioned tip prepared with PolyW AX resin and Cis disk. Sample is passed through pipet tip 
with a help of syringe and flow through is collected. 3. Sample is washed with loading buffer (70 % A C N , 
10 mM Ammonium Bicarbonate, pH 7) and wash is collected. 4. All the peptides left in the colmun are 
eluted with elution buffer (70% A C N , 0.5 % FA). 5. Each collected samples are analyzed by mass 
spectrometry.
4.1.3. Using Hybrid Technique in BSA Analysis
4.1.3.1. Efficient Enrichment of Cysteine Containing Peptides
A t this point, the hybrid technique was quite efficient in enrichment o f cysteic acid 
containing peptides. There were only a few cysteic-acid containing peptides in the flow
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through and wash steps coming from BSA samples. Furthermore, ~90% of the peptides 
in eluate contained at least one cysteic acid (Figure 4 .12), which demonstrates that the 
separation is both efficient and specific. The final optimized conditions fo r the in-tip ERLIC 
chromatography were 70% of ACN, lOmM Ammonium bicarbonate, at pH 7 fo r loading 
and washing steps) and the remain peptides were eluted with 70% of ACN, 0.1% FA.
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Figure 4.12. Efficient enrichment of cysteic acid peptides using ERLIC. BSA was oxidized and 
digested and the cysteic acid containing peptides were enriched using ERLIC chromatography. The graph 
shows the number of peptides (total number of peptides and total number of cysteic acid containing 
peptides) that are identified in each experimental step (flow through, washes, and elution). Assays were  
performed in triplicate and the graph displays the mean + /- s.d.
4 .1.3.2. Peptide Overlap between BSA Fractions
One measure of the separation efficiency o f a new method is to  determine the number 
o f shared components between fractions. Ideally, the fractions should contain few shared 
components. However, even if there are many shared components, this information can 
be leveraged to  make the method faster. For example, if there is a great deal o f overlap 
between the flow through and wash fraction, then these fractions can be pooled together 
and analyzed by MS as one fraction. Therefore, I manually curated the optimized ERLIC 
runs to  determine the overlap of peptides between fractions. There was a 15-20% overlap
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of peptides in flow  through and wash steps and there were no overlapping peptides shared 
w ith either of these tw o  fractions and the elution step (Figure 4.13.). This shows that 
ERLIC is a powerful method fo r peptide separation and that there is no need to  pool the 
flow  through and wash steps, as even here, at least 80% of the peptides are unique.
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Figure 4.13. Total and common peptides that are identified in BSA samples. Enrichment of 
cysteic acid peptides was performed as previously described and the common peptides found between 
three experimental steps were quantified. The total number of peptides and number of common peptides 
between experimental steps are shown. Assays were performed in triplicate and the graph displays the 
mean + /- s.d.
4.1.4. Using the Hybrid Technique with Complex Samples
Although, the results w ith BSA are very promising, it is important to  demonstrate that 
the hybrid method will also w o rk  on more complex, “ real life”  samples, such as tum or 
cell lysates. Cell lysates are incredibly complex samples and contain a multitude o f protein 
isoforms at widely varying concentrations. As I have shown, the hybrid method is very 
streamlined, so I decided to  help improve the analytic power o f my method by 
prefractionating the lysates by SDS-PAGE. The cell lysates are much more complex than 
a single protein, and the overall sample complexity was reduced by separating the proteins 
into 10 bands. The gel bands were processed and purified using the in-gel hybrid method 
as previously described.
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As expected, enriching cysteine-containing peptides from the whole cell lysates has 
proven more difficult than purifying them from  BSA. This is likely due to  the increased 
sequence complexity o f cell lysates and the fact that the ratio o f cysteine containing 
peptides is much lower. In order to  fix this problem, I tripled the amount of resin that I 
normally use w ith the same amount of BSA in order to  increase the selectivity of the 
column fo r cysteic acid containing peptides (Figure 4.14).
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Figure 4 .14. Enrichment of cysteic acid peptides by ERLIC from complex mixtures. H1229 total 
cell lysates were separated by SDS-PAGE for 30 minutes and the whole lane was divided into 10 equal sized 
bands. Each band was subjected to the hybrid purification protocol as previously described. All fractions 
(flow through, wash and elution) were analyzed with LC-MS/MS and the enrichment of cysteic acid 
containing peptides was determined and is expressed as the percentage of cysteine containing peptides. 
Assays were performed in triplicate and the graph displays the mean + /- s.d.
4.1.4.1. Increased Protein Identification by Hybrid Technique in Complex  
Samples
The main purpose fo r developing the hybrid method was to  increase the number of 
protein identifications from mass spectrometry based analysis. In o rder to  test if hybrid 
method increases the number o f peptide and protein identifications, H1299 cell lysates 
were analyzed w ith the standard, o r classic method, and the hybrid method.
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Both the samples were firs t separated with SDS-PAGE and each vertical lanes was cut 
into 10 bands to  reduce the sample complexity. All the bands from a lane were either 
processed w ith classic method (in-gel digestion, desalting) o r w ith the hybrid method. 
The data were then analyzed using XlTandem. Importantly, the number o f peptide and 
protein identifications were increased by 3 fold and 4.6 fold (Figure 4.15). So even 
though the separation efficiency of the hybrid method is somewhat compromised with 
complex mixtures, it still results in a significant increase in analytical efficiency at the mass 
spectrometer.
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Figure 4.15. Comparison of classic method and hybrid method in proteome analysis. Cysteic 
acid enrichment in H I 299 total cell lysates was performed as previously explained. 30 samples (10 bands 
and 3 fractions (flow through, was and elution)) were analyzed by LC-MS/MS and data files w ere merged 
together and analyzed as a single sample in XlTandem. Similarly, 10 bands were analyzed for classic method 
and results were compared. The graphic shows the total number of identified peptides and proteins using 
classic method and hybrid method where cysteic acid enrichment was performed. Assays w ere performed 
in triplicate and the graph displays the mean +/- s.d.
4.1.4.2. Decreased Peptide Overlap in Complex Samples
The significant improvements in both peptide and protein identifications are unlikely to  
be due to  the enrichment of cysteic acids, as these peptides only account fo r - 14% of the 
identified peptides in the most enriched fraction. A  key advantage of the hybrid technique
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is that all the fractions are analyzed, and previously I have shown w ith BSA that there are 
very few peptides found in more than one fraction. Therefore, I also determined the 
overlap between fractions from complex samples. Similarly to  BSA, there were very few 
shared peptides between fractions and the eluate contained no shared peptides (Figure 
4.16). This lack of shared peptides between fractions will greatly improve the analytical 
efficiency of the MS analysis because repeat acquisitions of the same peptide sequence 
will be minimized.
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Figure 4.16. Total and common peptides that are identified in H I 299 samples. H I299 cells 
were analyzed as previously explained. Common peptides were analyzed between three experimental 
steps (flow through, wash and elution). Total number of peptides and number of common peptides 
between experimental steps is shown on the graphic. Assays were performed in triplicate and the graph 
displays the mean +/- s.d.
4 .1.4.3. Increased Identification of PTMs by the Hybrid Technique
Besides increased the number o f identifications, the hybrid technique also improves the 
identification o f post translationally modified peptides. This was demonstrated by 
researching the original datasets to  include PTMs, such as phosphorylation, oxidation, and 
acetylation (Figure 4 .17). This shows that hybrid method can also be used fo r studies 
where the primary goal is the characterization of PTMs.
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Figure 4.17. Determination of the number of identified oxidation and phosphorylation sites 
using the standard method or the hybrid method. H I 299 cells were analyzed as previously 
described. For the analysis of oxidized samples, the cells were pretreated with hydrogen peroxide and the 
treatment with peroxide was omitted. Assays were performed in triplicate and the graphs display the mean 
+/- s.d.
4.1.5. Adaptation of the Hybrid Technique to Non-dividing Cells
One of the major goals o f this w ork  is the coupling o f the cysteic acid purification w ith 
SILAC labeling. However, during the development of this technique, I also tried to  adapt 
my method to  systems where SILAC labeling is difficult o r impossible, such as in post­
m itotic cells. The initial idea was to  use SILAC labeling w ith neuron cells, since it has been 
shown that non-dividing cells, such as neurons, can be tagged w ith SILAC amino acids in 
cell culture. Previously it was shown that the labeling is complete when the neurons are 
grown in SILAC media fo r at least 10 days 222. In order to  test if hybrid method can be 
coupled to  SILAC fo r neuronal samples, I obtained mouse primary cortical cells and plated 
them in SILAC media and I kept them in culture fo r tw o  weeks.
Initially I wanted to  evaluate the effects of resveratrol on neurons. Interestingly, 
resveratrol has similar biochemical targets as sirtinol, but instead of being an HDAC 
inhibitor, resveratrol functions as an agonist. I started by performing viability tests on the
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neuronal cultures upon resveratrol treatment. I treated primary cortical neurons 
separately w ith resveratrol o r DMSO, which is the resveratrol solvent, fo r 24 hours. The 
next day I used Alamar blue to  determine the viability of the cells in culture. Alamar blue 
oxidized by the mitochondria to  produce a fluorescent compound and this conversion 
can be measured w ith a spectrophotometer o r fluorimeter. The maximal concentration 
o f DMSO used when treating cells w ith resveratrol was 2 mM and Figure 4 .18 indicates 
that neurons tolerate much higher concentrations of DMSO. Although resveratrol is 
typically described as a beneficial compound, a dose response curve of resveratrol in these 
cells showed a slight toxic ity of the compound at high doses (Figure 4 .18).
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Figure 4.18. Cell viability of H I 299 cells in response to resveratrol and DMSO. Cortical 
neurons were isolated from E l3.5 mouse embryo cortex and cultured for ten days. Cells were treated 
with different concentrations of DMSO and resveratrol for 24 h. Cells were washed with PBS and 
mediums were changed. 24 h later cell viability was tested with Alamar Blue Assay. Graphic shows the 
percentage of cell viability with the changing concentrations of DMSO and resveratrol. Assays were 
performed in triplicate and the graphs display the mean viability and s.d.
Based on the viability curves, the neurons were grown in SILAC media and then treated 
w ith 150 uM resveratrol o r 2 mM DMSO (control), the next day cells are collected, lysed 
and mixed together and processed using the hybrid method and analyzed by MS (Figure 
4.19, A).
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Figure 4.19. SILAC labels are poorly incorporated into cultured cortical neurons. A.
Experimental s ch e m e  indicating the usage of SILAC in neuronal culturess. B. The rate of incorporation ot 
the heavy isotope was determined by comparing the number of labeled lysines and arginines identified by 
MS. Assays were performed in triplicate and the graph displays the mean +/- s.d.
Although neurons have been previously labelled w ith SILAC, I have observed that the 
incorporation rate was quite low after 10 days (25-30 %) (Figure 4.19, B). W hen the 
incorporation is low, quantification rate o f proteins w ill be unreliable, especially as it  is 
likely that the incorporation rate fo r each protein depends on its own unique turnover 
rate. A fte r several attempts to  keep the neurons in culture fo r longer periods, I decided 
not to  use SILAC fo r comparative analysis in neurons and instead try  to  adapt my sample 
preparation method to  label free quantification methods.
Label free methods are considered less accurate than labeled methods, however, label 
free methods are popular because they are far easier to  implement then methods that
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require sample labeling. In order to test the hybrid method coupled to label-free 
quantitation, cultured neurons were treated with resveratrol (150 uM) or DMSO (2 mM) 
(Figure 4.20, A). Instead of immediately mixing the samples as in the SILAC protocols, 
these samples were processed and analyzed separately, in this pilot experiment only a 
subset of the samples were analyzed by mass spectrometry. Importantly, the results 
showed that there is an increase in the identification rate, when samples are analyzed with 
hybrid method vs the classic method (Figure 4.20, B). Importantly, the increased 
identification rate also correlated with an increase in the number of proteins that can be 
quantified by the hybrid technique and this improved performance is likely due to the 
efficient separation of peptides into distinct pools, rather than enrichment of cysteic acid.
4.2. Therapeutic Triggering of Senescence with Sirtinol in Cancer Cells
Although the initial aims of my study were to use neuronal systems, these cultures proved 
to be difficult and time consuming to produce. Therefore, I chose to further characterize 
my system using cultured tumor cell lines. Since senescence is a powerful tumor 
suppressor mechanism, I decided to induce senescence with sirtinol in H 1299 cells, a non­
small cell lung carcinoma cell line. In order to investigate the effects of sirtinol in H I299 
cells, I began by characterizing their response to sirtinol. This allowed me to determine 
the best treatment conditions for investigating their response using the hybrid method.
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Figure 4.20. Using label-free quantification in mass spectrometry analysis of cortical neurons.
A. Experimental scheme indicating the usage of label-free quantification in neuronal samples for mass 
spectrometry analysis. B. Comparison of peptide and protein identifications in samples analyzed by classic 
method and hybrid method. Only top 3 band from each samples were analyzed for comparison. Assays 
were performed in triplicate and the graph displays the mean + /- s.d.
4.2 .1. Cell Viability of H 1299 Cells Treated with Sirtinol
I perform ed the same viability study on H I299 cells tha t I perform ed on the cultured 
neurons. The H I299 cells showed a high to lerance to  sirtino l treatm ent, because even 
trea tm ent w ith  300 uM s irtino l resulted in only a ~20% loss in v iability (Figure 4.21). As 
there  was a clear response at 300 uM sirtino l, I decided to  tre a t H I299 cells w ith  high 
concentration in the remaining experiments.
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Figure 4.21. Cell viability of H I 299 cells in response to sirtinol and DMSO. H I299 cells were 
treated with the indicate concentrations of DMSO and sirtinol for 24 h and the media changed to normal 
growth media. The cells were allowed to recover for another 24 h and the cell viability was determined. 
Assays were performed in triplicate and the graphs display the mean viability +/- s.d.
4.2.2. Sirtinol T reatm ent Prevents H I 299 Proliferation
The previous results indicated that sirtinol is not highly toxic to  H I299, and this is not 
too  surprising as sirtinol has been shown to  induce senescence rather than cell death in 
many tum or cell lines. Therefore, I decided to  test the effects o f sirtinol on H I299 
proliferation. H 1299 cells were treated w ith 200 uM o r 300 uM sirtinol fo r 24 h and then 
grown fo r an additional 10 days. Starting from  day I the cells were counted to  check the 
proliferation rate. I observed that at both the concentrations o f sirtinol there was a 
marked reduction in cell proliferation. However, 200 uM sirtinol treated cells began 
proliferating after 2 days in sirtinol free media. On the other hand, cell proliferation did 
not resume in the 300 uM sirtinol treated cells over the 10 day course of the experiment 
(Figure 4.22.).
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Figure 4.22. Sirtinol inhibits the proliferation of H I 299 cells. H I299 cells were treated with 200 
uM and 300 uM sirtinol for 24 h. Sirtinol was removed from cell and cells were cultured in inhibitor-free 
medium for another 10 days. Cell counts were determined and are expressed as raw cell counts + /- s.d.
4.2.3. Senescence-P-Gal Activity is Triggered in Sirtinol-Treated Cells
Cellular senescence is a permanent loss o f replication even after mitogenic stimuli. In 
addition to  the exit from the cell cycle, senescence is also characterized by the induction 
of a (3-galactosidase activity, SA-(3-gal. The SA-|3-gal activity o f senescent cells can be easily 
demonstrated by staining the cells fo r (3-galactosidase activity using chromogenic 
substrates at pH 6 l08. Since sirtinol treatm ent causes a prolonged inhibition o f cell 
proliferation in H I299 cells, I decided to  check the SA-(3-gal activity in sirtinol treated 
H 1299 cells, as this would demonstrate that sirtinol is inducing senescence in these cells. 
H 1299 cells were treated w ith 200 uM o r 300 uM sirtinol fo r 24 hours and then placed 
in sirtinol free media fo r 8 days. A fte r 8 days, the presence o f SA-(3-gal activity was 
determined as described l04. SA-(3-gal activity was easily detectable in sirtinol treated cells 
and not surprisingly was stronger in the 300 uM treated cells.
The percentage of SA-(3-Gal positive cells was approximately 90% in 300 uM sirtinol
treated cells (Figure 4.23. D). In addition to  the blue stain, many cells also became
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large and flat which are also characteristic features of senescent cells (Figure 4.23. A, 
B, C).
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Figure 4.23. SA-p-Gal staining of sirtinol-treated H 1299 cells. H1299 cells were treated with sirtinol 
for 24 h. The inhibitor was removed and the cells were cultured another 10 days in incubator and the SA- 
(3-gal assay was performed. A. Control cells; treated with DMSO. B. 200 uM sirtinol treated cells. C. 300 
uM sirtinol treated cells. D. Three randomly selected fields were counted and the mean percentage of SA- 
(3-gal is shown (+ /- s.d.) Scale bar = lOOum.
4.3. Sirtinol T reatm ent Alters the Proteom e of H 1299 Cells
4.3.1. Proteom e Analysis of Sirtinol Treated Tum or Cells
Since sirtinol causes a robust phenotype in H1299 cells, this appears to  be an ideal system 
to  further test the hybrid technique. Importantly, the phenotype is stable and does not 
involve cell death, which can complicate any quantitative analysis. H I299 cells were 
labeled with SILAC and treated with 300 uM sirtinol fo r 24 hours and allowed to  recover 
fo r a further 8 days. The cells were lysed and mixed. The mixture was normalized to
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protein amount, rather than cell number as preliminary experiments demonstrated that 
normalizing to  cell number results in skewed isotope ratios. The mixed samples were 
subjected to  the hybrid purification protocol and analyzed by mass spectrometry (Figure 
4.24, A).
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Figure 4.24. Proteome analysis of sirtinol treated H 1299 tum or cells. A. Experimental scheme 
indicating the preparation of sirtinol treated H I 299 cells for mass spectrometry analysis. B. Proteome 
analysis of sirtinol treated samples indicating the total number of peptide and protein identifications 
obtained from the mixed H I 299 cells using the hybrid method. (+ /- s.d.)
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4.3.2. Sirtinol T reatm ent Increased Total Num ber of Acetylation Sites
The HDAC inhibitory activity of sirtinol is well described and is believed to  be responsible 
fo r the induction o f senescence in tum or cells. Therefore, sirtinol treatment is expected 
to  result in a net increase in the number of acetylated proteins and this can be used to  
help determine the validity o f my analytical methods. In fact, there was a marked increase 
in the number o f identified acetylation sites in the coming from the sirtinol treated cells, 
w ith almost 200 acetylation sites identified in the Sirtinol treated samples, and 140 
identified from  the DMSO treated control cells (Figure 4.25.).
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Figure 4.25. Comparison of total number of acetylation sites in control and sirtinol-treated  
H 1299 cells. Sirtinol-treated samples were analyzed as previously explained. Graph shows the total number 
of acetylation sites after sirtinol treatment. (+ /- s.d.)
4.3.3. Protein Expression Changes A fte r Sirtinol treatm ent
Protein expression changes were obtained by analyzing the resulting data w ith ProteolQ  
software. ProteolQ  is a comprehensive program to  validate and quantify proteins and 
combines the results from  well-known mass spectrometry database search engines such 
as Mascot. ProteolQ allows you to  define different groups o r set of results into different 
grouping, including treatment groups and sample replicates. Importantly, ProteolQ  
performs the quantification fo r SILAC labeled samples. For quantification, the RAW  data
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from the MS is used to produce XICs for all identified peptides. In addition, ProteolQ 
performs a variety of statistical validations, such as determining the false discovery rate. 
ProteolQ also uses the ProteinProphet algorithm to solve the protein inference problem.
ProteolQ provides two methods for statistical analysis (validation) of protein and peptide 
identifications. Peptide or protein probability thresholds and false discovery rates are 
calculated to determine the confidence in peptide and protein assignments and are used 
to filter the data to exclude statistically insignificant identifications.
Database search results from Mascot were grouped and imported in ProteolQ. Control 
and sirtinol treated H I299 samples were compared to determine the relative changes in 
the levels of the identified proteins (Figure 4.26.) The relative protein levels were 
determined by calculating the peak areas of the peak pairs belonging to the same peptide 
labeled with heavy or light isotopes and proteins with at least two unique peptide 
identifications were included in the analysis. In addition, a protein also needed to be 
identified in at least two of the repeats or it was also excluded from analysis.
As shown in Figure 4.26, the vast majority of the quantified proteins show no change in 
relative abundance following sirtinol treatment. Importantly, errors in mixing appear as 
most proteins exhibiting the same change in protein level and this change is the mixing 
error. Although, SILAC analysis allows for small changes in protein level to be detected, 
I decided to only focus on proteins with at least a 2 fold change in expression. This helps 
focus the analysis on the proteins and pathways that change the most, as well as making 
the downstream validation of the data easier. For example, a 20% change in protein level 
would be difficult to demonstrate using western blots. Using the 2 fold filter, I observed 
that 88 proteins were up regulated and 140 proteins were down regulated following
sirtinol treatment. The lists of up regulated and downregulated proteins are appended to
the end of results section.
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Figure 4.26. Relative protein expression levels following sirtinol treatm ent of H I 299 cells.
Relative expression levels were calculated with ProteolQ software and sorted by magnitude of the change. 
The graph shows the upregulated (ascending) and downregulated (descending) proteins for all the analyzed 
proteins. Changes in protein levels were obtained from the measurement of different signal intensities of 
light (control cells) and heavy (sirtinol-treated cells) peptides (inset).
4.3.4. Validation of Proteomic Analysis with W estern Blot Analysis
The ProteolQ results revealed the proteins which were strongly upregulated o r 
downregulated in sirtinol treated cells. I used an independent method to  verify some of 
these changes. Since there were more than 200 proteins whose levels changed, I decided 
to  focus on a few of these to  verify the ProteolQ  analysis.
I chose tw o proteins which ProteolQ  indicated had reduced levels in treated samples: 
fatty acid synthase (FAS) and AH N AK. In the mass spectrometry results, A H N A K  and 
FAS were found to  be down regulated by 2.8 x and 3.2 x respectively. I validated the 
change in protein levels by western blotting fo r these proteins. Actin was used as a loading
132
control and as can be seen in Figures 4.27. A  & B, FAS and A H N A K  are downregulated 
by sirtinol treatment.
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Figure 4.27. W estern blot analysis of FAS and A H N A K  proteins in sirtinol-treated H I 299 
tum or cells. A. H I299 cells were treated with 300 uM sirtinol for 24 h. Cells were collected at I day 
intervals for 8 days. W hole cell lysates were analyzed by western blotting using antibodies to FAS (A), 
A H N A K  (B). Antibodies to pan-Actin were used as a loading control.
In addition to  the downregulated proteins, I also selected tw o upregulated proteins fo r 
verification: eukaryotic translation initiation factor 2 alpha (EIF2a) and protein 
phosphatase 2 regulatory subunit B isoform R3 (PPP2R3A). These protein were 
upregulated by 3.2X and 3. IX  respectively and western blotting was also used to  validate 
the changes in protein levels fo r these proteins (Figure 4.28. A, B.). Although no 
attempt was made to  verify the absolute magnitude of the change in expression, the 
western blot analysis reveals that ProteolQ reliably predicts the changes in protein level 
following sirtinol treatment.
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Figure 4.28. W estern blot analysis of EIF2aand PPP2R3A proteins in sirtinol-treated H I 299 
tum or cells. A. H 1299 cells were treated with 300 uM sirtinol for 24 h and the cells were collected at I 
day intervals for 8 days. W hole cell lysates were analyzed by western blotting using antibodies to EIF2 a 
(A) or PPP2R3A (B). Antibodies to pan-Actin were used as a loading control.
4.3.5. Investigation of Differentially Expressed Proteins with Bioinformatics 
Approaches
Functional annotations can be used to  help determine if there are specific pathways o r 
functions being affected by sirtinol treatment. Tools, such as DAVID (Database fo r 
Annotation, Visualization and Integrated Discovery) can be used to  determine if the up 
o r down regulated proteins consistently affect the same pathways. These typically w o rk  
by extracting the gene ontology terms, o r other functional annotation, fo r all differentially 
expressed proteins and then a simple statistical algorithm is used to  determine significantly 
enriched biological functions. This type of analysis can help focus the downstream 
characterization of the response to  those pathways that are most important.
Analysis of the ~220 proteins identified by ProteolQ indicated that the acetylation 
pathway was the most strongly affected functional group following sirtinol treatm ent
134
(Figure 4.29.). Since sirtinol is known to  target HDACs, this DAVID result further 
validates the analytical methods that I used.
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Figure 4.29. D A V ID  functional annotation chart for differentially expressed proteins in sirtinol 
treated H 1299 cells. David software was used for determining the Gene Ontology terms that are most 
altered following sirtinol treatment (include reference for DA VID ). As shown in the figure, the genes 
involved in the acetylation pathways were the most strongly affected by sirtinol treatment.
4.3.6. Long Term  Effect of Sirtinol on Sirtuin Levels in H 1299 Cells
Since sirtuins are involved in senescence and are considered one of the primary targets 
o f sirtinol, I decided to  also determine the effect o f sirtinol treatment on sirtuin levels by 
western blot analysis.
Although it has been described as a direct target o f sirtinol, I did not observe any 
significant change in S irtl levels (Figure 4.30). However, I did notice that S irtl is 
hyperphosphorylated on Ser47 in response to  sirtinol (Figure 4.30.). Phosphorylation 
of S irtl has been suggested to  regulate its activity 223 and moreover, Sirt I phosphorylation 
is also associated w ith senescence 224.
Interestingly, the levels of Sirt2 was found to  be upregulated in response to  sirtinol 
treatment (Figure 4.30). Like, w ith the phosphorylation of S irtl, this may be involved in 
maintaining the senescent phenotype. In addition to  S irtl and Sirt2, the protein levels of 
other sirtuins were found to  be decreased (Figure 4.30). Decreased levels o f Sirt 3 225 226, 
Sirt6 227, Sirt7 228 have also been observed in several different studies.
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Figure 4.30. W estern blot analysis of mammalian sirtuins in sirtinol treated H 1299 tum or cells.
H 1299 cells were treated with 300 uM sirtinol for 24 h. Cells were collected after I and 10 days and blotted 
with the indicated antibodies. Antibodies to pan-Actin were used as a loading control.
4.2.7. Changes in Retinoblastoma Protein
Since sirtinol causes cell cycle arrest, I also wanted to  determine if sirtinol treatm ent 
changes the level o f the tum or suppressor proteins that are involved in the senescence 
pathways. H1299 cells have a homozygous partial deletion of the TP53 gene, hence do 
not express the p53 protein. Therefore, the senescent phenotype is likely to  require pRb. 
Importantly, the activity o f pRb is regulated by phosphorylation, and the hypo- 
phosphorylated form  is the most active. In order to  check if the activity level o f Rb is 
changed, I checked Rb levels and phosphorylation status by western blot analysis. Sirtinol 
treatment did not change the overall levels o f pRb, but, as expected, sirtinol treatm ent 
inhibits Rb phosphorylation, at three different sites (Ser780, Ser795, Ser807/8I I) (Figure 
4.31).
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Figure 4.31. W estern blot analysis of phosphorylation of retinoblastoma protein in sirtinol 
treated H 1299 tum or cells. H1299 cells were treated with 300 uM sirtinol for 24 h. After 24 h, sirtinol 
was removed and cells were cultured for further 10 days. Cells were collected and lysed and blotted against 
pRB (Ser780), pRB (Ser795), pRB (Ser 807/81 I) and Rb proteins. Figure shows the changes in 
phosphorylation levels at three different points.
4.3.8. Comparing Results Mouse Embryonic Fibroblast
Sirtinol is a strong inducer of senescence in H I299 cells and a number o f sirtinol 
responses were uncovered. However, it is not clear if any of these changes also occur in 
other forms of senescence. In order to  test this, mouse embryo fibroblasts were used as 
they are a classic model o f replicative senescence.
4.3.8.1. Obtaining Mouse Prim ary Fibroblast
MEFs were isolated from E l3 mouse embryos. The protocol was optimized fo r obtaining 
viable MEF cultures. A fte r a limited time in culture, 8-10 passages, MEFs undergo 
senescence, stop proliferating and enter a ‘crisis phase’ l66. The continued serial passaging 
of the senescent cells eventually allows some cells to  escape crisis and restart proliferative 
growth (Figure 4.32. A ). These steps result in the creation o f immortalized MEF cells 
This method is known as the 3T3 protocol and refers to  passaging the cells every 3 days 
at a concentration of 1,5x104cells/cm2.
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In the 3T3 protocol, MEF cells start to  arrest growth around 10th and 12th passages. The 
growth arrest is prominent by the 15th passage. This situation continues until 
approximately around the 23th passage. By this point, some cells have escaped crisis and 
they begin to  take over the culture (Figure 4.32. B).
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Figure 4.32. Senescence and immortalizaiton of MEF cells. A. Timeline indicating the steps 
necessary to make immortalized MEFs. B. Changes in total cell number during passages from senescence 
to immortalization.
4.3.8.2. Common Expression Changes between Sirtinol-lnduced Senescence 
and Replicative Senescence
Sirtinol is a chemical inducer of senescence and may induce changes that are distinct from 
other senescence inducers. Therefore, I decided to  test if similar changes occur during 
replicative senescence. MEFs were isolated and cultured under the 3T3 protocol and a 
portion of the cells were harvested at each passage.
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Interestingly, as in sirtinol-treated tum or cells, senescent cells also down regulate in FAS. 
The pattern of FAS expression was clearly correlated to  replicative senescence, as FAS 
levels started to  decrease at passage 10 at the beginning of the crisis phase, and FAS levels 
returned as cell began exiting crisis at passage 20 (Figure 4.33.).
M EFs-3T3 Protocol
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Figure 4.33. W estern blot analysis of FAS protein in MEF cells. MEF cells were isolated from El 3.5 
mouse embryos and passaged under the 3T3 protocol. Cells were collected at each passage and blotted 
against FAS and pan Actin. The crisis phase is from PIO to P I9.
4.3.9. Lists of Up-regulated and Down-regulated Proteins
The hybrid protocol was used to  determine the changes in protein levels in response to  
sirtinol treatment. The changes were quantitated by the ProteolQ software package and 
filtered to  exclude all proteins that did not change by at least 2X. The list o f down 
regulated proteins can be found in Table 4.1 and the list of up-regulated proteins can be 
found in Table 4.2. Sequence ID and Sequence names are given fo r protein 
identifications. In addition the total sequence coverage, protein expression changes 
(ratios) and standard deviations between biological repeats are listed.
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Table 4.1. List of down-regulated proteins. UniProt sequence IDs and sequence names are given for 
identification of proteins. Total sequence coverage (percentage of identified part of sequence in total 
protein sequence), protein expression ratios (C; control signal intensity, E; experimental signal intensity), 
C/E; expression ratio) and standard deviations (Std. Dev; measured by triplicate analysis), were given for 
each protein.
Sequence
ID Sequence Nam e
Total
Sequence
Coverage
%
Ratio
C/E
Std. 
Dev. %
A6NKB5 PCX2 HUMAN Pecanex-like protein 2 OS=Homo sapiens GN=PCNXL2 PE=2 SV=3 8,28 2,93 0,91
A6NM62
LRC53_HUMAN Leucine-rich repeat-containing 
protein 53 OS=Homo sapiens GN=LRRC53 PE=4 
SV=2
17,32 3,00 1,54
A6NMY6 AXA2L HUMAN Putative annexin A2-like protein OS=Homo sapiens GN=ANXA2P2 PE=5 SV=2 26,84 2,08 0,24
A6NNS2
DRS7C_HUMAN Dehydrogenase/reductase SDR 
family member 7C OS=Homo sapiens 
GN=DHRS7C PE=2 SV=3
8,65 2,32 1,23
A8MYBI
TMC5B_HUMAN Transmembrane and coiled-coil 
domain-containing protein 5B OS=Homo sapiens 
GN=TMC05B PE=3 SV=I
8,79 13,76 1,51
B4DXR9 ZN732 HUMAN Zinc finger protein 732 OS=Homo sapiens GN=ZNF732 PE=2 SV=I 4,79 4,46 1,94
000512 BCL9_HUMAN B-cell CLL/lymphoma 9 protein OS=Homo sapiens GN=BCL9 PE=I SV=4 21,53 4,93 1,17
043399 TPD54 HUMAN Tumor protein D54 OS=Homo sapiens GN=TPD52L2 PE=I SV=2 30,10 4,43 2,46
060673 DPOLZ HUMAN DNA polymerase zeta catalytic subunit OS=Homo sapiens GN=REV3L PE= 1 SV=2 14,63 4,76 0,69
075083 W DRI HUMAN W D  repeat-containing protein 1 OS=Homo sapiens GN=WDRI PE=I SV=4 18,15 3,84 1,42
075132
ZBED4_HUMAN Zinc finger BED domain- 
containing protein 4 OS=Homo sapiens 
GN=ZBED4 PE=I SV=2
12,38 2,76 1,73
075390 CISY_HUMAN Citrate synthase, mitochondrial OS=Homo sapiens GN=CS PE= 1 SV=2 9,44 2,11 1,54
075533 SF3BI_HUMAN Splicing factor 3B subunit 1 OS=Homo sapiens GN=SF3BI PE=I SV=3 12,50 1,87 0,61
095025 SEM3D HUMAN Semaphorin-3D OS=Homo sapiens GN=SEMA3D PE=2 SV=2 9,01 3,40 0,41
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095336 6PGL HUMAN 6-phosphogluconolactonase OS=Homo sapiens GN=PGLS PE=I SV=2 37,60 6,27 0,58
095817
BAG3_HUMAN BAG family molecular chaperone 
regulator 3 OS=Homo sapiens GN=BAG3 PE= 1 
SV=3
13,39 2,04 0,80
P00505
AATM_HUMAN Aspartate aminotransferase, 
mitochondrial OS=Homo sapiens GN=GOT2 
PE=I SV=3
10,00 2,90 2,93
P00558 PGKI_HUMAN Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGKI PE=I SV=3 23,98 2,35 2,16
P00568 KADI_HUMAN Adenylate kinase isoenzyme 1 OS=Homo sapiens GN=AKI PE=I SV=3 16,49 2,63 2,37
P04II4 APOB HUMAN Apolipoprotein B-IOO OS=Homo sapiens GN=APOB PE=I SV=2 8,83 6,64 2,28
P04843
RPNI_HUMAN Dolichyl- 
diphosphooligosaccharide—protein 
glycosyltransferase subunit 1 OS=Homo sapiens 
GN=RPN 1 PE=I SV=I
14,66 3,41 0,41
P06576
ATPB_HUMAN ATP synthase subunit beta, 
mitochondrial OS=Homo sapiens GN=ATP5B 
PE=I SV=3
26,28 2,82 1,42
P08I33 ANXA6 HUMAN Annexin A6 OS=Homo sapiens GN=ANXA6 PE=I SV=3 16,05 5,89 1,75
P08758 ANXA5 HUMAN Annexin A5 OS=Homo sapiens GN=ANXA5 PE= 1 SV=2 31,88 2,04 0,80
P09936
UCHLI_HUMAN Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 OS=Homo sapiens 
GN=UCHLI PE=I SV=2
21,97 2,90 2,13
PI 1279
LAMPI_HUMAN Lysosome-associated membrane 
glycoprotein 1 OS=Homo sapiens GN=LAMPI 
PE=I SV=3
19,18 4,78 2,06
PI 2236 ADT3_HUMAN ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 PE=I SV=4 28,19 2,44 1,69
PI3533 MYH6 HUMAN Myosin-6 OS=Homo sapiens GN=MYH6 PE=I SV=5 8,46 2,52 2,86
PI4678
RSMB_HUMAN Small nuclear ribonudeoprotein- 
associated proteins B and B1 OS=Homo sapiens 
GN=SNRPB PE=I SV=2
20,83 4,95 0,39
PI4868
SYDC_HUMAN Aspartate—tRNA ligase, 
cytoplasmic OS=Homo sapiens GN=DARS PE= 1 
SV=2
13,17 13,66 2,07
PI 5822 ZEPI_HUMAN Zinc finger protein 40 OS=Homo sapiens GN=HIVEPI PE=I SV=3 10,01 2,15 4,89
PI 5924 DESP HUMAN Desmoplakin OS=Homo sapiens GN=DSP PE=I SV=3 9,93 2,69 2,47
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PI 8085 ARF4_HUMAN ADP-ribosylation factor 4 OS=Homo sapiens GN=ARF4 PE= 1 SV=3 39,44 2,45 1,13
P20929 NEBU HUMAN Nebulin OS=Homo sapiens GN=NEB PE=I SV=4 8,49 2,13 0,56
P223I4
UBAI_HUMAN Ubiquitin-like modifier-activating 
enzyme 1 OS=Homo sapiens GN=UBAI PE= 1 
SV=3
15,22 5,39 2,03
P23246
SFPQ_HUMAN Splicing factor, proline- and 
glutamine-rich OS=Homo sapiens GN=SFPQ PE= 1 
SV=2
12,45 2,11 1,54
P239I9 KTHY HUMAN Thymidylate kinase OS=Homo sapiens GN=DTYMK PE=I SV=4 10,85 2,52 4,46
P24539
AT5FI_HUMAN ATP synthase F(0) complex 
subunit Bl, mitochondrial OS=Homo sapiens 
GN=ATP5FI PE=I SV=2
6,25 2,22 1,94
P25054 APC_HUMAN Adenomatous polyposis coli protein OS=Homo sapiens GN=APC PE=I SV=2 15,20 6,39 0,58
P26640 SYVC HUMAN Valine-tRNA ligase OS=Homo sapiens GN=VARS PE=I SV=4 10,21 2,76 2,73
P27708 PYRI_HUMAN CAD protein OS=Homo sapiens GN=CAD PE=I SV=3 4,85 2,55 1,42
P27797 CALR HUMAN Calreticulin OS=Homo sapiens GN=CALR PE=I SV=I 7,67 7,30 1,85
P27824 CAI_X_HUMAiN Calnexin OS=Homo sapiens GN=CANX PE=I SV=2 13,34 1,87 2,39
P2940I TKT HUMAN Transketolase OS=Homo sapiens GN=TKT PE= 1 SV=3 30,18 2,69 0,81
P30044 PRDX5_HUMAN Peroxiredoxin-5, mitochondrial OS=Homo sapiens GN=PRDX5 PE=I SV=4 17,29 3,31 1,36
P30048
PRDX3_HUMAN Thioredoxin-dependent 
peroxide reductase, mitochondrial OS=Homo 
sapiens GN=PRDX3 PE=I SV=3
22,66 6,95 1,14
P30I0I PDIA3_HUMAN Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE= 1 SV=4 16,04 2,91 0,55
P35579 MYH9 HUMAN Myosin-9 OS=Homo sapiens GN=MYH9 PE=I SV=4 20,15 1,86 2,73
P37I08 SRPI4_HUMAN Signal recognition particle 14 kDa protein OS=Homo sapiens GN=SRPI4 PE= 1 SV=2 38,97 12,63 1,69
P38II7
ETFB_HUMAN Electron transfer flavoprotein 
subunit beta OS=Homo sapiens GN=ETFB PE= 1 
SV=3
19,22 2,28 0,17
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P40925
MDHC_HUMAN Malate dehydrogenase, 
cytoplasmic OS=Homo sapiens GN=MDHI PE=I 
SV=4
17,37 3,05 0,64
P40939
ECHA_HUMAN Trifunctional enzyme subunit 
alpha, mitochondrial OS=Homo sapiens 
GN=HADHA PE= 1 SV=2
13,37 3,12 1,97
P4I252
SYIC_HUMAN Isoleucine-tRNA ligase, 
cytoplasmic OS=Homo sapiens GN=IARS PE= 1 
SV=2
13,55 5,25 0,20
P42224
STATI_HUMAN Signal transducer and activator of 
transcription 1 -alpha/beta OS=Homo sapiens 
GN=STATI PE=I SV=2
18,40 5,02 0,71
P42858 HD HUMAN Huntingtin OS=Homo sapiens GN=HTT PE=I SV=2 7,99 2,75 2,73
P49327 FAS HUMAN Fatty acid synthase OS=Homo sapiens GN=FASN PE=I SV=3 19,75 3,20 1,25
P49748
ACADV_HUMAN Very long-chain specific acyl- 
CoA dehydrogenase, mitochondrial OS=Homo 
sapiens GN=ACADVL PE=I SV=I
25,04 3,65 0,66
P 5 I148 RAB5C_HUMAN Ras-related protein Rab-5C OS=Homo sapiens GN=RAB5C PE= 1 SV=2 25,93 1,97 1,31
P52272
HNRPM_HUMAN Heterogeneous nuclear 
ribonucleoprotein M OS=Homo sapiens 
GN=HNRNPM PE=I SV=3
15,21 1,94 2,54
P54577
SYYC_HUMAN Tyrosine-tRNA ligase, 
cytoplasmic OS=Homo sapiens GN=YARS PE=I 
SV=4
18,18 2,62 1,52
P55072
TERA_HUMAN Transitional endoplasmic 
reticulum ATPase OS=Homo sapiens GN=VCP 
PE=I SV=4
21,84 2,39 1,31
P60I74 TPIS HUMAN Triosephosphate isomerase OS=Homo sapiens GN=TPII PE=I SV=3 54,55 2,45 1,13
P60900 PSA6_HUMAN Proteasome subunit alpha type-6 OS=Homo sapiens GN=PSMA6 PE= 1 SV= 1 23,17 3,59 2,63
P6224I RS8_HUMAN 40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE= 1 SV=2 26,44 2,35 2,16
P62249 RS16_HUMAN 40S ribosomal protein S16 OS=Homo sapiens GN=RPSI6 PE=I SV=2 45,21 2,23 1,50
P62820 RABIA_HUMAN Ras-related protein Rab-IA OS=Homo sapiens GN=RABIA PE=I SV=3 33,66 9,54 1,94
P62906 RLIOA_HUMAN 60S ribosomal protein LlOa OS=Homo sapiens GN=RPLI0A PE=I SV=2 13,36 5,98 1,72
P62937 PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=I SV=2 43,64 2,08 2,62
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P67809
YBOXI_HUMAN Nuclease-sensitive element- 
binding protein 1 OS=Homo sapiens GN=YBXI 
PE=I SV=3
22,53 2,22 1,94
P98I64
LRP2_HUMAN Low-density lipoprotein receptor- 
related protein 2 OS=Homo sapiens GN=LRP2 
PE=I SV=3
4,43 2,66 3,02
Q00577
PURA_HUMAN Transcriptional activator protein 
Pur-alpha OS=Homo sapiens GN=PURA PE=I 
SV=2
8,07 4,69 2,27
Q00839
HNRPU_HUMAN Heterogeneous nuclear 
ribonucleoprotein U OS=Homo sapiens 
GN=HNRNPU PE=I SV=6
6,79 1,86 0,81
Q02446 SP4 HUMAN Transcription factor Sp4 OS=Homo sapiens GN=SP4 PE=I SV=2 7,40 5,22 0,20
Q09666
AHNK_HUMAN Neuroblast differentiation- 
associated protein AHNAK OS=Homo sapiens 
GN=AHNAK PE=I SV=2
9,68 2,8 3,70
Q 13634 CAD 18 HUMAN Cadherin-18 OS=Homo sapiens GN=CDH 18 PE=2 SV= 1 10,25 1,97 0,80
Q 13813
SPTN l_HUMAN Spectrin alpha chain, non- 
erythrocytic 1 OS=Homo sapiens GN=SPTANI 
PE=I SV=3
8,70 2,60 1,82
Q I4 II8 DAG 1 HUMAN Dystroglycan OS=Homo sapiens GN=DAG 1 PE=I SV=2 7,04 24,27 0,44
Q 14207 NPAT HUMAN Protein NPAT OS=Homo sapiens GN=NPAT PE=I SV=3 11,70 3,32 1,41
Q 15075 EEAI_HUMAN Early endosome antigen 1 OS^Homo sapiens GN=EEAI PE=I SV=2 7,16 2,48 0,50
Q 15365 PCBPI_HUMAN Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBPI PE=I SV=2 23,88 2,30 2,54
Q 16555
DPYL2_HUMAN Dihydropyrimidinase-related 
protein 2 OS=Homo sapiens GN=DPYSL2 PE= 1 
SV=I
10,49 5,75 1,38
Q 16650 TBRI_HUMAN T-box brain protein 1 OS=Homo sapiens GN=TBRI PE=I SV=I 7,77 2,01 1,21
Q 16822
PCKGM_HUMAN Phosphoenolpyruvate 
carboxykinase [GTP], mitochondrial OS=Homo 
sapiens GN=PCK2 PE=I SV=3
10,78 7,84 0,75
Q3KNSI
PTHD3_HUMAN Patched domain-containing 
protein 3 OS=Homo sapiens GN=PTCHD3 PE=I 
SV=3
5,74 2,18 1,94
Q58FF3 ENPLL_HUMAN Putative endoplasmin-like protein OS=Homo sapiens GN=HSP90B2P PE=5 SV=I 17,79 2,43 1,69
Q5D862 FILA2 HUMAN Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=I SV=I 17,06 2,81 0,62
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Q5HYW2 NHSL2 HUMAN NHS-like protein 2 OS=Homo sapiens GN=NHSL2 PE=2 SV=I 27,36 2,63 3,02
Q5JPF3
AN36C_HUMAN Ankyrin repeat domain- 
containing protein 36C OS=Homo sapiens 
GN=ANKRD36C PE=2 SV=3
10,12 2,09 1,00
Q63HN8 RN2I3_HUMAN Isoform 2 of E3 ubiquitin-protein ligase RNF2I3 OS=Homo sapiens GN=RNF2I3 5,16 2,90 0,55
Q68DE3
K20I8_HUMAN Basic helix-loop-helix domain- 
containing protein KIAA20I8 OS=Homo sapiens 
GN=KIAA2018 PE= 1 SV=3
6,82 5,20 0,77
Q6PCD5
RFWD3 HUMAN E3 ubiquitin-protein ligase 
RFWD3 OS=Homo sapiens GN=RFWD3 PE=I 
SV=3
7,75 2,05 0,80
Q6PI48
SYDM_HUMAN Aspartate--tRNA ligase, 
mitochondrial OS=Homo sapiens GN=DARS2 
PE=I SV=I
13,02 12,30 1,95
Q6PRDI
GPI79_HUMAN Probable G-protein coupled 
receptor 179 OS=Homo sapiens GN=GPRI79 
PE=I SV=2
6,17 2,57 1,82
Q7LIT6 NB5R4_HUMAN Cytochrome b5 reductase 4 OS=Homo sapiens GN=CYB5R4 PE= 1 SV=I 18,43 2,46 1,13
Q7Z494 NPHP3_HUMAN Nephrocystin-3 OS=Homo sapiens GN=NPHP3 PE=I SV=I 7,44 3,75 4,74
Q86VI5
CASZI_HUMAN Zinc finger protein castor 
homolog 1 OS=Homo sapiens GN=CASZI PE=I 
SV=4
6,42 2,29 0,17
Q86WII PKHLI HUMAN Fibrocystin-L OS=Homo sapiens GN=PKHDILI PE=2 SV=2 7,40 4,25 1,28
Q8IVF2 AHNK2 HUMAN Protein AHNAK2 OS=Homo sapiens GN=AHNAK2 PE=I SV=2 7,90 1,99 1,20
Q8IWJ2
GCC2_HUMAN GRIP and coiled-coil domain- 
containing protein 2 OS=Homo sapiens 
GN=GCC2 PE=I SV=4
12,35 5,17 0,71
Q8IZL2 MAML2_HUMAN Mastermind-like protein 2 OS=Homo sapiens GN=MAML2 PE=I SV=2 22,49 2,71 0,02
Q8N0V5
GNT2A_HUMAN N-acetyllactosaminide beta-1,6- 
N-acetylglucosaminyl-transferase, isoform A 
OS=Homo sapiens GN=GCNT2 PE=2 SV=I
15,67 3,93 0,07
Q8N442
GUFI_HUMAN Translation factor GUFI, 
mitochondrial OS=Homo sapiens GN=GUFI PE=I 
SV=I
8,07 25,66 2,40
Q8NCM8
DYHC2_HUMAN Cytoplasmic dynein 2 heavy 
chain 1 OS=Homo sapiens GN=DYNC2HI PE=I 
SV=4
9,52 2,32 1,05
Q8NDH2
CCI68_HUMAN Coiled-coil domain-containing 
protein 168 OS=Homo sapiens GN=CCDC 168 
PE=2 SV=2
10,73 2,93 0,91
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Q8NF9I SYNEI HUMAN Nesprin-I OS=Homo sapiens GN=SYNEI PE=I SV=4 6,81 3,23 0,68
Q8WUM4
PDC6I_HUMAN Programmed cell death 6- 
interacting protein OS=Homo sapiens 
GN=PDCD6IP PE=I SV=I
5,88 1,89 1,08
Q92889 XPF_HUMAN DNA repair endonuclease XPF OS=Homo sapiens GN=ERCC4 PE=I SV=3 5,24 3,56 1,23
Q92900
RENTI_HUMAN Regulator of nonsense 
transcripts 1 OS=Homo sapiens GN=UPFI PE=I 
SV=2
8,24 3,05 0,64
Q96CI0
DHX58_HUMAN Probable ATP-dependent RNA 
helicase DHX58 OS=Homo sapiens GN=DHX58 
PE=I SV=I
12,98 2,26 1,50
Q96SI9
STRBP_HUMAN Spermatid perinuclear RNA- 
binding protein OS=Homo sapiens GN=STRBP 
PE— 1 SV=I
5,36 5,26 2,03
Q96T58 MINT_HUMAN Msx2-interacting protein OS=Homo sapiens GN=SPEN PE= 1 SV=I 5,21 5,73 1,38
Q96TAI NIBLI HUMAN Niban-like protein 1 OS=Homo sapiens GN=FAM 129B PE= 1 SV=3 3,89 2,80 0,62
Q9BYK8 HELZ2_HUMAN Helicase with zinc finger domain 2 OS=Homo sapiens GN=HELZ2 PE=I SV=6 4,27 3,26 0,68
Q9BZZ5 API5 HUMAN Apoptosis inhibitor 5 OS=Homo sapiens GN=API5 PE= 1 SV=3 12,98 3,10 1,97
Q9C0J8
WDR33_HUMAN pre-mRNA 3' end processing 
protein WDR33 OS=Homo sapiens GN=WDR33 
PE=I SV=2
16,99 4,77 4,74
Q9H0KI SIK2 HUMAN Serine/threonine-protein kinase SIK2 OS=Homo sapiens GN=SIK2 PE=I SV=I 4,97 3,81 1,17
Q9H2Y7 Z N 106_HUMAN Zinc finger protein 106 OS=Homo sapiens GN=ZNFI06 PE=I SV=I 7,97 2,43 0,60
Q9H4A6 GOLP3_HUMAN Golgi phosphoprotein 3 OS=Homo sapiens GN=GOLPH3 PE=I SV=I 7,38 4,48 1,94
Q9H6S0
YTDC2_HUMAN Probable ATP-dependent RNA 
helicase YTHDC2 OS=Homo sapiens 
GN=YTHDC2 PE=I SV=2
13,08 3,38 0,41
Q9HDC5 JPHI HUMAN Junctophilin-I OS=Homo sapiens GN=JPH 1 PE=I SV=2 7,56 2,36 1,88
Q9NS40
KCNH7_HUMAN Potassium voltage-gated 
channel subfamily H member 7 OS=Homo sapiens 
GN=KCNH7 PE=2 SV=2
11,45 5,43 0,26
Q9NVH0
EXD2_HUMAN Exonuclease 3'-5' domain- 
containing protein 2 OS=Homo sapiens 
GN=EXD2 PE=I SV=2
6,12 12,02 1,95
1
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Q9NXZI SAGEI_HUMAN Sarcoma antigen 1 OS=Homo sapiens GN=SAGEI PE=I SV=2 12,17 5,19 0,77
Q9NYQ6
CELRI_HUMAN Cadherin EGF LAG seven-pass 
G-type receptor 1 OS=Homo sapiens 
GN=CELSRI PE=I SV=I
9,19 1,97 0,09
Q9NYW7 TA2RI_HUMAN Taste receptor type 2 member I OS=Homo sapiens GN=TAS2RI PE=I SV=I 3,68 2,81 0,62
Q9P031
TAP26_HUMAN Thyroid transcription factor 1 - 
associated protein 26 OS=Homo sapiens 
GN=CCDC59 PE=I SV=2
11,62 3,21 1,33
Q9P2E3
ZNFX l_HUMAN NFX1 -type zinc finger- 
containing protein 1 OS=Homo sapiens 
GN=ZNFXI PE=I SV=2
3,44 2,87 0,05
Q9P2J5 SYLC_HUMAN Leucine—tRNA ligase, cytoplasmic OS=Homo sapiens GN=LARS PE= 1 SV=2 10,37 1,97 0,80
Q9UPN3
MACFI_HUMAN Microtubule-actin cross-linking 
factor 1, isoforms 1 /2/3/5 OS=Homo sapiens 
GN=MACFI PE=I SV=4
5,51 1,87 1,08
Q9UQ35
SRRM2 HUMAN Serine/arginine repetitive matrix 
protein 2 OS=Homo sapiens GN=SRRM2 PE=I 
SV=2
8,94 6,19 1,58
Q9UQ80 PA2G4 HUMAN Proliferation-associated protein 2G4 OS=Homo sapiens GN=PA2G4 PE= 1 SV=3 24,62 2,63 3,02
Q9Y2WI
TRI50_HUMAN Thyroid hormone receptor- 
associated protein 3 OS=Homo sapiens 
GN=THRAP3 PE=I SV=2
5,45 4,66 2,27
Q9Y5S2
MRCKB_HUMAN Serine/threonine-protein kinase 
MRCK beta OS=Homo sapiens GN=CDC42BPB 
PE=I SV=2
9,12 1,96 0,04
Q9Y696
CLIC4_HUMAN Chloride intracellular channel 
protein 4 OS=Homo sapiens GN=CLIC4 PE=I 
SV=4
24,51 2,26 1,50
Q9Y6L7 TLL2 HUMAN Tolloid-like protein 2 OS=Homo sapiens GN=TLL2 PE=I SV=I 4,83 3,66 1,10
Q9Y6N5
SQRD_HUMAN Sulfide:quinone oxidoreductase, 
mitochondrial OS=Homo sapiens GN=SQRDL 
PE=I SV=I
16,22 3,53 2,04
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Table 4.2. List of up-regulated proteins. UniProt sequence IDs and sequence names are given for 
identification of proteins. Total sequence coverage (percentage of identified part of sequence in total 
protein sequence), protein expression ratios (C; control signal intensity, E; experimental signal intensity), 
E/C; expression ratio) and standard deviations (Std. Dev; measured by triplicate analysis), were given for 
each protein.
Sequence
ID Sequence Nam e
Total
Sequence
Coverage
%
Ratio Std. Dev. %
000571
DDX3XJHUMAN ATP-dependent RNA helicase 
DDX3X OS=Homo sapiens GN=DDX3X PE=I 
SV=3
10,25 2,39 0,89
015067
PUR4_HUMAN
Phosphoribosylformylglycinamidine synthase 
OS=Homo sapiens GN=PFAS PE= 1 SV=4
6,65 3,73 0,99
043175
SERA_HUMAN D-3-phosphoglycerate 
dehydrogenase OS=Homo sapiens GN=PHGDH 
PE=I SV=4
8,13 2,90 1,02
043181
NDUS4_HUMAN NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 4, mitochondrial 
OS=Homo sapiens GN=NDUFS4 PE=I SV=I
9,64 3,10 1,06
060503 ADCY9 HUMAN Adenylate cyclase type 9 OS=Homo sapiens GN=ADCY9 PE=I SV=4 9,5 3,33 1,02
060741
HCNI_HUMAN Potassium/sodium 
hyperpolarization-activated cyclic nucleotide-gated 
channel 1 OS=Homo sapiens GN=HCN 1 PE=2 
SV=3
6,2 3,41 0,99
060811 PRAM2 HUMAN PRAME family member 2 OS=Homo sapiens GN=PRAMEF2 PE=2 SV=2 7,3 2,06 0,79
075486
SUPT3_HUMAN Transcription initiation protein 
SPT3 homolog OS=Homo sapiens GN=SUPT3H 
PE=I SV=2
9,1 2,53 0,65
075531 BAF_HUMAN Barrier-to-autointegration factor OS=Homo sapiens GN=BANFI PE=I SV=I 10,2 5,67 1,12
076094 SRP72 HUMAN Signal recognition particle subunit SRP72 OS=Homo sapiens GN=SRP72 PE=I SV=3 8,25 1,95 1,09
094927
HAUS5_HUMAN HAUS augmin-like complex 
subunit 5 OS=Homo sapiens GN=HAUS5 PE=I 
SV=2
6,14 2,96 1,2
095425 SVIL HUMAN Supervillin OS=Homo sapiens GN=SVIL PE=I SV=2 6,07 5,25 0,95
P06753 TPM3_HUMAN Tropomyosin alpha-3 chain OS=Homo sapiens GN=TPM3 PE= 1 SV=2 10,53 3,01 0,63
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P07900 HS90A_HUMAN Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AAI PE=I SV=5 11,36 2,10 0,8
P10412 H I4  HUMAN HistoneH 1.4 OS=Homo sapiens GN=HISTIHIE PE=I SV=2 38,81 4,69 1,44
PI6I04 H2AX HUMAN Histone H2AX OS=Homo sapiens GN=H2AFX PE=I SV=2 52,45 2,01 2,63
PI 6401 H I5 HUMAN Histone HI.5 OS=Homo sapiens GN=HISTIHIB PE=I SV=3 28,32 2,24 0,79
PI 6402 H 13 HUMAN Histone H 1.3 OS=Homo sapiens GN=HISTIHID PE=I SV=2 24,43 4,14 1,45
PI 6403 H 12 HUMAN Histone H 1.2 OS=Homo sapiens GN=HISTIHIC PE=I SV=2 22,54 4,14 1,45
PI 8621 RLI7 HUMAN 60S ribosomal protein L I7 OS=Homo sapiens GN=RPLI7 PE=I SV=3 38,04 2,58 3,49
P20042
IF2B_HUMAN Eukaryotic translation initiation 
factor 2 subunit 2 OS=Homo sapiens GN=EIF2S2 
PE=I SV=2
10,81 3,1 2,62
P2I333 FLNA_HUMAN Filamin-A OS=Homo sapiens GN=FLNA PE=I SV=4 19,25 1,90 1,25
P23396 RS3_HUMAN 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=I SV=2 32,51 2,13 0,46
P304I4 NKTR_HUMAN NK-tumor recognition protein OS=Homo sapiens GN=NKTR PE=I SV=2 9,87 3,06 1,26
P3I629 ZEP2 HUMAN Transcription factor HIVEP2 OS=Homo sapiens GN=HIVEP2 PE=I SV=2 10,36 3,11 1,16
P3I939
PUR9_HUMAN Bifunctional purine biosynthesis 
protein PURH OS=Homo sapiens GN=ATIC PE=I 
SV=3
10,20 2,51 1,65
P35555 FBNI HUMAN Fibrillin-1 OS=Homo sapiens GN=FBNI PE=I SV=3 28,10 11,70 1,87
P40227 TCPZ_HUMAN T-complex protein 1 subunit zeta OS=Homo sapiens GN=CCT6A PE=I SV=3 15,60 2,10 0,99
P42345 MTOR_HUMAN Serine/threonine-protein kinase mTOR OS=Homo sapiens GN=MTOR PE=I SV=I 9,30 2,02 0,63
P49368 TCPG_HUMAN T-complex protein 1 subunit gamma OS=Homo sapiens GN=CCT3 PE=I SV=4 15,90 1,93 1,12
P49593 PPMIF_HUMAN Protein phosphatase IF OS=Homo sapiens GN=PPMIF PE=I SV=3 12,30 8,14 0,95
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P55884
EIF3B_HUMAN Eukaryotic translation initiation 
factor 3 subunit B OS=Homo sapiens GN=EIF3B 
PE=I SV=3
14,10 2,15 0,63
P567I5 RPI_HUMAN Oxygen-regulated protein 1 OS=Homo sapiens GN=RPI PE=I SV=I 9,25 5,67 0,97
P60842 IF4AI_HUMAN Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4AI PE=I SV=I 20,44 1,92 0,30
P6I247 RS3A_HUMAN 40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE= 1 SV=2 14,39 2,83 0,86
P62805 H4 HUMAN Histone H4 OS=Homo sapiens GN=HISTIH4A PE=I SV=2 45,63 2,13 1,62
P62829 RL23_HUMAN 60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 PE= 1 SV= 1 15,23 2,16 1,20
P629I7 RL8_HUMAN 60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE= 1 SV=2 14,79 1,79 1,39
{
Q 01813 K6PP_HUMAN 6-phosphofructokinase type C OS=Homo sapiens GN=PFKP PE= 1 SV=2 9,45 2,18 1,02
QO1959
SC6A3_HUMAN Sodium-dependent dopamine 
transporter OS=Homo sapiens GN=SLC6A3 PE=I 
SV=I
8,17 3,11 1,30
Q06I90
P2R3A_HUMAN Serine/threonine-protein 
phosphatase 2A regulatory subunit B" subunit alpha 
OS=Homo sapiens GN=PPP2R3A PE= 1 SV= 1
8,11 3,2 2,11
Q07954
LRPI_HUMAN Prolow-density lipoprotein 
receptor-related protein 1 OS=Homo sapiens 
GN=LRPI PE=I SV=2
8,20 3,68 0,78
Q 12888
TP53B_HUMAN Tumor suppressor p53-binding 
protein 1 OS=Homo sapiens GN=TP53BPI PE=I 
SV=2
16,63 2,32 1,23
Q 13201 MMRNI_HUMAN Multimerin-I OS=Homo sapiens GN=MMRNI PE=I SV=3 not in gPM 8,63 3,67 0,95
Q 13283
G3BPI_HUMAN Ras GTPase-activating protein- 
binding protein 1 OS=Homo sapiens GN=G3BPI 
PE=I SV=I
8,57 6,29 1,06
Q 14152
EIF3A_HUMAN Eukaryotic translation initiation 
factor 3 subunit A OS=Homo sapiens GN=EIF3A 
PE=I SV=I
5,35 1,94 1,09
Q 14240 IF4A2 HUMAN Eukaryotic initiation factor 4A-II OS=Homo sapiens GN=EIF4A2 PE=I SV=2 21,62 2,02 0,17
Q 14258 TRI25_HUMAN E3 ubiquitin/ISGI5 ligaseTRIM25 OS=Homo sapiens GN=TRIM25 PE=I SV=2 9,98 1,94 1,1 1
Q 14315 FLNC HUMAN Filamin-C OS=Homo sapiens GN=FLNC PE=I SV=3 30,17 1,93 1,21
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Q 14573
ITPR3_HUMAN Inositol 1,4,5-trisphosphate 
receptor type 3 OS=Homo sapiens GN=ITPR3 
PE=I SV=2
15,60 3,93 1,30
Q 14847 LASPI_HUMAN LIM and SH3 domain protein 1 OS=Homo sapiens GN=LASPI PE=I SV=2 16,86 1,94 2,35
Q 15596 NCOA2_HUMAN Nuclear receptor coactivator 2 OS=Homo sapiens GN=NCOA2 PE=I SV=2 13,69 2,00 1,21
Q 15751
HERCI_HUMAN Probable E3 ubiquitin-protein 
ligase HERCI OS=Homo sapiens GN=HERCI 
PE= 1 SV=2 3 peptides loge -11
11,25 2,90 0,57
Q 16099
GRIK4_HUMAN Glutamate receptor ionotropic, 
kainate 4 OS=Homo sapiens GN=GRIK4 PE=2 
SV=2
10,40 2,19 0,95
Q 16222
UAPI_HUMAN UDP-N-acetylhexosamine 
pyrophosphorylase OS=Homo sapiens GN=UAPI 
PE=I SV=3
9,96 3,52 0,98
Q 16880
CGT_HUMAN 2-hydroxyacylsphingosine l-beta- 
galactosyltransferase OS=Homo sapiens 
GN=UGT8 PE=2 SV=2
8,95 3,73 1,14
Q4G0N4 NAKD2_HUMAN NAD kinase 2, mitochondrial OS=Homo sapiens GN=NADK2 PE= 1 SV=2 14,71 2,47 0,57
Q52LR7 EPC2_HUMAN Enhancer of polycomb homolog 2 OS=Homo sapiens GN=EPC2 PE=I SV=2 12,78 2,65 0,95
Q68EM7
RHGI7_HUMAN Rho GTPase-activating protein 
17 OS=Homo sapiens GN=ARHGAPI7 PE=I 
SV=I
10,63 3,19 1,14
Q7Z4L5 TT2IB_HUMAN Tetratricopeptide repeat protein 21B OS=Homo sapiens GN=TTC21B PE= 1 SV=2 9,98 2,02 1,05
Q8IUE6 H2A2B HUMAN Histone H2A type 2-B OS=Homo sapiens GN=HIST2H2AB PE=I SV=3 52,31 1,90 1,09
Q8IZT6
ASPM_HUMAN Abnormal spindle-like 
microcephaly-associated protein OS=Homo 
sapiens GN=ASPM PE=I SV=2
6,79 7,13 1,12
Q8N394
TMTC2_HUMAN Transmembrane and TPR 
repeat-containing protein 2 OS=Homo sapiens 
GN=TMTC2 PE=2 SV=I
10,20 3,05 1,14
Q8N4B4 FBX39 HUMAN F-box only protein 39 OS=Homo sapiens GN=FBX039 PE=2 SV=I 6,33 5,30 0,99
Q8N7XI
RMXL3_HUMAN RNA-binding motif protein, X- 
linked-like-3 OS=Homo sapiens GN=RBMXL3 
PE=2 SV=2
10,86 2,35 0,57
Q8TBJ5 FEZF2_HUMAN Fez family zinc finger protein 2 OS=Homo sapiens GN=FEZF2 PE=2 SV=2 10,23 4,37 1,25
Q92574 TSCI HUMAN Hamartin OS=Homo sapiens GN=TSCI PE=I SV=2 8,67 3,53 1,12
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Q969M2 CXAIO_HUMAN Gap junction alpha-10 protein OS=Homo sapiens GN=GJAI0 PE=2 SV=I 9,68 3,34 1,04
Q96K78
GPI28_HUMAN Probable G-protein coupled 
receptor 128 OS=Homo sapiens GN=GPRI28 
PE=2 SV=2
8,71 4,66 1,09
Q96M42
CUI29_HUMAN Putative uncharacterized protein 
encoded by LINC00479 OS=Homo sapiens 
GN=LINC00479 PE=5 SV=2
28,87 3,63 1,12
Q96QV6 H2AIA_HUMAN Histone H2Atype l-A  OS=Homo sapiens GN=HISTIH2AA PE=I SV=3 35,11 3,44 1,12
Q9954I PLIN2 HUMAN Perilipin-2 OS=Homo sapiens GN=PLIN2 PE=I SV=2 25,6 5,58 0,57
Q99832 TCPH_HUMAN T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 PE=I SV=2 21,36 2,03 0,95
Q99880 H2BIL_HUMAN Histone H2Btype l-L OS=Homo sapiens GN=HISTIH2BL PE= 1 SV=3 34,13 3,14 0,23
Q9BYE9
CDHR2_HUMAN Cadherin-related family 
member 2 OS=Homo sapiens GN=CDHR2 PE= 1 
SV=2
23,65 2,15 0,86
Q9BYFI ACE2_HUMAN Angiotensin-converting enzyme 2 OS=Homo sapiens GN=ACE2 PE= 1 SV=2 23,73 3,55 2,01
Q9H2T7 RBPI7_HUMAN Ran-binding protein 17 OS=Homo sapiens GN=RANBPI7 PE=2 SV=I 9,56 2,71 1,01
Q9H583 HEATI_HUMAN HEAT repeat-containing protein 1 OS=Homo sapiens GN=HEATRI PE= 1 SV=3 15,69 5,67 1,04
Q9NXV6 CARF HUMAN CDKN2A-interacting protein OS=Homo sapiens GN=CDKN2AIP PE=I SV=3 20,30 2,13 1,15
Q9NZI8
IF2BI_HUMAN Insulin-like growth factor 2 
mRNA-binding protein 1 OS=Homo sapiens 
GN=IGF2BPI PE=I SV=2
13,17 2,18 1,26
Q9P2P5
HECW2_HUMAN E3 ubiquitin-protein ligase 
HECW2 OS=Homo sapiens GN=HECW2 PE=I 
SV=2
18,4 3,05 1,13
Q9UKN1 MUCI2 HUMAN Mucin-12 OS=Homo sapiens GN=MUCI2 PE=I SV=2 12,5 6,56 1,26
Q9UL63 MKLNI HUMAN Muskelin OS=Homo sapiens GN=MKLNI PE=I SV=2 14,63 10,30 1,21
Q9UM73 ALK_HUMAN ALK tyrosine kinase receptor OS=Homo sapiens GN=ALK PE=I SV=3 15,69 16,00 1,14
Q9Y262
EIF3L_HUMAN Eukaryotic translation initiation 
factor 3 subunit L OS=Homo sapiens GN=EIF3L 
PE=I SV=I
8,95 3,38 1,09
152
Q9Y3SI
WNK2 HUMAN Serine/threonine-protein kinase 
WNK2 OS=Homo sapiens GN=WNK2 PE=I 
SV=4
4,53 1,91 2,46
Q9Y5Y6 STI4_HUMAN Suppressor of tumorigenicity 14 protein OS=Homo sapiens GN=STI4 PE=I SV=2 16,3 2,12 1,02
Q9Y6I7 SERC_HUMAN Phosphoserine aminotransferase OS=Homo sapiens GN=PSATI PE=I SV=2 20,54 2,10 1,13
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5. CONCLUSIONS
Proteomics is a rapidly growing field of biology that is used for the study of proteins. Since 
proteins regulate and mediate virtually all cellular functions, proteomic studies have been 
used for diverse research areas including drug discovery and systems biology. Information 
gained from proteomics studies is particularly useful in helping to understand cellular 
mechanisms, especially because the proteome can be altered in many ways that cannot 
be predicted from genetic analysis.
Typically proteomics studies attempt to identify or characterize all the proteins that are 
found in a particular biological context. For example, using proteomics to identify the 
changes in protein levels in response to different stimulants will lead to a better 
understanding of how the stimulant functions. However, analyzing the alterations in a 
proteome is highly dependent on choosing the right techniques and applying them in a 
way that maximizes their analytical power.
Although a large number of proteomics techniques have been developed, there are still 
many areas where even the most advanced analysis are insufficient. In this regard, further 
improvements are needed to increase the sensitivity and throughput of proteomics 
analysis. Unlike genomic analysis, it is currently impossible to identify all the proteins 
found in a complex biological fluid, such as serum. With this perspective, one of the major 
goals of my thesis was to develop a method for mass spectrometry analysis that improves 
the number of peptide and protein identifications from a sample. Importantly, I also 
thought a method that was easily adaptable to quantitative studies.
In the second part, I used the method I developed, referred to here as the “hybrid 
method” to investigate the changes in the proteome of cancer cells to sirtinol. The second 
part of my thesis gives information on the relationship between cancer and senescence.
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5.1. Advantages of Hybrid Method
The method I developed, which I refer to as the hybrid method, uses classical SILAC 
labeling coupled to a “novel” scheme for enriching cysteine containing peptides. The 
hybrid method has a cysteine enrichment step similar to ICAT. However, ICAT uses 
complex chemical reagents to modify cysteines in order to enrich cysteine containing 
peptides. The hybrid method uses much simpler chemistry where cysteines and cystines 
are oxidized to cysteic acid.
5.1.1. Cysteine Oxidation with Performic Acid
Classic sample preparation methods involve reduction and alkylation of cysteines in order 
to break the peptide disulfide bonds and prevent the creation of new disulfide bonds. 
Importantly, these steps ensure that all the cysteines in the sample have the same 
molecular weight, which facilitates their analysis by MS. The hybrid method also uses 
cysteine modification for similar reasons, as well as for creating additional negative 
charges. The complete oxidation of cysteine to cysteic acid, by performic acid treatment, 
is an irreversible modification that breaks and prevents new disulfide bonds from forming. 
The treatment of the sample with performic acid is relatively simple and can be performed 
before or after the digestion step. In the case of in-gel protocols, the peroxide treatment 
is performed prior to digestion as the immobilization of the proteins in the gel matrix 
facilitates the removal of the peroxide.
I found that complete oxidation of cysteines and cystines can be achieved with 3% 
performic acid treatment for I h at room temperature. Importantly, hydrogen peroxide 
alone resulted in only partial oxidation of the sample (Figure 4.2). This is most likely 
due to the inability of hydrogen peroxide to break the disulfide bonds in cystine. Although 
performic acid can be considered as a strong oxidant, at the concentration used (3%) it
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did not artifactually increase the sample complexity, by forming multiple oxidation 
products of tryptophan, formylation of lysine, oxidation and chlorination of tyrosine etc 
229,230 . In addition to the oxidation of cysteine, the only other amino acid that was found 
to be oxidized by performic acid treatment was methionine. Methionine is typically found 
partially oxidized in most samples, as this amino acid is very easily oxidized, even by the 
oxygen in the air.
As already stated, partial oxidation states are generally unwanted as they make the analysis 
of the sample by mass spectrometry more difficult. For example, if a cysteine is partially 
or not fully oxidized, it is likely to be missed from the database searches, especially if it is 
forming new disulfide bonds, as these changes are virtually impossible to account for 
bioinformatically. The other 3 redox states can be accounted for by allowing for these 
molecular masses of cysteine, however the addition of these partial modification greatly 
expand the search space, which has the unwanted effect of increasing the false discovery 
rate. In addition, partial oxidation states would make the quantitation of a peptide very 
difficult as it would be split into many forms and all of these forms would have to be taken 
into account This would be particularly difficult as these forms would likely have different 
chromatographic behavior and would elute at different times. These changes in 
chromatographic behavior would be particularly detrimental for the hybrid technique, 
which was developed to enrich for cysteic acid residues.
5.1.2. ERLIC Enables Enrichment of Cysteic Acid Peptides
The conversion of cysteine to cysteic acid creates a new strongly negative species in the 
sample. My initial attempts to enrich for this species focused on ion-exchange 
chromatography techniques, because ion exchange chromatography depends on the 
interaction between charged proteins/peptides and an oppositely charged
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chromatography medium. In addition, SCX has been used to enrich for phospho-peptides, 
which also contain a strong negatively charged modification. I explored the use of both 
SCX and SAX chromatography to enrich cysteic acid peptides. However, I was unable to 
find conditions where I could efficiently enrich the cysteic acid containing peptides 
(Figures 4.4 and 4.5.). One reason could be that the usage of ‘strong’ type of resins 
which refers how much the ionization state of the functional groups vary with pH. This 
means that a SCX or a SAX has the same charge density on the surface over a broad pH 
range, whereas the charge density of a weak ion exchanger changes with pH. This limits 
the selectivity of the strong ion exchangers. I initially tried these resins because of their 
successful use in enriching for phosphorylated residues. This success is based on the 
differences in pKa (strength) of phosphoric acid relative to the carboxylic acids found in 
peptides. However, cysteic acid sits in between phosphoric acid and these carboxylic 
acids, and perhaps this difference is not great enough to provide enrichment in ion 
exchange chromatography.
In order to eliminate these factors, I switched to ‘weak’ type of resins where a peptide 
with a specific isoelectric point might be selected more easily. Furthermore, a specific 
chromatography technique based on weak ion exchangers, called ERLIC is particularly 
useful in providing chromatographic selectivity between similar groups. As my results with 
SCX and SAX suggested that anion exchange chromatography was superior to cation 
exchange chromatography (Figure 4.5), I used ERLIC based on the weak anion exchange 
resin PolyWAX. The enrichment of cysteic acid was successful using ERLIC (Figure 
4.12). Moreover, when the conditions are optimized, this enrichment was also easy to 
perform and could be reduced to three steps that can be performed in a chromatography 
tip. However, the enrichment is dependent on the pH of the buffers (Figure 4.8), the
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loading capacity of the PolyWAX resin (Figure 4.9), the amount of starting material 
(Figure 4 .10) and the complexity of the sample (Figure 4 .14).
5.1.3. Hybrid Method Provides Increased Identification of Peptides and 
Proteins
The initial optimizations were done using BSA as a model protein, principally because it 
contains a large number of cysteines and cystines. However, the hybrid method is meant 
to be used for more complex samples, such as tumor cell lysates. The standard, or classic 
methods and the hybrid method were therefore compared using whole cell lysates. 
Approximately 5000 proteins and 13000 peptides were identified with the hybrid method, 
while the total number of identified proteins and peptides was approximately 1200 and 
4200 using the classic method (Figure 4 .15). These results demonstrate that the hybrid 
method is useful for getting increased number of protein identifications in complex 
samples.
This dramatic increase in protein identification is unlikely to be solely due the enhanced 
enrichment of cysteic acid containing peptides (Figure 4.14.). All the fractions produced 
by the hybrid technique (flow through, wash and elution) are analyzed, and all of them 
contribute to the increase in protein identification. This is specifically due to the excellent 
fractionation seen with ERLIC. The high degree of fractionation can be seen by the 
minimal overlap seen between fractions (Figures 4 .13 and Figure 4 .16), which means 
most of the peptides are unique to each fraction and the mass spectrometer is more 
efficient, because the number of redundant acquisitions is minimized. Furthermore, this 
makes the quantification of samples subjected to multiple dimension chromatography 
easier to quantify, as the same peptide signal will not be split over multiple runs.
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5.1.4. Hybrid Method Increases the Identification of Post Translational 
Modifications
When compared to classic techniques, hybrid technique improves the identification of 
post translationally modified peptides. Database search results indicated that there is also 
an increased identification in phosphorylation and oxidation sites (Figure 4.17). This 
shows that hybrid method can also be used for quantitative mapping of in vivo PTMs, 
especially those that increase the acidity of the peptides such as phosphorylation, 
oxidation, acetylation, etc.
5.1.5. Hybrid Method is an Accurate and Straightforward Method
The hybrid method was developed with the goal of improving the rate of protein 
identification and quantification, ideally with minimal sample handling. Although hybrid 
technique increases the number of identifications, the efficiency, reproducibility and speed 
of the technique are three other important aspects that make the hybrid technique useful 
for quantitative differential proteomics. Compared to ICAT, which takes at least 2 days 
for sample processing, the hybrid technique can be completed in a few hours.
In addition to ICAT, there are many methods where the effects of complex sample 
preparation is high. In order to avoid variations between samples due to the experimental 
bias and to minimize sample loss, sample preparation should be minimized to remove 
unnecessary steps. The hybrid technique can be considered one of the fastest techniques 
and even with the hybrid technique, unnecessary steps have been removed (Figure 
4 .11.). Reducing experimental steps is also beneficial when working with many samples 
and/or biological replicates, since it reduces the total analysis time.
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In order to provide increased accuracy, the hybrid technique is coupled to SILAC, a stable 
isotope labeling approach for accurate quantification of proteins. SILAC uses the 
metabolic incorporation of stable isotopes in living cells and the quantitative difference in 
protein levels is then measured by mass-shifts. SILAC allows for the samples to be mixed 
at a very early stage and this helps minimize “experimenter induced errors” as the mixing 
ensures that the two (or more) labeled samples are treated identically.
5.1.6. Versatility of the Hybrid Technique
The initial development of the hybrid technique involved coupling the ease of cysteic acid 
enrichment to the power of SILAC. However, label-free techniques can also be coupled 
to the enrichment scheme. Label-free techniques are particularly useful when it is 
impossible or impractical to label the sample metabolically, such as with clinical samples 
or samples from non-dividing cells, such as neurons.
It is particularly difficult to perform SILAC on non-dividing cells. Since the cultures cannot 
be expanded, it can be difficult to obtain enough cells to provide the necessary biological 
replicates, and culture to culture variations may mask any real changes in the experimental 
conditions. Moreover, SI A C  preferentially labels proteins that have high turnover rates. 
For the proteins that have low or very low turnover rates the stable isotope labeling will 
not be complete and this will skew the results for these proteins. This is usually not a 
factor with dividing cells as these unlabeled, stable proteins are diluted out as the culture 
expands.
In order to test label-free approaches with hybrid method, mouse primary cortical 
neurons treated with resveratrol and analyzed with hybrid technique. The technique was 
found successful with label-free approaches, since protein identification is found increased 
(Figure 4.20). Even in workflows where the samples are never mixed, such as in the
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various label free techniques, the hybrid method will be advantageous (Figure 4.20), as 
the increased number of peptide identifications improves the reliability of the 
quantification. Even in the case of the streamlined hybrid protocol, the standard deviations 
between biological replicates was higher with the label-free approach than with the SILAC 
approach.
Another advantage of the hybrid technique is the experimental set up. In these studies, 
the sample preparation was mostly performed using small columns made from pipette 
tips. As the columns can be prepared in a few minutes, it is easy to custom make the 
columns based on the volume or amount of protein in the samples (Figure 4 .1 1).
Although, I typically performed the purification steps manually, throughput of the 
technique can be improved by integrating the columns into 1.5 mL tubes and the 
purification steps can be performed with the aid of a centrifuge 231.
5.2. Limitations of the Hybrid Technique
The limitations of hybrid technique mainly come from the isotopic labeling technique 
itself. As mentioned before, while providing an accurate quantification, SILAC increasing 
the sample complexity. In isotope labeling strategies, the stable isotope tags produce a 
mass shift, which is used to track which experimental group (sample) produced that 
peptide. In this case of a binary system, each peptide appears as two peaks, one from the 
heavy labeled sample and one from the light. This effectively doubles the sample 
complexity and is much worse for higher orders of multiplexing. This isotope-induced 
increase in sample complexity is one of the main advantages of cysteic acid enrichment. 
As cysteine is found in about 5% of peptides, the enrichment will immediately give a 20 
fold loss of complexity.
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Sample complexity can also limit the efficiency of the hybrid technique. While the hybrid 
technique works well when the complexity is low, the efficiency is lower when the 
complexity is high. However, this is compensated by the fact that there is very little 
overlap between the three fractions produced by the hybrid technique.
5.3. Investigation of Sirtinol-lnduced Senescence in T u m o r Cells by Hybrid  
Method
In order to verify that the hybrid technique can be used on “real world” samples, I used 
it to investigate the response of tumor cells to therapeutic compounds, such as sirtinol. 
Sirtinol has been found to induce senescence in tumor cells and is being explored as 
potential therapeutic agent. In fact, the role of senescence in tumor progression has been 
shown in many studies. Conventional anticancer therapies have also indicated that 
senescence plays a role, even when cell death is the main effect of the treatment 232_234.
Driving tumor cells into senescence could have more benefits than simply killing the cells. 
In contrast to apoptosis, senescence may have fewer side effects related to toxicity 235 
and senescent cells also change the microenvironment, including the recruitment of 
immune cells, which may help eliminate any actively proliferating tumor cells. Therefore, 
there is growing interest in using chemically induced senescence as a treatment for some 
cancers. With that idea in mind, I wanted to explore the effects of sirtinol, an HDAC 
inhibitor that has been used to therapeutically induce senescence in some tumor cells. I 
believed this could be an ideal system to test the hybrid method, as quantitative 
proteomics is difficult to perform on a dying cell population.
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5.3.1. Sirtinol Induces Senescence in H I 299 Tum or Cells
I initially chose H1299 cells as they were already being used in the laboratory and the first 
step was to determine if sirtinol could induce senescence in these cells. I was able to show 
that a single, high dose of sirtinol was enough to cause a long term (10 days) block in cell 
proliferation (Figure 4.22.). This was also accompanied by a morphological change in 
the cells, which became large and flat (Figure 4.23 A , B and C).
Senescence is typically induced and maintained by the tumor suppressor Rb. Rb is found 
to be hypo-phosphorylated in senescent cells and the hypo-phosphorylated form is also 
the form that actively suppresses the E2F transcription factor. Sirtinol treated H1299 cells 
were checked for Rb phosphorylation, and hypo-phosphorylation was observed on three 
different points on Rb protein (Figure 4.31). These data indicate that, similar to other 
senescent cells, Rb plays a role in inhibiting cell proliferation in sirtinol treated cells.
The block in cell proliferation and the morphological change are indicative of sirtinol 
inducing senescence in the H I299 cells. However, to verify that senescence is being 
induced, I stained the cells for a histochemical marker of senescence, SA-p-gal activity ,04. 
In fact, sirtinol caused an increase in the histochemical staining for SA-p-gal activity 
(Figure 4.23.). In order to verify these in-situ experiments I checked the quantitative 
MS experiments for the relative levels of the P-galactosidase responsible for this staining. 
Indeed, there was a 1.7 fold increase for this p-galactosidase between control and 300 uM 
sirtinol treated samples. This indicates that the SA-p-gal activity detected by X-gal in 
response to sirtinol, is due to the induction of the same protein induced by other forms 
of senescence. Taken together, these data indicate that sirtinol induces senescence in 
H I299 cells.
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Interestingly, there was a difference in the behavior of the cells when treated with a lower 
does (200 uM) of sirtinol. A single 300 uM sirtinol treatment caused a long term inhibition 
of cell proliferation and resulted in ~90% of the cells becoming SA-0-gal positive. 
Whereas, 200 um sirtinol was only able to delay the initiation of cell proliferation for a 
few days and resulted in far fewer SA-p-gal positive cells. Cell proliferation was probably 
reinitiated in the 200 uM treated sample by these cells that at least by SA-p-gal did not 
undergo senescence. Both doses of sirtinol are well above the dose required to inhibit 
Sirt I , so it is unclear why such high doses are necessary. This could be due to cell specific 
factors, such as the presence of multidrug transporters in the plasma membrane, or it 
may indicate that Sirt I is not the only sirtinol target. Furthermore, I found that two doses 
of 200 uM sirtinol spaced I day apart also resulted in a long term inhibition of cell 
proliferation (data not shown), which suggests that sirtinol may be more effective at 
certain stages of the cell cycle.
5.3.2. Quantitative Analysis of Sirtinol Treated T u m or Cells
In order to better understand the effects of sirtinol on H I299 cells, I used the hybrid 
method to quantitate the changes produced by sirtinol at the proteome level. I used 
SILAC labeling for ten generations and then one pool of cells was treated for I day with 
300 uM sirtinol. Cells were harvested 8 days after sirtinol treatment and quantitative data 
was obtained using the hybrid method coupled to mass spectrometry.
This workflow resulted in approximately 4000 quantified proteins and 228 of these 
proteins were found to be changed by more than two-fold. Specifically, 88 proteins were 
up regulated and 140 proteins were down regulated (Table 4.1 and Table 4.2). As 
expected, most of the protein levels were not changed. Importantly, this indicates that 
the samples were properly mixed. For example if the twice as much of one sample was
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added, then most proteins would show a 2 fold change in expression levels. This shows 
that the hybrid technique can be used for binary comparisons such as characterizing the 
response of mammalian cells to pharmacological agents.
In order to further validate the results obtained by the hybrid method, the levels of two 
downregulated proteins (FAS and AHNAK) (Figure 4.27) and two upregulated proteins 
(EIF2a and PPP2R3A) (Figure 4.28) were analyzed by western blotting. Although these 
blots were not quantitated, they do indicate that the hybrid technique can identify both 
up and down regulated proteins. It is particularly difficult to quantitate protein levels 
accurately by western blotting and in order to verify that the absolute change in levels 
reported by the mass spectrometry is correct would require a truly quantitative 
technique, such as ELISA or a targeted mass spectrometry based approach, such as 
multiple reaction monitoring (MRM).
5.3.3. Biological Relevance of A ltered Proteins
The functional annotations of a protein can be used to help decipher which proteins are 
critical for the cells response to sirtinol. This is particularly useful as the quantitative MS 
results have already reduced the number of candidates down to ~200. However, even on 
a short list of 200 proteins this can be daunting task and probably cannot be done 
manually. For example, I further characterized FAS protein levels in order to validate the 
MS results. However, FAS was not chosen randomly.
Fatty acid metabolic pathways have been previously reported to be associated with 
carcinogenesis and FAS can also be used as a biomarker for certain cancers 236. In fact, the 
FAS antibodies were already being used in the laboratory as a marker for liver cancer. 
Fatty acid synthase (FAS) is an important enzyme which involved in endogenous 
lipogenesis in mammals and also responsible for catalyzing the synthesis of long-chain fatty
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acids. FAS has also been identified as a crucial factor for sustaining several biological 
features of cancer cells 237.
In all sirtinol treated tumor cells, FAS levels were found downregulated. I checked 
whether this situation has any relevance with senescence and cancer states. Indeed, FAS 
levels has been previously found at high levels in a variety of tumors 238-240 while in normal 
tissues it remains at normal levels. Also, it has been reported in several studies that 
inhibition of FAS expression suppresses cancer cell proliferation in vivo and in vitro 241,242. 
Hence, a reduction in FAS levels may be one of the therapeutic effects of sirtinol and 
inhibition of FAS has even been proposed as a potential therapeutic strategy 243.
If FAS is playing a role in sirtinol induced senescence, then it would also be expected to 
be important in other forms of senescence, such as replicative senescence. In order to 
check the levels of FAS during replicative senescence, I used MEF cells. MEF cells were 
cultured until they underwent crisis, which is a form of senescence, and then upon further 
passaging a few cells escape crisis and begin to proliferate and they quickly take over the 
culture. Interestingly, there was a correlation between FAS levels and replication of the 
cells (Figure 4.33). FAS levels began decreasing at the start of replicative crisis and 
remained low until the cell proliferation resumed. These results further highlight the 
possible role of FAS in senescence, cancer and aging 244. However, it is possible that FAS 
is simply a marker of a high metabolic rate and can be thought of as a metabolic marker 
of cell proliferation 24s.
FAS was chosen for further study, mostly because my laboratory was already familiar with 
its role in cancer. However, one of the strengths of the proteomics approach is being 
able to uncover pathways that were not previously known to be key players in senescence 
and bioinformatics approaches are used to uncover these relationships.
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5.4. Bioinformatics
High throughput expression level data, both transcriptomic and proteomic, can be difficult 
to interpret, because these approaches typically uncover a large number of changes. 
However, layering this expression data on top of data such as metabolic pathways, 
interaction maps, or even Gene Ontologies (GO) is often used to help discover common 
functional pathways that are part of the cellular response. Many of these changes will be 
part of the biological response and many will not. Pathway analysis is a powerful way to 
identify the proteins involved in the response, as typically many proteins in a pathway will 
be altered.
STRING is a databases of known and predicted protein: protein interactions and it can 
be used to help uncover related proteins 246. Protein interaction maps are a particularly 
powerful way to analyze proteomics data, because most proteins work in concert with 
other proteins. In fact, early work on the high throughput mapping of protein interactions 
was justified because mapping protein-protein interactions is a quick way to functionally 
annotate genomic databases.
In order to help uncover new relationships among the proteins whose expression level 
changes in response to sirtinol, I analyzed both the up and down regulated proteins using 
the STRING database (Figure 5.1. and 5.2.). Importantly STRING uncovered several 
pathways that were strongly enriched in either the up or down regulated protein lists. 
Significantly, protein-protein interactions involved in regulating protein synthesis were 
found in the upregulated protein lists and include members of the mTOR signaling 
cascade, including the translation elongation and initiation factors (EIF proteins) (Figure
5 .1.). Significantly, the mTOR pathway has been shown to be responsible for regulating 
the translation of SASP in senescent cells 247. Specifically when the mTOR complex is
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inhibited with rapam/cin, SASP factors were also found to be reduced. Hence, up- 
regulation of mTOR activity by sirtinol is expected to regulate SASP in H 1299 cells after 
treatment.
Eukaryotic initiation factor proteins (EIF2, EIF3 proteins) and ribosomal proteins (RL8, 
RLI7, and RL23) also clustered in the protein interaction map shown in Figure 5.1. Up- 
regulation of these proteins may indicate a change in protein synthesis that promotes the 
senescent phenotype and maybe regulated by mTOR, as these proteins were also found 
interacting with mTOR (Figure 5.1).
Another cluster of interactions is centered on the histone proteins. The histones are the 
known targets of the sirtuin family of histone deacetylases. One of the most interesting 
proteins in the histone protein cluster is H2AX (histone H2A variant) which is a well- 
known biomarker for DNA-damage (specifically DSBs) 248. H2AX has been found to be 
up-regulated and phosphorylated in senescent cells 248. The sirtinol dependent 
upregulation of histone proteins is consistent with the chromatin remodeling and DNA- 
damage markers seen in other models of senescence. Furthermore, these results suggest 
that sirtinol is inducing senescence via well-known senescence pathways.
One of the weaknesses of this type of network analysis is that it does not provide 
additional information about those proteins such as PPR23A, FLNC and W NK2 that do 
no connect with other proteins found to be up-regulated (Figure 5.1). This may be due 
to lack of experimental evidence or their activities are not really required for sirtinol 
induced senescence.
Similarly, STRING also revealed the presence of a single protein-protein interaction 
network in the down regulated proteins (Figure 5.2). Many of these down regulated 
proteins are involved in regulating protein quality. Including chaperones (BAG3), the
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ubiquitination machinery (UCHLI, UBAI, RN2I3, PFWD3, HECW2, HERCI, TRIM25), 
proteasome subunits (PSA6), prolyl isomerases (PPIA). It is currently unclear why the 
protein quality control machinery is down regulated during senescence, but this may be 
related to the upregulation of mTOR activity, as mTOR also functions to inhibit the 
protein quality control system, and specifically BAG3 and the proteasome 249.
As with the up-regulated proteins, many down-regulated proteins did not form 
connections, such as AHNAK. AHNAK’s function and its involvement in several states 
such as cancer has been recently investigated 2S0. AHNAK is involved in different cellular 
processes and pathways, ranging from regulating calcium channels, cell architecture, and 
cell migration. AHNAK has been shown to be highly abundant in lipid rafts of breast 
cancer cells and AHNAK is suggested to be involved in tumor metastasis 2S0. However 
there are also studies suggesting that AHNAK may work as a tumor suppressor251. 
Although AHNAK has several different functions, it was not found to interact with other 
proteins downregulated by sirtinol. AHNAK’s function in response to sirtinol needs 
further characterization.
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Figure 5.1. Protein interaction mapping of sirtinol up-regulated proteins. The list of proteins 
up-regulated by sirtinol was analyzed using STRING 246. Protein: protein interactions found in the database 
are indicated by connections being drawn between the proteins.
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Figure 5.2. Protein interaction mapping of sirtinol down-regulated proteins. The list of proteins 
down-regulated by sirtinol was analyzed using STRING 246. Protein: protein interactions found in the 
database are indicated by connections being drawn between the proteins.
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5.5. Future W o rk
The Hybrid method was developed with the aim of maximizing protein identifications and 
it was applied to determine how a tumor cell line responds to the HDAC inhibitor sirtinol.
During the experiments I used a gel-based separation before cysteic acid enrichment in 
order to reduce the complexity of the samples, specifically for cell lysates. I believe that 
with more experimentation the gel separation and in-gel digestion steps can actually be 
removed from the method and cysteine enrichment can then be performed on total 
lysate. Protein identification from total cell lysate has been previously shown with a 
relatively simple technique based on precipitation of the samples onto a chromatographic 
bed packed in a pipette tip 23‘. I believe that this technique can be optimized to be used 
in the cysteic acid enrichment process. Although conceptually simple several 
optimizations should be considered such as the removing any contaminants, such as 
detergents that might degrade the chromatographic purification.
The quantitative mass spectrometry analyses produced a list of differentially expressed 
proteins and I have begun confirming the changes in protein levels using another assay. 
But so far the expression levels for only a few of them have been verified by western 
blotting. This is necessary to determine if the changes reported by the hybrid method are 
reliable. Ideally the levels of all the proteins should be verified by another method, 
however this is not possible, and a more through bioinformatics analysis should be 
performed to focus the verification process onto those proteins that are most likely to 
be involved in senescence.
Importantly, the relevance of the changes in protein levels reported by the hybrid method 
also needs to be studied in a biological context. Especially in their roles in establishing and 
maintaining the senescent phenotype in response to sirtinol. This is best performed with
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gene knockdowns using siRNA and over expression studies. For example, in the case of 
FAS, siRNA knockdown may result in a lower dose of sirtinol being needed to induce the 
senescent phenotype, and the knockdown cells may even become senescent without 
chemical treatment. Over expression of FAS, on the other hand, would be expected to 
make it even more difficult for sirtinol to produce a fully senescent culture. These cells 
with altered protein levels can also be subjected to another round of quantitative mass 
spectrometry to determine, if any of the other changes in protein level are dependent on 
FAS. Moreover, that the proteins that interact with FAS can be identified, because these 
proteins are also likely to be involved in regulating the transition to the senescent state.
My results also revealed an increase in the number of acetylated proteins in response to 
sirtinol treatment. This was not surprising given that sirtinol is an HDAC inhibitor. 
However, these acetylated proteins were found many days after the cessation of sirtinol 
treatment. Therefore, I believe that characterizing the “acetylome”, as many acetylated 
proteins as possible, would also reveal interesting results. This would be especially 
powerful, if it were performed at different time points, starting immediately after sirtinol 
treatment. Although immunological methods could be used to enrich for acetylated 
peptides, I believe that ERLIC chromatography could also be adapted to these studies as 
acetylation of lysine residues changes its charge state. This would likely require a new 
round of optimization steps. However, if successful, would make ERLIC a very important 
technique for proteomic studies.
Tremendous efforts have been put into cancer research, and there is a critical need for 
the discovery of new therapeutic compounds. Quantitative proteomics can also be used 
to characterize the direct mechanism of action of these drugs. Most drugs have more 
than one target, these are the targets for which the drug was developed, Sirt I, plus all 
the other “non-specific” targets that also interact with the sirtinol. Proteomic techniques
173
can be used to identify both the specific and non-specific actions of a drug, like sirtinol252,
234. For example, sirtinol-coated beads can be used as an affinity reagent to perform pull­
down experiments with the interacting proteins being identified by mass spectrometry. 
Although sirtinol is a known inhibitor of Sirt I, the full spectrum of interacting proteins 
can help reveal any unknown targets of the compound. This is especially interesting, for 
a drug like sirtinol where the doses required to induce senescence are well above the 
doses required to inhibit the known target.
The hybrid technique that I developed can be adapted to virtually any proteomics 
workflow and not just those requiring cysteine enrichment to reduce sample complexity. 
I used the technique specifically to characterize how sirtinol affects a specific tumor cell 
line and the continuation of these studies should result in a better understanding of sirtinol 
action, as well as, expanding the use of the hybrid method I developed.
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